ASSA ABLOY to acquire SKIDATA

ASSA ABLOY has signed an agreement to acquire SKIDATA, an international leading provider of access management solutions. "I am very pleased to welcome the SKIDATA team into the ASSA ABLOY Group. This acquisition delivers on our strategy to grow our business in mature markets through adding complementary products and solutions to our core business,” says Nico Delvaux, President and CEO of ASSA ABLOY. “SKIDATA's attractive product portfolio and strong performance in access solutions will enhance and complement our current offering,” says Massimo Grassi, Executive Vice President of ASSA ABLOY and Head of Entrance Systems Division. “Its commitment to secure, reliable access solutions and excellent customer service aligns perfectly with our values, and I’m convinced that together, we will continue our successful journey.” SKIDATA was founded in 1977 and is part of the Public Access division of Swiss listed Kudelski Group (SWX:KUD) and has some 1,280 employees. SKIDATA is headquartered in Salzburg, Austria and will be part of the Business Segment Pedestrian within the Entrance Systems Division. Sales for 2023 amounted to about MEUR 305 (approx. MSEK 3,500). The acquisition will initially have a small dilutive effect to EPS. The acquisition is subject to regulatory approval and customary closing conditions and is expected to close during the third quarter of 2024. For more information, please contact: Nico Delvaux, President and CEO, tel.no:+46850648582Erik Pieder, CFO and Executive Vice President, tel. no: +46 8 506 485 72              Björn Tibell, Head of Investor Relations, tel.no:+46 70275 67 68, e-mail: bjorn.tibell@assaabloy.com About ASSA ABLOY The ASSA ABLOY Group is the global leader in access solutions. The Group operates worldwide with 61,000 employees and sales of SEK 141 billion. The Group has leading positions in areas such as efficient door openings, trusted identities and entrance automation. ASSA ABLOY's innovations enable safe, secure and convenient access to physical and digital places. Every day, we help billions of people experience a more open world.

Sivers Semiconductors Appoints Vickram Vathulya as New President & CEO

Kista // Sweden // July 22, 2024 // Sivers Semiconductors AB (Sivers), a leading supplier of integrated chips and photonics modules for the most advanced communications and sensor solutions, today announced the appointment of Vickram Vathulya as its new President & CEO, succeeding Anders Storm, effective August 19, 2024. Dr. Vathulya brings over 25 years of experience in the semiconductor industry with a proven track record in building strategically sound businesses backed by strong organizational talent while navigating complex market dynamics to lead Sivers through its next phase of growth. As CEO, Vathulya will leverage his senior leadership experience, extensive network, and deep understanding of the semiconductor industry to drive Sivers' strategic initiatives worldwide. Dr. Vathulya most recently served as President of Nuvotronics, spearheading a strategic, operational, and cultural transformation for long-term growth and value creation. Prior to that, he revitalized the standard products business at Maxim Semiconductors, the largest and most profitable business in the company portfolio. His experience also includes other executive leadership roles, such as successfully growing a variety of RF and wireless businesses at Maxim Integrated and NXP Semiconductors. Vathulya has a Ph.D. in Electrical Engineering from Lehigh University in Pennsylvania and an MBA from the Berkeley Haas School of Business, University of California. Dr. Bami Bastani, recently appointed Chairman of the Board for the Sivers Semiconductors AB, said: "Vickram’s leadership qualities and industry expertise are exactly what Sivers was looking for in this CEO appointment in order to accelerate our aggressive growth strategy in the US and worldwide. His proven ability to deliver profitable growth and build high-performance teams will be invaluable as we aim to cement our position as a leader in advanced semiconductor and photonic solutions." "I’m excited to join Sivers and work alongside our talented wireless and photonics leaders, teams and innovative customers to expand our footprint in the global markets, driving the next phase of our growth journey,” said Vathulya. “Our portfolio of RF products for Satcom & 5G systems and optical products for AI computing and sensing demonstrates the truly cutting-edge capability Sivers brings to the market. With several marquee customers recently selecting Sivers for their solutions, I am confident the company is on the cusp of remarkable growth and shareholder value creation.” The appointment of Dr. Vathulya comes at an exciting time for Sivers, as the company gains significant market momentum in SATCOM, 5G and AI Photonics. During the first 6 months of 2024 the company announced multiple new customer wins, including two major satellite communication deals valued at $7.6 million and a $1.3 million collaboration with a strategic customer to develop photonic chipsets for AI solutions. During 2023 the company grew net revenue by 80%, and continues to see significant growth in product revenue in 2024. The company is implementing a new incentive plan, including stock option grants. The new CEO, Vickram, has made a sizable commitment to buy and, or subscribe to 2 million shares up to $1m, subject to EGM approval of the plan. For more information, please contact:Dr. Bami Bastani, Chairman of the BoardTel: +1 908 87 28 370E-mail: bami.bastani@sivers-semiconductors.com  (bami.bastani@sivers-semiconductors.com%20) This disclosure contains information that Sivers Semiconductors is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the contact person set out, on July 22, 2024, 08:00 CET. Sivers Semiconductors AB (SIVE.ST) is a leader in SATCOM, 5G, 6G, Photonics, and Silicon Photonics that drives innovation in global communications and sensor technology. Our business units, Photonics and Wireless, supply cutting-edge, integrated chips and modules critical for high-performance gigabit wireless and optical networks. Catering to a broad spectrum of industries from telecommunication to aerospace, we fulfill the increasing demand for computational speed and AI application performance, replacing electric with optical connections for a more sustainable world. Our wireless solutions are forging paths in advanced SATCOM/5G/6G systems, while our photonics expertise is revolutionizing custom semiconductor photonic devices for optical networks and optical sensing, making us a trusted partner to Fortune 100 companies as well as emerging unicorns. With innovation at our core, Sivers Semiconductors is committed to delivering bespoke, high-performance solutions for a better-connected and safer world. Discover our passion for perfection at www.sivers-semiconductors.com.

Kindred’s Journey Towards Zero: Q2 revenue from high-risk players

Kindred Group plc’s (Kindred) share of revenue from high-risk players showed a decrease to 3.0 per cent (Q1 2024 3.2 per cent) in the second quarter of 2024. Compared to the second quarter of 2023, the high-risk revenue share decreased marginally. The percentage of detected customers who exhibited improved behaviour after interventions came in at 86.8 per cent (compared to 87.1 per cent in Q1 2024 and 86.4 per cent in Q2 2023). The sustained level in the improvement effect after interventions, observed over an extended period, serves as a testament to the strong dedication and collective efforts throughout the company. It reflects Kindred's ongoing commitment to fostering positive change within the industry. Global statistics from Q2 Q3 Q4 2023   Q1 2024 Q2 2024*Kindred Group    2023   2023  Share of gross winnings 3.1%    3.3%    3.1%    3.2% 3.0%revenue from high-riskplayers   Improvement effect after 86.4%    86.7%    87.4%    87.1% 86.8%interventions    *90 day rolling period between 19 March 2024 and 18 June 2024 “Our share of revenue from high-risk players has been stable over the past quarters, however we are pleased to see the long-term trend of a slow decline. We are working hard across the Group to ensure our customers enjoy our products in a safe and sustainable way, which includes educating customers, stakeholders, and partners about safer gambling initiatives”, says Alexander Westrell, Director of Communications at Kindred Group. “We classify all customers who self-exclude for more than six months as high-risk to ensure we prioritise responsible gambling. However, we see that some customers self-exclude for reasons other than gambling concerns. We are actively working on improving our user experience to better distinguish self-exclusions related to actual behavioural risks, so that our high-risk data accurately reflects customers who genuinely need support to stop gambling”, continues Alexander Westrell. In February 2021, Kindred started to communicate about its share of revenue of harmful gambling and reports this data and the improvement effect after interventions each quarter. This is a key part of Kindred’s work with fostering a factual and transparent dialogue, paving the way for a more sustainable industry. Kindred also publishes specific RG data for the Swedish market together with ATG and Svenska Spel. Kindred’s RG data for the first half of 2024 can be found here . About Kindred’s Journey towards Zero  Kindred Group is committed to transform gambling by being a trusted source of entertainment that contributes positively to society. Therefore, Kindred has set an ambition to reach zero per cent revenue from harmful gambling and to report this metric on a quarterly basis. This is done to increase transparency, to support a fact-based dialogue about harmful gambling, and to raise awareness of the Group’s sustainability work. To read more, visit: www.kindredgroup.com/zero 

CapMan Growth together with the consortium announces a public tender offer for all the shares in Innofactor Plc

CapMan Growth press release22 July 2024 at 09:10 a.m. EEST CapMan Growth together with the consortium announces a public tender offer for all the shares in Innofactor Plc The CapMan Growth Equity III fund and Innofactor’s founder, main shareholder and long-time CEO Sami Ensio, through his company Ensio Investment Group Ltd, have formed a consortium for a voluntary, recommended public cash tender offer for all shares issued by Innofactor Oyj. Osprey Capital Ltd is involved in the consortium as a co-investor. Innofactor offers IT services, such as design services for critical IT solutions, delivery projects, implementation support and maintenance services with the Microsoft ecosystem solutions. The company also develops its own software and services. Innofactor is a respected and strong partner for about 1,000 private and public sector organizations in the Nordic countries. In 2023, Innofactor’s net sales was around 80 million euros and EBITDA was around 9 million euros. With the experience and versatile resources offered by CapMan Growth and Sami Ensio’s company and industry knowledge, the consortium has exceptional operational experience and know-how to further develop Innofactor 's operations and grow the business. ”As a strategic partner, CapMan Growth provides the company with extensive experience in developing IT service companies and a range of resources to accelerate Innofactor’s growth strategy, particularly through acquisitions, as well as a stable and secure domestic owner for the demanding Nordic customer base. I am excited about the opportunity to develop the company together with the company's founder Sami Ensio”, says Antti Kummu, Managing Partner of CapMan Growth. As a private company, Innofactor would be able to better focus on its customers, innovations and the implementation of the growth strategy, as well as obtain more flexible financing opportunities. ”I have acted as the CEO of Innofactor during its almost 15 years as a listed company and, in my view, while being a listed company has brought about many positive things to Innofactor, it has also limited Innofactor’s growth and profit potential due to, among others, increased reporting obligations and low liquidity in shares. After careful consideration and exploring a wide range of options, I believe that the current tender offer, supported by CapMan Growth, is the best option for Innofactor ‘s future and its existing shareholders. I am very committed to continue leading the company and to executing its growth strategy. At the same time, I will increase my ownership stake in the company if the public tender offer is completed”, says Sami Ensio, main shareholder of Innofactor and member of the consortium. Osprey Capital Ltd is involved in the consortium as a co-investor. Osprey Capital Ltd is an investment company founded in 2014 and owned by Timo Larjomaa, a Senior Advisor of CapMan Growth, and his family. Osprey Capital invests e.g. in IT-companies and private equity funds. CapMan Growth is the leading Finnish growth investor making investments in entrepreneur-led growth companies with revenues ranging between €10–200 million euros. CapMan Growth offers entrepreneurs an alternative to selling the majority of their business by facilitating a partial exit while also supporting growth and internationalisation. CapMan Growth has been part of building companies such as Coronaria, Cloud2, Digital Workforce, Fennoa, Fluido, Neural DSP, Picosun, Sofigate, Silmäasema and Unikie. For further information, please contact:   Antti Kummu, Managing Partner, CapMan Growth, +358 50 432 4486 About CapMan CapMan is a leading Nordic private asset expert with an active approach to value creation and €5.7 billion in assets under management. As one of the private equity pioneers in the Nordics we have developed hundreds of companies and assets creating significant value for over three decades. Our objective is to provide attractive returns and innovative solutions to investors by enabling change across our portfolio companies. An example of this is greenhouse gas reduction targets that we have set under the Science Based Targets initiative in line with the 1.5°C scenario and our commitment to net-zero GHG emissions by 2040. We have a broad presence in the unlisted market through our local and specialised teams. Our investment strategies cover real estate and infrastructure assets, natural capital and minority and majority investments in portfolio companies. We also provide wealth management solutions. Our service business includes procurement services. Altogether, CapMan employs around 200 professionals in Helsinki, Jyväskylä, Stockholm, Copenhagen, Oslo, London and Luxembourg. We are listed on Nasdaq Helsinki since 2001. www.capman.com Innofactor Innofactor is the leading driver of the modern digital organization in the Nordic Countries for its about 1,000 customers in commercial and public sector. Innofactor has the widest solution offering and leading know-how in the Microsoft ecosystem in the Nordics. Innofactor has about 600 enthusiastic and motivated top specialists in Finland, Sweden, Denmark and Norway. For more information: www.innofactor.com

Metso strengthens its slurry handling offering by acquiring Jindex in Australia

Metso has signed an agreement to acquire Jindex Pty Ltd, a privately owned Australian company specializing in valves and process flow control.  Combining Metso’s extensive experience and offering in slurry handling, hydrocyclones and minerals processing equipment solutions with Jindex’s valve offering will further strengthen Metso’s capacity to provide more comprehensive slurry handling solutions for the mining industry.   “This acquisition is yet another important step in the development of Metso’s Pumps business line offering to bring us closer to being our customers’ lifecycle partner of choice. Flow and isolation control play a vital role in ensuring smooth slurry handling to maximize the productivity and efficiency of minerals processing plants. In the past, we have collaborated with Jindex on many customer projects and are now glad to welcome the Jindex experts to the Metso team. Jindex has extensive expertise and strong capabilities in valve technology and control equipment, as well as in many types of slurry valve projects, and thus their products complement our offering well,“ says Tiago Oliveira, Head of Pumps business line at Metso.  “This is a great development and an exciting next step. The Jindex product offering and our technical expertise in valves are an excellent addition to Metso’s Pumps business and will enable Metso to provide more extensive flow control solutions to the mining industry. We look forward to contributing our unique knowledge and experience as part of the Metso team, and providing enhanced outcomes to all our collective customers,” says Stephen Fowler, Managing Director, Jindex Pty Ltd.  Metso’s Pumps business line offers complete solutions for slurry handling and hydrocyclones, including equipment, parts, aftermarket and lifecycle services and digital services. The equipment offering includes slurry pumps, pipes, hoses, valves and hydrocyclones.   The acquisition is expected to be closed in August 2024. The parties have agreed not to disclose the transaction value, which has no material impact on Metso’s financials.  About Jindex   Jindex Pty Ltd is a privately owned technology company established in 1995. The company is based in Sydney, Australia, and has 25 employees. Jindex serves the mining and minerals processing sector with approximately 50% of sales in Australia. More information is available on their website.   Further information:   Tiago Oliveira, Vice President, Pumps business line, Metso, tel. +351 915419713, email: tiago.marques.oliveira(at)metso.com  Christian Trulsson, Director, Slurry Valves, Metso, tel. +46 761 387 771, email: christian.trulsson(at)metso.com  Stephen Fowler, Managing Director, Jindex Pty Ltd, tel. +61 417 228 060, email: stephen(at)jindex.com.au  Helena Marjaranta, Vice President, Communications and Brand, Metso Corporation, tel. +358 20 484 3212, email: helena.marjaranta(at)metso.com   Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.    Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. Metso.com, x.com/metsoofficial 

Swedish company TikoMed announces successful outcome of phase II safety trial on patients with confirmed Amyotrophic Lateral Sclerosis (ALS) treated with weekly ILB® injections

Viken, Sweden July 22[nd], 2024: Swedish drug development company TikoMed AB today announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB® is safe and well tolerated in patients with ALS. Eleven patients participated in the prospective, single-arm, open-label, phase II clinical trial encompassing long-term weekly ILB® injections for up to 48 weeks of 2 mg/kg, a dose that was twice that of the dosing of similar patients in a previously published shorter term clinical safety study.[1] The principal investigator of the Birmingham trial, Venkataramanan Srinivasan, MRCP, MRCP (Neurology) of the Queen Elizabeth Hospital comments: “This trial demonstrated the good safety profile of long-term weekly injected ILB® in patients with ALS. I am very grateful for the engaging participation by the patients in especially difficult circumstances due to the onset of the pandemic during the trial period.” TikoMed’s Scientific Advisor, Professor Ann Logan, Honorary Professor of Regenerative Medicine at the University of Warwick, states: “Taken together, the previous study at the Sahlgrenska Hospital in Gothenburg and the more recent Birmingham trial demonstrate the safety and tolerability of ILB® in patients with ALS and further suggest a long-term slowing of disease progression in addition to the already reported rapid improvements in patient biochemistry and residual motor function. The delivery of fast functional benefit alongside long-term disease stabilisation would make ILB® a unique treatment option for this devastating disease. These encouraging results indicate the future potential of ILB® to be the first disease-modifying drug to treat both familial and sporadic ALS with minimal side-effects.” “This trial represents another significant milestone for the company, and I am very impressed and grateful that the trial results are now peer-reviewed and published. I also want to extend my sincere thanks to all teams involved for their extraordinary dedication and effort in working towards finding a treatment that could improve the lives of ALS patients,” says Lars Bruce, one of the founders of TikoMed and responsible for the ILB® program. [*]ALSFRS-R score: A predictor of survival time in ALS patients [**]ALSAQ-40: A disease-specific health-related quality of life instrument for use in studies of patients with ALS or other motor neuron diseases The clinical trial: EudraCT 2017-005065-47 and clinicaltrials.gov: NCT03705390. Sponsor: This clinical trial was undertaken independently with academic leads (VS, SPB), via the Drugs, Devices, Diagnostics and Biomarkers Team (D3B) at Birmingham’s Cancer Research UK Clinical Trials Unit and was sponsored by the University of Birmingham. Funding: TikoMed AB provided support in the form of salary contribution for some authors as part of the clinical trial funding, but did not have any additional role, either direct or indirect, in the clinical trial study design, data collection, data analysis, decision to publish, or preparation of the manuscript through the participation of the co-authors. The published article: Srinivasan V, Homer V, Barton D, Clutterbuck-James A, Jenkins S, Potter C, Brock K, Logan A, Smith D, Bruce L, Nagy Z and Bach S.P (2024) A low molecular weight dextran sulphate, ILB[®], for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial. PLoS ONE 19(7): e0291285. https://doi.org/10.1371/journal.pone.0291285 For more information: TikoMed, Christian Treschow, Chairman, TikoMed, Lars Bruce, responsible for of the ILB® program news.ilb@tikomed.com To the editors About TikoMed TikoMed is a Swedish, private company founded in 2002 by the Bruce family. Lars Bruce, who is the lead of the ILB® program, is an entrepreneur and inventor with several commercial inventions in mechanics, metallurgy and medicine. Inventor Lars Bruce refers to the drug, called ILB®, as the discovery of the ‘Missing Link’ that can orchestrate the body’s natural tissue repair signals. ILB® is a drug that directly addresses the dysregulated neuro-degenerative and neuro-inflammatory processes that underlie many neuronal diseases through endogenous activation of a unique repertoire of growth factors. About D3B The Drugs, Devices, Diagnostics and Biomarkers (D3B) collaborative was established in August 2016 to support design and delivery of high-quality, early phase translational research within Birmingham Health Partners (BHP). D3B is located at the heart of Birmingham’s Institute of Translational Medicine (ITM) with team members derived from Birmingham’s Cancer Research UK Clinical Trials Unit (CRCTU). D3B was created to support development of a research portfolio that aligned with the Government’s strategy for UK Life Sciences; this aims to provide patients with early access to novel treatments. Publications: 1. Logan A, Nagy Z, Barnes NM, Belli A, Di Pietro V, Tavazzi B, Lazzarino G, Lazzarino G, Bruce L, Persson LI. (2022) A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis. PLoS One 17(5):e0267183. https://doi.org/10.1371/journal.pone.0267183  PMID: 35613082; PMCID: PMC9132272.

Interim report Q2, 2024

Second quarter · Net sales amounted to SEK 2.8 (4.4) million · EBITDA amounted to SEK -3.7 (-1.8) million · EBIT amounted to SEK -11.2 (-31.4) million · EBT amounted to SEK 93.9 (-32.2) million SpectrumOne AB sells more than 50 % of its shareholding in Eniro Group AB to industrial partner Azerion Group N.V. at a price of SEK 0.90 per share   SpectrumOne continues to execute on its strategic direction – divests its shares in BizWell Sweden AB CEO STATEMENT Dear Shareholders, As we embrace the summer season, I hope everyone is finding time to relax, enjoy the sunshine, and spend quality moments with friends and family. I would like to take this opportunity to provide a brief update on our recent activities and progress during Q2. Additionally, I invite you to join us for a shareholder update meeting at the beginning of September, where we will offer more detailed insights into our ongoing activities and progress, continuing our commitment to transparency and good communication. Since assuming the role of CEO, it has become evident that our organization must streamline operations, reduce costs, and eliminate non-performing areas. Our focus will be on our strengths and core areas, developing them to their full potential and advancing in a more strategic manner. During Q2, we have concentrated on our core areas, particularly with Cloud Explorers and Qbim. Both organizations are dedicated to providing SaaS-based product solutions to the rapidly expanding market of data insights, analysis, and AI-related solutions. Qbim has been committed to maintaining strong revenue streams, increasing client projects, and transforming into a SaaS-based product delivery company. We look forward to sharing more details about their progress in August and at our September meeting. Cloud Explorers has been working intensively with its two main partners, D&B and Tietoevry. PRISM, our flagship product, has gained unique features that distinguish it from competing solutions. PRISM now offers a wider range of solutions, including comprehensive vehicle, business, and property data. This new release has generated significant interest, with August already booked with numerous client meetings and sales activities, including a second webinar with Tietoevry. We anticipate strong results in Q3. Our strategic actions related to Eniro have also strengthened our financial position, enabling us to further develop and maximize the commercial success of our core businesses, Qbim and Cloud Explorers. I look forward to reconnecting with you all after the summer and am excited to present more detailed information at our next meeting regarding our client activities, increased sales efforts, and the growing market interest in our offerings. Yours faithfully, Stephen Karl Ranson CEO, SpectrumOne AB For further information contact: Stephen Ranson CEO+47 99288 221, stephen@spectrumone.com Certified Adviser:Aktieinvest FK AB (556072-2596) Box 7415 103 91 StockholmTelefon: +46 8 506 517 03ca@aktieinvest.se www.aktieinvest.se SpectrumOne AB (publ) is obligated to publish this information under the EU Market Abuse Regulation. The information was provided by the above contact person's auspices, for publication on July 22, 2024 at 8.30 a.m. CET. This report is to be found on our webpage About SpectrumOne ABSpectrumOne is a leading technology company delivering an advanced Data Management, Analytics & Communications platform suite. Offered in a SaaS online service shipping with rich market data from various professional providers, SpectrumOne provides a unique solution to many leading actors across industry segments in various countries. Enabling clients with fast and easy access to data insight and visualization coupled with powerful search, segmentation, and mapping features. SpectrumOne allows data to be quickly enabled and operationalized, driving activities from customer communication to data science supporting business analysis, strategy, and growth. All of which can be enabled the same day with immediate results. SpectrumOne´s headquarter is based in Stockholm, Sweden, responsible for Nordic sales and strategy, with additional sales and business development located in Norway, Finland and Belgium.  SpectrumOne is listed on Nasdaq First North Growth Market in Stockholm.

Techstep strengthens its position within public sector with two new contracts in Norway

Techstep has secured two new public sector agreements for delivering mobile devices, accessories and related mobile technology services and solutions to all municipalities in the Vestfold region, managed by the public sector purchasing agency VOIS, as well as the Nordre Follo Municipality. Techstep's dedication to lifecycle management and circular economy influenced the selection process, underscoring the company’s commitment to responsible and sustainable business practices. This is a direct result of a new legislation introduced in Norway from 1 January 2024, requiring climate and environmental considerations to be weighted at least 30% in public tenders. By leveraging its expertise in mobile technology solutions, Techstep will be responsible for delivering, repairing and recycling mobile devices, as well as giving the municipalities’ employees the tools for self-service through a modern webshop to order and repair the devices and replace or buy them out in compliance with Norwegian tax requirements. "This is a direct result of Techstep’s revised commercial strategy, becoming the preferred mobile technology partner for all type of municipal workers, from office workers to those working in the field and frontline. Our approach is designed to empower them to derive greater value, productivity and efficiency from their mobile eco-systems. We are proud to be acknowledged for our strong sustainability focus and our commitment to ESG," says Morten Meier, CEO of Techstep.  The two agreements have an estimated total value of NOK 55 million over four years. The initial contract period for the Nordre Follo agreement is two years, with options for an additional two years’ extension with annual renewal. For more information Morten Meier, CEO Techstep ASA, tel: +47 970 57 717 About Vestfold Offentlige Innkjøpsseksjon (VOIS) VOIS the public sector purchasing agency in Vestfold serving around 20,000 employees in six municipalities (Færder, Holmestrand, Horten, Larvik, Sandefjord and Tønsberg) and underlying companies.  About Nordre Follo Kommune Nordre Follo Kommune is one of the largest employers in the Akershus county with around 5,000 employees. About Techstep Techstep is a mobile technology company, enabling organisations to perform smartly, securely, and sustainably by combining mobile devices, software and expertise to meet customers’ business and ESG goals. We are a leading provider of managed mobility services in Europe, serving more than 2,100 customers in Europe with an annual revenue of NOK 1.1 billion in 2023. The company is listed on the Oslo Stock Exchange under the ticker TECH. To learn more, please visit www.techstep.io.

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 164 – 22 JULY 2024 On 25 April 2024, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 26 April 2024 up to and including no later than 1 August 2024. For details, please see announcement no. 96 of 25 April 2024. Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 21 million (approximately DKK 145 million). Under the programme, the following transactions have been made: Date Number Average purchase price (DKK) Transaction value (DKK) of sharesTotal, last 423,000 307.78 130,192,080announcement15/07/2024 7,000 292.16 2,045,12016/07/2024 5,000 306.79 1,533,95017/07/2024 5,000 303.34 1,516,70018/07/2024 5,000 299.89 1,499,45019/07/2024 5,000 297.71 1,488,550Accumulated 450,000 307.28 138,275,850 Since the share buy-back programme was initiated on 26 April 2024, the total number of repurchased shares is 450,000 at a total amount of DKK 138,275,850. With the transactions stated above, NORDEN holds a total of 1,328,701 treasury shares, corresponding to 4.15%. The total number of shares in NORDEN is 32,000,000 million. Adjusted for treasury shares, the number of shares is 30,671,299. During the same period (15/7-24 -22/7-24) major shareholder, Motortramp A/S, has sold 8,495 shares. Please see announcement no. 97/24 and daily reporting. Kind regards, Dampskibsselskabet NORDEN A/S Klaus Nyborg Chairman For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Capital update – negotiations ongoing for early release of second milestone payment

LED iBond had expected to win two larger sales projects in Q3 2024 within indoor farming, but unfortunately, LED iBond did not win these projects. The value of these projects amounts to approximately DKK 5 million, resulting in a revised outlook for 2024.   Revised Outlook LED iBond now expects 2024 revenue of DKK 7 – 8 million, a reduction from the previous DKK 10 – 12 million as stated in Company Announcement no. 95, 26 March 2024. As a result of revised growth expectations and related working capital impact, LED iBond is working on a plan to still ensure positive cash flow from operations being realized by the end of 2025. As such, the revised financial outlook is: · Revenue of DKK 7 – 8 million for 2024 · Positive cash flow from operations by the end of 2025 Tight liquidity As stated in Company Announcement no. 81, 29 November 2023, LED iBond reached agreements for DKK 10 million in new funding. The first step was completed in December 2023 by issuance of 12,857,141 new shares, raising DKK 4.5 million. The second step was to raise the remaining DKK 5.5 million through issuance of two tranches of convertible loans, contingent on two sequential milestone deliveries in, respectively, April 2024 and November 2024. LED iBond has secured the first milestone payment, leading to a payout of DKK 2.75 million as announced in Company Announcement no. 100, 22. April 2024. The second milestone payment of DKK 2.75 million is due in November 2024 contingent on certain performance milestones being met.  With the present outlook the Company is running short on liquidity, and it will not be possible to meet the conditions for the release of the second milestone payment in November. Consequently, the Company is in negotiations with the investors who have committed to the original terms of the milestone payments to achieve an earlier release. The company has ensured liquidity for the next short-term period – however not enough for the next 3 months, which is dependent upon an early release of the second milestone payment. In this context, the company is presently working on taking additional actions to support the negotiations for an early release of the second milestone payment. At present, it is not clear whether this will be sufficient support. Furthermore, the management and Board of Directors are currently assessing relevant opportunities to raise capital to support the business going forward, expected during Q4 2024.

Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB

Right to participate and notification Shareholders who wish to participate in the general meeting must: ·be recorded as shareholder in the share register prepared by Euroclear Sweden AB regarding the conditions on the record date of 9 August 2024, and ·notify the Company no later than 13 August 2024. Notification can be made in writing to Phase Holographic Imaging PHI AB, Skiffervägen 48, 224 78 Lund, or by e-mail to ir@phiab.com. The notification shall state the shareholder´s name, personal identity number or corporate registration number, shareholding, address, telephone number, email address and, where applicable, information about representatives and advisors (maximum 2). Where applicable, the notification should be accompanied by powers of attorney, registration certificates and other authorisation documents. Proxy If a shareholder is to be represented by a proxy, the proxy must bring a written, dated and signed power of attorney, in original, to the meeting. The power of attorney may not be older than one year, unless a longer period of validity (but not more than five years) has been specified in the power of attorney. If the power of attorney is issued by a legal entity, the proxy must also bring the current registration certificate or equivalent authorisation document for the legal entity. To facilitate entry, a copy of the power of attorney and other authorisation documents should be attached to the notification to the meeting. Proxy form are available on the Company's website, www.phiab.com, and are provided by the Company on request. Nominee registered shares In order to be entitled to participate in the general meeting, shareholders with shares registered in the name of a nominee, through a bank or other nominee, must, in addition to giving notice of attendance at the meeting, have the shares registered in their own name in the share register maintained by Euroclear Sweden AB so that the shareholder is entered in the share register as of 9 August 2024. Such registration may be temporary (so-called voting right registration) and should be requested from the nominee in accordance with the nominee's routines in such time in advance as the nominee determines. Voting rights registrations made no later than 13 August 2024, will be taken into account in the preparation of the share register. Proposed agenda 1.Opening of the meeting.  2.Election of chairman of the meeting. 3.Preparation and approval of the voting list. 4.Approval of the agenda. 5.Election of one or two persons to verify the minutes. 6.Determination as to whether the meeting has been duly convened. 7.Election of board member. 8.Closing of the meeting. Proposed resolutions Item 2 – Election of chairman of the meeting The board of directors proposes that attorney-at-law Micael Karlsson, from Advokatfirman Delphi, be elected chairman of the meeting. Item 7 – Election of board members The board of directors proposes that the general meeting elects John Moore as new ordinary member of the board of directors until the end of the next annual general meeting, therefore filling the vacancy after the resignation of the previous member of the board of directors Leland Foster. John Moore is an active investor and entrepreneur in the life science and energy industries. He currently serves as Chairman of two public life science companies Nyrada (NYR-ASX) and Scientific Industries (SCND-OTCQB) and two private companies Trialogics, a clinical trial software business and Cormetech, a leading carbon capture business. Documents available The board’s complete resolution proposals are included in the notice. A proxy form will be available at the Company’s office at Skiffervägen 48, in Lund and on the Company’s website, www.phiab.com, at least two weeks before the general meeting and will be sent free of charge to shareholders who so request and states their postal address. Information at the general meeting The members of the board and the CEO shall, if any shareholder so requests, and the board considers that it can be done without substantial harm to the Company, provide information at the general meeting on circumstances that may affect the assessment of an item on the agenda. Processing of personal data For information regarding how your personal data is processed in the context of the general meeting, see: https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. __________________ Lund in July 2024 Phase Holographic Imaging PHI AB (publ) The Board

Buyback of Class B shares in Essity during week 29, 2024

The share purchase is part of the SEK 3bn buyback program announced by Essity on June 17, 2024. The buyback program will extend from June 17, 2024, until the 2025 Annual General Meeting and be implemented in accordance with the EU Market Abuse Regulation (MAR) and the European Commission’s Delegated Regulation 2016/1052 (Safe Harbour Regulation). The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity’s capital allocation. Class B shares in Essity were repurchased as follows: Date Aggregated daily Weighted average Total daily volume (no. of price per day transaction value shares): (SEK): (SEK):July 15, 2024 54,000 280.4824 15,146,050July 16, 2024 54,000 277.4855 14,984,217July 17, 2024 54,000 279.4560 15,090,624July 18, 2024 54,000 295.9771 15,982,763July 19, 2024 54,000 301.3221 16,271,393Total accumulated 270,000 286.9446 77,475,047during week 29, 2024Total accumulated 1,296,000 277.9877 360,272,032during the buybackprogram All purchases were conducted on Nasdaq Stockholm by Danske Bank on behalf of Essity. Following the above purchases, Essity’s holding of treasury shares amounted on July 19, 2024, to 1,296,000 Class B shares. The total number of shares in Essity amounted on the date of this press release to 702,342,489, of which 60,969,986 Class A shares and 641,372,503 Class B shares.  The full details concerning the completed transactions are appended to this press release.

Catch The Best Norse Atlantic Airways deals in the Early Bird Sale

From today until 29[th] July customers seeking even better deals can take advantage of the Norse Atlantic ‘Early Bird Sale’ and book their autumn and winter travel at unbeatable prices. Return promotional fares from London Gatwick to the US start from: London to New York JFK               £299 London to Los Angeles                 £319 London to Miami                           £319 London to Orlando                        £319 London to Las Vegas                     £299 London to Cape Town                   £449 One-Way promotional fares from the US to Europe start from: New York JFK to -London              $ 109 New York JFK – Oslo                     $ 139 New York JFK to -Paris                  $ 139 New York JFK to -Berlin                 $ 109 New York JFK to -Rome               $ 139 New York JFK to -Athens              $ 139 Miami-Oslo                                     $ 139 Miami -London                             $ 139 Orlando -London                           $ 139 Los Angeles -London                   $ 149 Los Angeles -Paris                         $ 149 Los Angeles -Oslo                          $ 149 Las Vegas – London                     $ 199 One-Way promotional fares from Paris to the US start from: Paris -New York JFK                     € 139 Paris -Los Angeles                       € 149 One-Way promotional fares from Berlin to the US start from: Berlin -Miami                               € 149 Berlin -New York JFK                 € 149 One-Way promotional fares from Athens to the US start from: Athens – New York JFK           € 139 One-Way promotional fares from Oslo to the US start from: Oslo -Miami                                  kr 1,899 Oslo – New York JFK                   kr 1,899 Oslo – Los angeles                      kr  1,999 Oslo -Bangkok                             kr 1,999 One-Way promotional fares from Rome to the US start from: Rome – New York JFK                 € 139 For more information and to book visit the Norse Atlantic Airways official website at www.flynorse.com “Our Early Bird sale is a great opportunity for customers looking to secure their autumn and winter travel plans at great prices without compromising on quality or comfort,” said Bård Nordhagen, Chief Commercial Officer Norse Atlantic Airways. Norse Atlantic exclusively operates modern Boeing 787 Dreamliner aircraft. The cabin offers passengers a relaxed and comfortable travel experience with each seat including a personal, state-of-the-art entertainment experience. Our Norse Premium cabin offers an industry leading 43” seat pitch and 12” recline, allowing passengers to arrive at their destination feeling refreshed and ready to explore their destination. Norse Atlantic offers two cabin choices: Economy and Norse Premium. Passengers can choose from a simple range of fares, Light, Classic and Flextra, that reflect the way that they want to travel, and which options are important to them. Light fares represent Norse’s value option, while Flextra fares include the maximum baggage allowance, two meal services and increased ticket flexibility. Promotion Details: Offers are valid for sale until 29 July, for travel in Economy between 01 September 2024 and 28 March 2025 and in Premium between 01 September and 31 December 2024, excluding peak travel dates.  Applicable travel dates vary by destination.

ABS and the U.S. Coast Guard Research and Development Center to Collaborate on Cutting-Edge Maritime Technologies

(HOUSTON) American Bureau of Shipping (ABS) and the United States Coast Guard Research and Development Center (USCG-RDC) signed a memorandum of understanding (MOU) that opens the door to collaborative research and development on top-of-mind technologies impacting the maritime industry. ABS and the USCG-RDC each have robust portfolios of maritime innovation projects that will benefit from cooperative efforts in areas of mutual interest. Activity under the MOU can include developing joint research publications, new technology qualifications and information sharing in a variety of research areas including remote and autonomous systems for uncrewed surface and underwater vehicles; advanced data analytics involving artificial intelligence and machine learning for maritime assets; cybersecurity for vessels, ports and transportation infrastructure; analysis of changing risks associated with the marine transportation system; and impacts of energy transition and alternative fuels in the maritime domain. “Given the rapid pace of change and technological evolution across the maritime industry, it is critical to share best practices, advancements and developments with trusted stakeholders and partners. Signing this MOU formalizes our collaboration with the U.S. Coast Guard Research and Development Center and brings ABS’ global perspective and a joint framework to further maritime innovation on a range of technical and safety topics,” said Bruce Baffer, ABS Senior Vice President for Global Government. “The MOU with ABS marks another milestone for the U.S. Coast Guard Research and Development Center in our expanded partnership engagement effort. ABS' exceptional reputation as an internationally recognized maritime class society is well earned. Their expertise and the research they have and will be conducting will mesh well with research efforts within the RDC. This MOU will expand the USCG RDC’s ability to support the Coast Guard at the strategic, operational, and tactical level. We eagerly look forward to future joint collaborations,” said Captain Michael P. Chien, Commanding Officer of the Research & Development Center for the United States Coast Guard. The two organizations have a long history of collaboration and partnership with a shared focus on maritime safety, security, and protecting the environment. Photo Caption: Captain Michael P. Chien, Commanding Officer of the Research & Development Center for the United States Coast Guard, and Bruce Baffer, ABS Senior Vice President for Global Government, met virtually to review and sign the new MOU.

Nokian Tyres plc: Managers' transactions – Pölönen

Nokian Tyres plc Managers’ transactions July 22, 2024, at 2:25p.m. EEST____________________________________________ Person subject to the notification requirement Name: Jouko Pölönen Position: Member of the Board/Deputy member Issuer: Nokian Renkaat Oyj LEI: 743700YQIO8Y4L4WKR40 Notification type: INITIAL NOTIFICATION Reference number: 70489/4/6 ____________________________________________ Transaction date: 2024-07-22 Venue: CEUX Instrument type: SHARE ISIN: FI0009005318 Nature of transaction: ACQUISITION Transaction details (1): Volume: 152 Unit price: 7.86 EUR (2): Volume: 201 Unit price: 7.85 EUR Aggregated transactions (2): Volume: 353 Volume weighted average price: 7.85431 EUR ____________________________________________ Transaction date: 2024-07-22 Venue: AQEU Instrument type: SHARE ISIN: FI0009005318 Nature of transaction: ACQUISITION Transaction details (1): Volume: 23 Unit price: 7.85 EUR Aggregated transactions (1): Volume: 23 Volume weighted average price: 7.85 EUR ____________________________________________ Transaction date: 2024-07-22 Venue: TQEX Instrument type: SHARE ISIN: FI0009005318 Nature of transaction: ACQUISITION Transaction details (1): Volume: 177 Unit price: 7.85 EUR Aggregated transactions (1):Volume: 177 Volume weighted average price: 7.85 EUR ____________________________________________ Transaction date: 2024-07-22 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009005318 Nature of transaction: ACQUISITION Transaction details (1): Volume: 4,172 Unit price: 7.86 EUR Aggregated transactions (1): Volume: 4,172 Volume weighted average price: 7.86 EUR ____________________________________________ Transaction date: 2024-07-22 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009005318 Nature of transaction: ACQUISITION Transaction details (1): Volume: 275 Unit price: 7.85 EUR Aggregated transactions (1): Volume: 275 Volume weighted average price: 7.85 EUR Further information:Päivi AntolaSVP, Communications, Investor Relations and BrandTel. +358 10 401 7327, IR@nokiantyres.com Nokian Tyres develops and manufactures premium tires for people who value safety, sustainability and predictability. Inspired by our Scandinavian heritage, we craft innovative products for passenger cars, trucks and heavy machinery that give you peace of mind in all driving conditions. Our Vianor chain provides tire and car services. In 2023, our net sales totaled EUR 1,174 million. At the end of 2023 we employed over 3,400 professionals. Nokian Tyres is listed on Nasdaq Helsinki. Further information: www.nokiantyres.com 

Fortaco sells its marine and energy business in Kalajoki and Sepänkylä in Finland

Fortaco Group Holdco Plc’s subsidiary, Fortaco Oy (“Fortaco”) has signed an agreement to sell its marine and energy business in Kalajoki and Sepänkylä in Finland to Componenta, an international technology company and a Finnish contract manufacturer of metal components. The purchase price is some EUR 2.8 million. The transaction is part of the strategic evaluation of Fortaco’s marine, energy, and heavy project businesses announced on 28 February 2024. Fortaco’s Business Site Kalajoki & Sepänkylä manufacturers steel fabricated components for marine and energy industries. The original company was founded in 1974 by Rauma-Repola to manufacture components for ship building and marine industry. The business was acquired by Fortaco in 2012. In 2023, the net sales of Business Site Kalajoki & Sepänkylä were some EUR 9.6 million and EBITDA some EUR -1.6 million. In January–June 2024, the net sales of Business Site were some EUR 7.0 million and EBITDA some EUR 25 thousand. The Business Site employs in total some 60 people. All personnel will be transferred to Componenta with their existing terms and conditions. More information about the financial performance of Business Site Kalajoki & Sepänkylä can be found in Componenta’s stock exchange release about the transaction. “The selling of our operations in Kalajoki and Sepänkylä is a next step in the strategic evaluation of our marine, energy, and heavy project businesses. The new owner, Componenta, has over 200 years of expertise in metal industry. I’m confident they are a good new home for our people in Kalajoki and Sepänkylä. I want to thank our customers for their trust and cooperation throughout these years, and the Kalajoki & Sepänkylä teams for their excellent performance. I wish the team a successful and continuous journey to Make Tomorrow Safer and Better,” says Lars Hellberg, President & CEO of Fortaco. "We are very pleased to have the comprehensive know-how of Kalajoki and Sepänkylä as well as the technology that nicely expands our current production portfolio as a part of Componenta. The acquired entity perfectly complements Componenta's total offering also as a contract manufacturer of heavier production. As a result of the transaction, Componenta will clearly strengthen its position in the direction of its strategic customers in the selected industries. With this business acquisition, the expansion of our service offering will enable, for its part, a significant increase in cross-selling and an even better and more comprehensive service capability for our strategic customers”, says Sami Sivuranta, CEO of Componenta. “Fortaco Business Site Kalajoki & Sepänkylä is well-known for its high quality, delivery accuracy, and uncompromising professionalism. Our modern welding factory in Kalajoki has a lot of potential for volume increase. I am very satisfied that Componenta will become our new owner. The know-how and excellent location of Componenta’s machining workshops enable the expansion of our business to other sectors as well. This transaction seems to me a win-win solution for both companies,” says Jyri Paavola, General Manager of Business Site Kalajoki & Sepänkylä. The transaction is subject to some customary closing conditions, and companies aim to close it on 1 October 2024. The strategic evaluation concerning Fortaco’s marine and energy business in Serbia is still ongoing. Fortaco expects to complete the evaluation during 2024. Further InformationLars Hellberg, President & CEO+358 40 572 9488lars.hellberg@fortacogroup.com Fortaco GroupFortaco is the leading strategic partner in Europe to the heavy off-highway equipment and marine industries, providing premium offerings, like technology & zero emission solutions, vehicle cabins, steel fabrications, and assemblies. Fortaco Group has operations in multiple European and Asian business sites and technology hubs, which support our global customers.www.fortacogroup.com. ComponentaComponenta Corporation is an international technology company and Finland’s leading contract manufacturer in the machine building industry. Sustainability and customer needs are at the core of the company’s broad technology portfolio. Componenta Corporation manufactures components for its customers, which are global manufacturers of machinery and equipment. The company’s stock is listed on Nasdaq Helsinki. www.componenta.com

Dolphin Drilling AS – Update on Blackford Dolphin

(Oslo, 22 July 2024) Dolphin Drilling AS (Dolphin Drilling, OSE: DDRIL) refers to the 1 July 2024 announcement regarding the submission of a bank guarantee in relation to the on going arbitration process with GHL. Dolphin Drilling today confirms the previously submitted USD 20 million bank guarantee has been discharged and is no longer in effect. The Blackford Dolphin is confirmed to have left Nigerian waters on 1 July 2024 and continues on transit for her next contract in India. Dolphin Drilling will continue to update the market on material developments as they occur. ENDS For further information, please contact: Ingolf Gillesdal, Corporate Finance and Investor Relations, tel: +47 920 45 320 Stephen Cox, CFO, tel: +44 7800 612 130 About Dolphin Drilling | www.dolphindrilling.com Dolphin Drilling is a leading harsh environment drilling contractor for the offshore oil and gas industry. Dolphin Drilling owns a fleet of three high-technical standard 4th and 5th generation enhanced Aker H3 and H4 units, Borgland Dolphin, Blackford Dolphin, and Paul B. Loyd, Jr., operated by an experienced team with a strong operational track record. The company has offshore and onshore offices and operations in Norway, Scotland, and Brazil. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Ingolf Gillesdal, VP Corporate Finance and Investor Relations Dolphin Drilling AS on 22 July 2024 at 14:45 CET on behalf of the company.

Nordea Bank Abp flagging notification: Norges Bank’s shareholding crosses threshold of five percent

Nordea Bank AbpStock exchange release – Major shareholder announcements22 July 2024 at 17.30 EET Norges Bank’s (The Central Bank of Norway) shareholding of Nordea Bank Abp’s shares and voting rights has crossed the threshold of five percent, according to a notification Nordea received on 19 July 2024 under Chapter 9, Section 10 of the Securities Markets Act (SMA). The threshold was crossed on 18 July 2024. The total number of shares and voting rights in Nordea Bank Abp is 3,505,587,395. The total position of Norges Bank according to the notification: +----------------+--------------------+---------------------+-------------+| | % of shares and | % of shares and |Total of both|| |voting rights (total| voting rights |in % (A + B) || | of A) | through financial | || | |instruments (total of| || | | B) | |+----------------+--------------------+---------------------+-------------+|Resulting |5.01% |0.03% |5.03% ||situation on the| | | ||date on | | | ||which threshold | | | ||was crossed or | | | ||reached | | | |+----------------+--------------------+---------------------+-------------+|Position of |N/A |N/A |N/A ||previous | | | ||notification | | | ||(if applicable) | | | |+----------------+--------------------+---------------------+-------------+ Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rights +------------+-----------+----------------------+---------+-------------------+| Class/type |Number of shares and voting rights|% of shares and voting rights|| of shares | | || ISIN code | | || (if | | || possible) | | |+------------+-----------+----------------------+---------+-------------------+| |Direct |Indirect |Direct |Indirect || |(SMA 9:5) |(SMA 9:6 and 9:7) |(SMA 9:5)|(SMA 9:6 and 9:7) |+------------+-----------+----------------------+---------+-------------------+|FI4000297767|175,515,660| |5.01% | |+------------+-----------+----------------------+---------+-------------------+|SUBTOTAL A |175,515,660 |5.01% |+------------+-----------+----------------------+---------+-------------------+ B: Financial instruments according to SMA 9:6a +--------------+----------+-----------+----------+----------+---------------+| Type of |Expiration|Exercise/Co| Physical |Number of |% of shares and|| financial | date | nversion | or cash |shares and| voting rights || instrument | | period |settlement| voting | || | | | | rights | |+--------------+----------+-----------+----------+----------+---------------+|Shares on loan|N/A |At any |Cash |949,800 | ||(right to | |time | | | ||recall) | | | | | |+--------------+----------+-----------+----------+----------+---------------+| | | |SUBTOTAL B|949,800 |0.03% |+--------------+----------+-----------+----------+----------+---------------+ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. For further information: Ilkka Ottoila, Head of Investor Relations, +358 9 5300 7058Media inquiries, +358 10416 8023 or press@nordea.com The information provided in this stock exchange release was submitted for publication, through the agency of the contacts set out above, at 17.30 EET on 22 July 2024. We are a universal bank with a 200-year history of supporting and growing the Nordic economies – enabling dreams and aspirations for a greater good. Every day, we work to support our customers’ financial development, delivering best-in-class omnichannel customer experiences and driving sustainable change. The Nordea share is listed on the Nasdaq Helsinki, Nasdaq Copenhagen and Nasdaq Stockholm exchanges. Read more about us at nordea.com.

ABS Issues AIP for Novel Offshore Wind Installation Technology from CLS Wind

(HOUSTON) ABS awarded approval in principle (AIP) to CLS Wind for its innovative wind turbine assembly system. The patented elevator style assembly system promises easier, safer and faster wind turbine and nacelle installation and maintenance, without the use of large cranes and heavy-lift barges or vessels. ABS completed design reviews based on class and statutory requirements. “This is an exciting milestone for CLS Wind and domestic renewable energy production. ABS is committed to supporting the U.S. offshore wind industry, helping our partners and clients throughout the full life cycle of their projects,” said Rob Langford, ABS Vice President, Global Offshore Renewables. “As an American company working on a unique solution to solve some of the pressing issues that are affecting the offshore wind market, we appreciate ABS’ support for the AIP process and visit to our industrial demo unit. In the renewable energy market, it is important that we work together to find solutions that lower the cost and increase installation efficiencies to support offshore wind energy production, and we are delighted to be working with ABS in these technologies,” said Kent A. Johnson, CEO of CLS Wind. ABS is a trusted partner for offshore wind stakeholders by delivering advisory and technical review solutions that help minimize risk and enhance safety for offshore wind projects. For more information on ABS Global Offshore Renewables services, click here . Photo Caption 1: ABS attended a demonstration of a 1:5 scale prototype of the elevator style wind turbine assembly system from CLS Wind. (L to R) Jason Folsom, ABS Director, Business Development; Andres Garcia, CLS Wind Chief Technology Officer; Rob Langford, ABS Vice President, Global Offshore Renewables; Kent Johnson, CLS Wind CEO; Lars Samuelsson, ABS Manager, Global Offshore Renewables. Photo Caption 2: Rendering of the elevator style wind turbine assembly system from CLS Wind – Courtesy CLS Wind.

Sedana Medical to acquire its main supplier to take control of supply chain and reduce cost of goods

“I am excited about acquiring Innovatif Cekal as this transaction is a perfect fit with our strategy. After streamlining our non-customer-facing functions and implementing a vigorous shift of resources towards the frontline, this strategic move represents a logical next step towards building a long-term profitable company.”, said Johannes Doll, President and CEO of Sedana Medical. Innovatif Cekal (IC) is a manufacturer of medical devices based in Klang near Kuala Lumpur, Malaysia. IC has two customers: Sedana Medical (SM) and another Nordic medical technology company. IC produces SM’s main product Sedaconda ACD and certain accessories such as adapters, and SM has accounted for the majority of IC’s sales in recent years. On average during the period 2019-2023, IC reported annual sales of 10.9 million Malaysian Ringgit (approx. 24.7 MSEK based on today’s exchange rate). Rationale for the acquisition The acquisition of IC is a good strategic fit and is expected to be financially accretive for SM. · Improved control of the supply chain: By vertically integrating IC, SM assumes direct control over a larger share of its cost of goods sold, which reduces the risks related to future cost fluctuations and supply disruptions. The acquisition enables improved control of the future scale-up of production capacity to meet SM’s growth plans. In addition, it allows for potential cost reduction initiatives to be implemented over time. · Improved profitability: The acquisition is expected to improve SM’s margin on its main device and drive value creation, in particular over time as sales are expected to grow further. Integrating IC is estimated to add approximately 2 percentage points to SM’s EBITDA margin when the inventory at the time of closing has been depleted. Consequently, SM expects value creation from the acquisition well in excess of the purchase price. Purchase price and valuation metrics SM will purchase all shares in IC for 34 MSEK on a cash and debt free basis. 75% of the purchase price is paid upon closing of the transaction, and the remaining 25% is to be paid 2 years after closing. Based on IC’s financial result for the year 2023, the purchase price corresponds to an EBITDA multiple of 4.3x and a P/E multiple of 5.7x. There is no long-term debt in IC. Financing and effects on cash flow SM will finance the transaction with existing cash. At the end of Q1 2024, SM had a cash balance of 361 MSEK. The acquisition is expected to have a net positive impact on SM’s cash flow from operations from 2025 and a net positive impact on its cash balance from 2028. Importantly, SM remains financed to deliver on the company’s strategic plan also after the acquisition, including obtaining market approval in the USA. Timeplan Closing of the transaction is expected to take place during the second half of 2024. For additional information, please contact:Johannes Doll, CEO, +46 (0)76 303 66 66Johan Spetz, CFO, +46 (0)730 36 37 89ir@sedanamedical.com This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on July 22, 2024 at 20:00 (CEST). About Sedana Medical Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors. Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.

Vestas secures 136 MW repowering order in the USA

News release fromVestas-American Wind Technology Portland, 22 July 2024Vestas has received a 136 MW order to repower an undisclosed wind project in the USA. The order consists of 62 V120-2.2 MW™ wind turbines. The order includes supply, delivery, and commissioning of the turbines, as well as a multi-year Operational Support Agreement, designed to ensure optimised performance of the asset. Turbine delivery begins in the third quarter of 2025 with commissioning scheduled for the fourth quarter of 2025. For more information, please contact: Matt CopemanLead Specialist, Marketing & CommunicationsMail: mtcoe@vestas.comTel: +1 (503) 475-6428 About Vestas Vestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service onshore and offshore wind turbines across the globe, and with more than 179 GW of wind turbines in 88 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled more than 149 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 30,000 employees are bringing the world sustainable energy solutions to power a bright future.  For updated Vestas photographs and videos, please visit our media images page on:https://www.vestas.com/en/media/images.  We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels: · www.twitter.com/vestas  · www.linkedin.com/company/vestas · www.facebook.com/vestas  · www.instagram.com/vestas   · www.youtube.com/vestas

Embla Medical hf: Interim Report Q2 2024

Announcement no. 11/2024 Interim report Q2 2024 23 July 2024 Sveinn Sölvason, President and CEO, comments: “We delivered our highest ever quarterly sales in Q2 2024 with sales amounting to USD 217 million. Organic growth was 6% for Q2 and local currency growth 9% with continued strong momentum in EMEA, driven by a strong performance in Prosthetics & Neuro Orthotics and Patient Care. In our Bracing & Supports business growth was more modest for the quarter. Our EBITDA margin came in strong for the quarter at 22%, supported by the cost reduction initiatives implemented in manufacturing in addition to a contribution from positive product mix and scalability. Toward the end of the quarter we introduced two new bionic knee products, NAVii[®] by Össur and Icon[®] by College Park, and we are very excited about their potential in improving people’s mobility. Medicare in the US has finalized a proposal which will create a pathway for K2 amputees, which account for a significant part of the amputee population, to utilize more functional knee and foot solutions than they have historically had access to. This is great news, and we look forward to helping these individuals become more active and able in their daily activities. We are executing well on our Growth’27 strategy. We are narrowing our full-year guidance to 6-8% organic sales growth and ~20% EBITDA margin before special items, as we expect continued good progress for the remainder of the year.” Highlights Q2 2024 · Sales amounted to USD 217 million and organic growth was 6%, compared to a strong comparison of 11% in Q2 2023. · Prosthetics & Neuro Orthotics sales grew by 6% organically, Patient Care grew by 9%, and Bracing & Supports grew by 2%. Growth is attributed to continued strong performance in EMEA. APAC also delivered strong growth while sales in Americas were soft. · Gross profit margin was 64%, compared to 63% in Q2 2023. The increase in gross profit can partly be ascribed to cost reduction initiatives in manufacturing implemented during Q1 as well as positive product mix and scalability.  · EBITDA was USD 47 million and EBITDA margin was 22% for Q2, compared to 19% for the same period last year. Increasing gross profit margin and cost control contributed to increased profitability despite slight negative currency effect. · Net profit amounted to USD 20 million and net profit margin was 9% of sales, compared to 8% of sales in Q2 2023. · Free cash flow amounted to USD 18 million or 8% of sales, compared to 5% of sales in Q2 2023. Free cash flow was strong with solid operating results and increasing profitability. · NIBD/EBITDA was 3.1x at the end of Q2 2024 approaching the high-end of our target ratio for share buybacks at 2.0-3.0x. Other highlights · Medicare in the US has finalized a proposal that grants active K2 patients access to prosthetic knees and feet previously restricted to K3-K4 patients. The finalized policy will take effect on 1 September 2024. · Launch of new bionic knee solutions for high active amputees during Q2 2024. Icon[®], a new microprocessor-based knee solution launched by College Park featuring responsive sensors and NAVii[®] by Össur, a fully waterproof bionic knee featuring a powerful actuator provided to support consistency for stair and ramp descent. · On 16 July 2024, Embla Medical announced its intention to unite its network of Patient Care facilities under a new common brand identity, called ForMotion[TM]. ForMotion will be introduced sequentially, beginning in select regions in the US 2024 outlook · The guidance for the full-year 2024 has been narrowed to 6-8% organic growth (previously 5-8%) and EBITDA margin before special items is narrowed to ~20% (previously 19-20%).  Conference call details Embla Medical will host a conference call on 23 July 2024 at 9:00 CET / 7:00 GMT / 3:00 ET. A conference call webcast can be accessed here: Embla Conference Call Webcast . To actively participate in the Q&A session of the call please click on this link: Registration form for Conference Call Q&A . Embla Medical IR materials and  press releases Link to our latest IR materials and Corporate Presentation http://www.emblamedical.com/investors Here you can also sign-up to receive Embla Medical press releases Further information Klaus Sindahl, Head of Investor Relations, KSindahl@emblamedical.com, +45 5363 0134 About Embla Medical Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in Reykjavik in 1971 with the mission to improve people's mobility. Embla Medical is home to several brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park Industries, creators of custom-built prosthetic solutions. Embla Medical also provides patients with world-class care through a global network of Orthotic and Prosthetic (O&P) facilities. Embla Medical is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women’s Empowerment Principles, and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has more than 4,000 employees. www.emblamedical.com

Kesko half-year financial report 1.1.-30.6.2024: Good performance in a weak market

FINANCIAL PERFORMANCE IN BRIEF: 4-6/2024 · Group net sales in April-June totalled €3,093.4 million (€3,104.7 million); reported net sales were down by 0.4%, and comparable net sales by 4.1% · Comparable operating profit totalled €178.3 million (€207.6 million) · Operating profit totalled €159.2 million (€206.3 million) · Cash flow from operating activities totalled €309.0 million (€285.2 million) · Comparable earnings per share €0.30 (€0.38); reported earnings per share €0.26 (€0.38) 1-6/2024 · Group net sales in January-June totalled €5,852.9 million (€5,932.7 million); reported net sales were down by 1.3%, and comparable net sales by 4.8% · Comparable operating profit totalled €277.7 million (€333.5 million) · Operating profit totalled €256.4 million (€328.9 million) · Cash flow from operating activities totalled €421.6 million (€312.2 million) · Comparable earnings per share €0.46 (€0.60); reported earnings per share €0.42 (€0.59) KEY PERFORMANCE INDICATORS 4-6/2024 4-6/2023 1-6/2024 1-6/2023 1-12/2023Net sales, € million 3,093.4 3,104.7 5,852.9 5,932.7 11,783.8Operating profit, 178.3 207.6 277.7 333.5 712.0comparable, € millionOperating margin, 5.8 6.7 4.7 5.6 6.0comparable, %Operating profit, € 159.2 206.3 256.4 328.9 695.4millionProfit before tax, 150.4 188.9 227.6 296.9 630.4comparable, € millionProfit before tax, € 131.1 187.6 205.9 292.3 613.5millionCash flow from 309.0 285.2 421.6 312.2 1,049.5operating activities, €millionCapital expenditure, € 128.4 161.2 457.4 393.0 678.9million Earnings per share, €, 0.26 0.38 0.42 0.59 1.25basic and dilutedEarnings per share, 0.30 0.38 0.46 0.60 1.28comparable, €, basic 4-6/2 4-6/2023 1-6/2024 1-6/2023 1-12/2023 024Return on capital employed, 11.8 15.1 11.8 15.1 13.4comparable, %, rolling 12monthsReturn on equity, comparable, 18.3 23.3 18.3 23.3 18.5%, rolling 12 months In this half-year financial report, the comparable change % in net sales has been calculated in local currencies and excluding the impact of acquisitions and divestments completed in 2023 and 2024. The comparable operating profit has been calculated by deducting items affecting comparability from the reported operating profit. OUTLOOK AND GUIDANCE FOR 2024 (SPECIFIED) Kesko Group’s profit guidance is given for the year 2024, in comparison with the year 2023. Kesko’s operating environment is estimated to remain challenging in 2024.Kesko’s net sales and operating profit are estimated to remain at a good level in 2024 despite the challenges in the company’s operating environment. Kesko estimates that its comparable operating profit in 2024 will amount to €620–680 million. Previously, the comparable operating profit was estimated to amount to €620-700 million. The profit guidance specification is based on development in the first year-half and on updated estimates regarding development in building and technical trade and car trade in latter half of the year. The profit guidance is based on an estimate of a relatively short recession in Kesko’s operating countries. Key uncertainties impacting Kesko’s outlook are developments in inflation and interest rate levels, and geopolitical crises and tensions. In grocery trade, B2C trade and the foodservice market are expected to remain stable despite tightened price competition, and inflation is expected to slow down in 2024. Profitability in grocery trade is estimated to remain good also in 2024. In building and technical trade, the market is expected to continue to decline in 2024. The economic cycle will have the biggest impact on new residential building, while the decline in other building construction, renovation building and infrastructure construction is expected to be smaller. The cycle is expected to turn in 2025. Profitability in building and technical trade is estimated to fall short of the 2023 level, but to still remain at a reasonably good level in 2024. In car trade, new car sales are expected to fall short of the 2023 level. Sales of used cars and services are expected to grow. Profitability in car trade is estimated to still remain good in 2024, but to fall short of the 2023 level. PRESIDENT AND CEO JORMA RAUHALA: The second quarter of the year came in line with expectations, and Kesko again managed a good performance in a challenging market. Our net sales totalled €3,093.4 million, representing a decrease of 0.4% year-on-year, or 4.1% in comparable terms. Our comparable operating profit totalled €178.3 million. The cash flow from operating activities was strong at €309.0 million, and our cost-efficiency remained good. Net sales for the grocery trade division totalled €1,596.5 million, representing a decrease of 1.7% year-on-year, while the comparable operating profit stood at €114.5 million. K Group grocery sales were down by 1.1%. Online grocery sales grew by 13.5%, driven especially by express deliveries. Net sales for the foodservice business decreased by 1.3%, but still exceeded market growth. Price inflation in groceries has clearly slowed down, and stood at 0.1%. Our customer flows have continued to grow thanks to campaigns, while price is an important consideration for customers. In June, legislative changes enabled the sales of beverages with an alcohol content of at maximum 8% in grocery stores: we introduced new products in a responsible manner, and have seen that wines are typically acquired alongside food. In the building and technical trade division, profitability weakened as expected due to the weak construction cycle in the Nordic countries. In Poland and the Baltic countries, the cycle has turned, leading to an upturn in Onninen’s sales in those markets. The division’s net sales totalled €1,203.7 million, and were up thanks to the Davidsen acquisition, while the comparable operating profit totalled €56.1 million. The sales and profit of solar power products in particular fell short of the levels of the comparison period, which impacted Onninen’s relative performance. Inventories are now at a healthier level in both building and home improvement trade and technical trade. The market is showing signs of picking up in all our operating countries, even though the cycle continues to be weak. In the car trade division, net sales and profit decreased in the second quarter as expected. The market demand for new cars was muted, while the market for used cars grew slightly. The division recorded net sales of €298.7 million and a comparable operating profit of €14.9 million. Although new car sales were down, customer demand for new models was at a good level. Growth in used car sales outpaced the market notably, and growth in service sales also continued strong. In May, we announced that we would be acquiring the operations of Autotalo Lohja to strategically strengthen our car dealership network in Southern Finland. In June, Kesko published a strategy update. The main pillars of the strategy remain intact, while each division’s competitive advantages and objectives have been refined. Kesko’s growth strategy continues to centre around profitable growth in three selected divisions, namely grocery trade, building and technical trade, and car trade. We seek sales growth, improved customer experience, and profitability and efficiency in all businesses, with the help of e.g. digital services and artificial intelligence. Kesko’s financial targets remain unchanged. Kesko’s net sales and operating profit are estimated to remain at a good level in 2024 despite the challenges in our operating environment. We are specifying our profit guidance, and now estimate that the comparable operating profit in 2024 will amount to €620–680 million. FURTHER INFORMATION, AUDIOCONFERENCE AND WEBCAST Further information is available from Anu Hämäläinen, Executive Vice President, Chief Financial Officer, tel.+358 105 323 713, Hanna Jaakkola, Vice President, Investor Relations, tel. +358 105 323 540, and Eva Kaukinen, Vice President, Group Controller, tel. +358 105 322 338. An English-language audio conference on the results briefing will be held on 23 July 2024 at 9.00 am (EEST). The audio conference login is available on Kesko's website at www.kesko.fi. A Finnish-language webcast of the interim report briefing can be viewed at 11.30 am (EEST) at www.kesko.fi. Kesko's interim report for January-September 2024 will be published on 30 October 2024. In addition, Kesko Group's sales figures are published monthly. News releases and other company information are available on Kesko's website at www.kesko.fi. This is a summary of Kesko Corporation’s January-June 2024 half-year financial report. The complete report is attached to this release and also available at www.kesko.fi/en/investor/ 

Vår Energi reports strong operational and financial performance in the second quarter and first half of 2024

Sandnes, Norway, 23 July 2024: Vår Energi ASA (OSE: VAR) reports strong operational performance and financial results in line or better than guidance. The Company is on track to deliver on the 2025 growth target and unlock future value.  Strong operational performance · Production of 293 kboepd in first half in the upper end of guidance range for the period · Good production efficiency on operated fields · Maintenance program successfully executed in the quarter Good financial performance · Total income in the quarter was USD 1 940 million, a decrease of USD 16 million from last quarter · Achieved realised gas price of USD 70 per boe, USD 10 per boe above spot price · Unit production cost below guided range with USD 12.4 per boe in the quarter · Solid cash flow from operations of USD 711 million · Long term gas contracts with key customers extended for an additional 12 years Progressing towards ~400 kboepd by end-2025 and unlocking future value · Balder X target fourth quarter 2024 start-up remains with sail-away decision in August · Recent start-ups of Eldfisk North and Kristin South projects.  Johan Castberg firmly on track for fourth quarter first oil · Portfolio optimisation resulting in sale of Norne and Bøyla assets with expected completion by year-end · Close-to-infrastructure exploration success in the Balder and Gjøa areas Continued attractive and predictable dividends · Dividend of USD 270 million (NOK 1.184 per share) for the second quarter will be distributed 6 August · Dividend guidance of USD 270 million for the third quarter of 2024, with a dividend distribution of approximately 30% of CFFO after tax for the full year · Solid balance sheet with leverage ratio of 0.8x “We are pleased to see another quarter of delivery, with strong operational and financial results. Production in the first half of the year averaged 293 thousand barrels of oil equivalent per day, in the upper end of the guided range for the period. While high realised gas prices above spot were maintained, the full year operating costs and capital spend will be in the lower end of the guided range. As a result, we continue to provide attractive and predictable shareholder returns. Vår Energi remains on track to increase production to around 400 kboepd by end 2025, as one of the world’s fastest growing E&P’s. We continue to make good progress on delivering on our portfolio of development projects with the recent start-ups of Eldfisk North and Kristin South. The Johan Castberg FPSO has left the yard and is firmly on track to start-up in the fourth quarter. At Balder X, the FPSO is nearing completion and modifications implemented to improve the flexibility to install the vessel on the field, enabling a decision on installation before the winter weather period to be made at the end of August. Our exploration program continues to add value with the commercial Cerisa discovery in the Gjøa area. Added to three recent discoveries, the area holds total gross recoverable resources to be developed of up to 110 million barrels of oil equivalent with potential to be tied back to the partly electrified Gjøa asset, ensuring low carbon emissions, and high margin barrels. In the quarter, two strategically important long-term gas sales agreements were extended with Eni and VNG, for the supply of up to an additional 10 billion standard cubic meters of natural gas until mid-2036. Portfolio optimisation continued, with sales announced for the non-core Norne and Bøyla assets. We maintain our ESG leading position, with top quartile carbon emissions intensity performance, while being awarded as operator the Iroko CO\2\ storage license in the North Sea.” says Nick Walker, the CEO of Vår Energi. Webcast and conference call The company will today hold a webcast and conference call followed by Q&A at 10:00 CET hosted by CEO Nick Walker and CFO Stefano Pujatti. You can follow the webcast with supporting slides, available on:https://events.webcast.no/vaar-energi/quarterly-reports/flfrQrJ8fHjBty4IRq6Y The report, presentation and webcast will be available at www.varenergi.no.   About Vår Energi Vår Energi is a leading independent upstream oil and gas company on the Norwegian continental shelf (NCS). We are committed to deliver a better future through responsible value driven growth based on over 50 years of NCS operations, a robust and diversified asset portfolio with ongoing development projects, and a strong exploration track record. Our ambition is to be the safest operator on the NCS, the partner of choice, an ESG leader with a tangible plan to reduce emissions from our operations by more than 50% within 2030. Vår Energi has around 1400 employees and equity stakes in 47 fields. We have our headquarters outside Stavanger, Norway, with offices in Oslo, Hammerfest and Florø. To learn more, please visit varenergi.no Contact Investor relations Ida Marie Fjellheim, Head of Investor Relations +47 90509291 ida.fjellheim@varenergi.no Media relations Andreas Wulff, VP Public Relations +47 92616759 andreas.wulff@varenergi.no This announcement may include projections and other “forward-looking” statements within the meaning of applicable securities laws. Any such projections or statements reflect the current views of Vår Energi AS (“Var Energi”) about further events and financial performance. No assurances can be given that such events or performance will occur as projected and actual results may differ materially from these projections. Var Energi undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this announcement. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange release was published by Ida Fjellheim, Head of Investor Relations at Vår Energi ASA, on 23 July 2024 at 07:00 CET.

Alfa Laval AB (publ) Interim report April 1 – June 30, 2024

Summary Second quarter Order intake increased by 4 percent* to SEK 18,916 (18,405) million.Net sales increased by 11 percent* to SEK 17,530 (15,880) million. Adjusted EBITA**: SEK 2,932 (2,378) million.Adjusted EBITA margin**: 16.7 (15.0) percent.Result after financial items: SEK 2,390 (2,003) million.Net income: SEK 1,696 (1,515) million.  Earnings per share: SEK 4.08 (3.63).Cash flow from operating activities: SEK 2,633 (1,342) million. First six months Order intake increased by 2 percent* to SEK 37,189 (36,790) million.Net sales increased by 9 percent* to SEK 32,435 (29,991) million. Adjusted EBITA**: SEK 5,367 (4,765) million.Adjusted EBITA margin**: 16.5 (15.9) percent.Result after financial items: SEK 4,639 (4,051) million.Net income: SEK 3,388 (3,030) million.     Earnings per share: SEK 8.15 (7.27).Cash flow from operating activities: SEK 4,383 (2,346) million.Return on capital employed (%) **: 22.1 (18.6).Net debt to EBITDA, times **: 0.83 (1.49). * Excluding currency effects. ** Alternative performance measures. Outlook for the third quarter“We expect demand in the third quarter to be on a somewhat lower level compared to the second quarter.”Earlier published outlook (April 25, 2024): “We expect demand in the second quarter to be somewhat higher than in the first quarter.” The Q2 2024 report has not been subject to review by the company’s auditors.This information is information that Alfa Laval AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at CEST 07.30 on July 23, 2024. For more information, please contact:Johan Lundin, Head of Investor RelationsPhone: +46 46 36 65 10,Mobile: +46 730 46 30 90,E-mail: : johan.lundin@alfalaval.com Alfa Laval AB (publ)PO Box 73SE-221 00 LundSwedenCorporate registration number: 556587-8054 Visiting address:Rudeboksvägen 1Phone: + 46 46 36 65 00Website: www.alfalaval.com

Akobo Minerals reports successful commissioning of Segele gold processing plant

OSLO, 23 July 2024:Akobo Minerals AB  (Euronext and Frankfurt: AKOBO) (OTCQX:AKOBF). Akobo Minerals, a leading gold exploration and mining company based in Scandinavia with operations in Ethiopia, is pleased to announce that the Segele processing plant is now operational. This milestone represents a significant advancement for the company’s operations in Ethiopia. [Et bilde som inneholder himmel, utendørs, vann, svømmebasseng Automatisk generert beskrivelse] The commissioning process has successfully activated the majority of the Segele plant, allowing Akobo Minerals to process a substantial amount of ore efficiently and safely. Last week, the first phase of commissioning was completed, with Gekko Systems and Solo Resources overseeing the setup of the milling, grinding, Falcon concentrator, InLine Leach Reactor, and furnace in the gold room. The final phase, the activation of the InLine Leach Reactor (ILR), was completed by Gekko Systems. The company anticipates an extraction efficiency of 76% from the concentrator and ILR system. Jørgen Evjen, CEO of Akobo Minerals, remarked, “This is a great achievement for our team and a testament to the quality and build of the processing plant. We have received solid feedback and are proud of the strong work from our team. We look forward to processing our first ore and moving forward with the project.” Akobo Minerals appreciates the strong support and interest from the Ethiopian Government in the Segele project. The company recently hosted a delegation, including Deputy Prime Minister Temesgen Tiruneh, Minister of Mines Habtamu Tegegne, and Gambella President Omod Ojulu, who were on-site to oversee the first run of operations. In line with a phased approach to optimize both operational efficiency and cost-effectiveness, the commissioning of the CIL (Carbon in Leach) system will be deferred until production volumes are increased. This strategy ensures that the plant operates in a cost-effective manner while allowing the team time to familiarize themselves with the initial phase of the plant. Tailing from the current ore will be stored and reprocessed once the CIL tanks are operational. The plant is designed with the capability to produce 4,000 ounces of gold per month, with an expected recovery rate of 96%. Additionally, its modular design allows for future upgrades as the Segele mine and adjacent targets are developed, ensuring the plant remains adaptable to evolving operational needs. Currently, the company is blasting and mining ore from the Western winze and expects to process low-grade ore through the plant in the coming weeks. For more information Jørgen Evjen, CEO, Akobo Minerals Mob: (+47) 92 80 40 14 Mail: jorgen@akobominerals.com LinkedIn: www.linkedin.com/company/akobominerals Web: www.akobominerals.com About Akobo Minerals Akobo Minerals is a Scandinavian-based gold exploration and boutique mining company, currently holding an exploration license covering 182 km2 and a mining license covering 16 km2 in the Gambela region and Dima Woreda, Ethiopia. The company has established itself as the leading gold exploration company in Ethiopia through more than 14 years of on-the-ground activity, which has now been enhanced further with the development of its Segele mine. Akobo Minerals’ Segele mine has an Inferred and Indicated Mineral Resource of 68,000 ounces, yielding a world-class gold grade of 22.7 g/ton. Still open to depth, the gold mineralised zone continues to expand and will have a positive impact on future resource estimates and the life expectancy of the mine. The exploration license holds numerous promising exploration resource-building prospects in both the vicinity of Segele and in the wider license area. Akobo Minerals has an excellent relationship with local communities all the way up to national authorities and the company places environment and social governance (ESG) at the heart of its activities – as demonstrated by a planned, industry-leading, extended shared value program. Akobo Minerals has built a strong local foothold based on the principles of sound ethics, transparency and communication, and is ready to take on new opportunities and ventures as they arise. The company is uniquely positioned to become a major player in the future development of the very promising Ethiopian mining industry. The company is headquartered in Oslo and is publicly listed on the Euronext Growth Oslo Exchange and the Frankfurt Stock Exchange under the ticker symbol AKOBO. For US investors, Akobo Minerals AB  (OTCQX: AKOBF) is traded on the OTCQX Best Market, adhering to high financial standards, best practice corporate governance, and compliance with U.S. securities laws. Additionally, the company has a professional third-party sponsor introduction, and investors can access current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Akobo Minerals places great emphasis on meeting and exceeding industry standards, fully complying with all aspects of the JORC code, 2012. For detailed information on their adherence to this code, please refer to https://www.jorc.org/. Akobo Minerals' unwavering commitment to ethical practices, community engagement, and environmental responsibility positions them as a formidable force in the evolving landscape of the Ethiopian mining sector.

Long-term treatment data for lecanemab to be presented at AAIC 2024

Eisai presentations of the latest data on lecanemab, will focus on the importance of continued treatment for Alzheimer's disease (AD). Key presentations include three-year efficacy and safety data from Phase 2 and Phase 3 studies, the mechanism of action of lecanemab in targeting toxic soluble aggregated amyloid-beta species (protofibrils), and the importance of maintenance treatment based on neurodegenerative biomarkers in plasma. Featured sessions will delve into the long-term imaging and fluid biomarkers, and the evidence supporting the rationale for continued lecanemab dosing. Presenters such as Dennis Selkoe, M.D., and Charlotte Teunissen, Ph.D., will provide insights into the ongoing benefits of lecanemab treatment, highlighting its potential to slow the progression of AD by clearing amyloid-beta protofibrils. In addition, BioArctic will present a poster of a study highlighting deficiencies in the healthcare system's ability to diagnose and treat Alzheimer's disease in the Nordic countries. The poster will be displayed by Mats Ekelund, Head of Market Access at BioArctic. +----+-------+-----------------+----------------------------------------------+|Date|Time |Presentation |Presenter(s)/Abstract ID || |(EDT) |Title/Poster | || | |Title | |+----+-------+-----------------+----------------------------------------------+|July|2:00 PM|Featured Research|Brian Willis, Ph.D., Arnaud Charil, Ph.D., ||30 |- 3:30 |Session: |Nick Fox, M.D., FRCP, FMedSci, || |PM | | || | |Beyond Amyloid |Charlotte Teunissen, Ph.D. || | |Removal with | || | |Lecanemab | || | |Treatment: Update| || | |on Long-Term | || | |Imaging and Fluid| || | |Biomarkers | || | | | || | |-    Amyloid | || | |Plaque Reduction | || | |as a Biomarker of| || | |Efficacy | || | | | || | |-    Lecanemab | || | |Slows Tau PET | || | |Accumulation | || | | | || | |-    | || | |“Paradoxical” | || | |Cerebral Volume | || | |Changes in Anti | || | |-Amyloid | || | |Immunotherapy | || | |Trials | || | | | || | |-    Long-Term | || | |Effects of | || | |Lecanemab on | || | |Biomarkers of | || | |Neurodegeneration| || | |in Plasma | || | | | || | |-    Panel | || | |discussion and | || | |Q&A | |+----+-------+-----------------+----------------------------------------------+|July|4:15 PM|Perspectives |Dennis Selkoe, M.D., Youfang Cao, Ph.D., ||30 |- 5:45 |Session: |Larisa Reyderman, Ph.D., Christopher van Dyck,|| |PM | |M.D. || | |Does the Current | || | |Evidence Base | || | |Support Lecanemab| || | |Continued Dosing | || | |for Early | || | |Alzheimer’s | || | |Disease? | || | | | || | |-    Does the | || | |Current Evidence | || | |for Lecanemab | || | |Mechanism Support| || | |a Rationale for | || | |Continued | || | |Lecanemab Dosing?| || | | | || | |-    How Does the| || | |Latest Clinical | || | |Pharmacology Data| || | |& Modeling | || | |Support Continued| || | |Lecanemab Dosing?| || | | | || | |-    Neuro | || | |-Dynamic | || | |Quantitative | || | |Systems | || | |Pharmacology | || | |(QSP) Model | || | |Supports | || | |Continued | || | |Lecanemab | || | |Treatment with | || | |Maintenance | || | |Dosing For | || | |Alzheimer’s | || | |Disease | || | | | || | |-    Is there | || | |Evidence for a | || | |Continued Benefit| || | |for Long-Term | || | |Lecanemab | || | |Treatment? A | || | |Benefit/Risk | || | |Update from Long | || | |-Term Efficacy, | || | |Safety and | || | |Biomarker Data | || | | | || | |-    Panel | || | |discussion and | || | |Q&A | |+----+-------+-----------------+----------------------------------------------+|July|2:42 PM|Oral |Kenjiro Ono, M.D. ||30 |– 2:49 |presentation: |Abstract ID #94585 || |PM | | || | |Examining | || | |Lecanemab | || | |-Associated | || | |Amyloid-Beta | || | |Protofibril as a | || | |Proximal | || | |Biomarker of | || | |Neurodegeneration| || | |Unlike Other | || | |Plaque-Associated| || | |Biomarkers | |+----+-------+-----------------+----------------------------------------------+|July|2:49 PM|Oral |Abstract ID #95507 ||30 |– 2:56 |Presentation: | || |PM |Lecanemab, | || | |Amyloid-Induced | || | |Tau Pathology as | || | |Supported CSF | || | |MTBR-tau243 in | || | |Clarity AD | |+----+-------+-----------------+----------------------------------------------+|July| |Poster |Brian Willis, Ph.D, Eisai Abstract ID #89308 ||28 | |presentation: | || | | | || | |Model-Based | || | |Assessment of | || | |Lecanemab | || | |Maintenance | || | |Dosing Regimen | || | |and Potential for| || | |Continued | || | |Suppression of | || | |Amyloid Plaque, | || | |Disease | || | |Progression | |+----+-------+-----------------+----------------------------------------------+|July| |Poster |Mats Ekelund, Ph.D., BioArctic ||30 | |presentation: | || | |Expected | || | |challenges for | || | |memory clinics | || | |introducing | || | |disease modifying| || | |treatments in the| || | |Nordics | |+----+-------+-----------------+----------------------------------------------+ Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer’s disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of lecanemab for Alzheimer’s disease. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with certain regulatory approvals, and sales milestones as well as royalty of 9 percent on global sales. In addition, BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region. --- The information was released for public disclosure, through the agency of the contact persons below, on July 23, 2024, at 08:00 a.m. CET. For further information, please contact:Oskar Bosson, VP Communications and IRE-mail: oskar.bosson@bioarctic.com (oskar.bosson@bioarctic.se)Phone: +46 70 410 71 80Jiang Millington, Director Corporate Communication and Social MediaE-mail: jiang.millington@bioarctic.com (jiang.millington@bioarctic.se)Phone: +46 79 33 99166 About lecanemab (generic name, brand name: Leqembi®)Lecanemab (Leqembi) is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong, and Israel. (See full US prescribing information  including boxed waring.) Lecanemab approvals were based on the large global Phase 3 Clarity AD study. In the Clarity AD study, lecanemab met its primary endpoint and all key secondary endpoints with statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference , and simultaneously published in the New England Journal of Medicine , a peer-reviewed medical journal. Eisai has also submitted applications for approval of lecanemab in 12 other countries and regions, including the European Union (EU). A supplemental Biologics License Application (sBLA) for intravenous maintenance dosing was submitted to the U.S. Food and Drug Administration (FDA) in March 2024. The rolling submission of a Biologics License Application (BLA) for maintenance dosing of a subcutaneous injection formulation, which is being developed to enhance convenience for patients, was initiated in the U.S. under Fast Track status in May 2024. Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the collaboration between BioArctic and EisaiSince 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales. About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

Tietoevry's Interim Report 2/2024: Steady performance in a mixed market

Tietoevry CorporationHALF-YEAR REPORT     23 July 2024, 9.00 a.m. (EEST) · Organic growth of 1% driven by software businesses · Improved profitability of 11% supported by Tietoevry Tech Services · Strong customer wins and order intake – book-to-bill 1.3 · Strategic review of Tietoevry Tech Services progressing – active sales process ongoing The full interim report with tables is available at the end of this release. 4–6/2024 4–6/2023 1–6/2024 1–6/2023Revenue, EUR million 715.0 695.2 1448.9 1439.5     Organic growth1), % 1 3 -1 5     Acquisitions and 2 0 2 0divestments, %     Foreign exchange 0 -8 -1 -7rates, % Total growth, % 3 -6 1 -2Organic growth adjusted -1 4 -1 6for working days4), %Operating profit (EBIT), 47.8 41.2 110.4 109.9EUR millionOperating margin (EBIT), 6.7 5.9 7.6 7.6%Adjusted2) operating 78.3 72.9 167.0 164.7profit (EBITA3)), EURmillionAdjusted2) operating 11.0 10.5 11.5 11.4margin (EBITA3)), %EPS, EUR 0.24 0.21 0.56 0.62Cash flow from operating 68.1 11.5 139.9 115.2activities, EUR millionCapital expenditure, EUR 24.5 18.9 48.7 39.6million Full-year outlook for 2024 unchanged Tietoevry expects its organic1) growth to be in the range of 0–3% (revenue in 2023: EUR 2 851.4 million). The company estimates its full-year adjusted operating margin2) (adjusted EBITA3)) to be 12.0–13.0% (12.6% in 2023). 1) Adjusted for currency effects, acquisitions and divestments 2) Adjustment items include restructuring costs, capital gains/losses, impairment charges and other items affecting comparability 3) Profit before interests, taxes and amortization of acquisition-related intangible assets 4) Company estimate CEO’s comment Comment regarding the interim report by Kimmo Alkio, President and CEO: “We delivered steady second-quarter performance in a mixed market environment. The company returned to growth and improved its profitability to 11%. Our software businesses, Tietoevry Banking and Tietoevry Industry posted healthy growth of 5%. Furthermore, Tietoevry Banking signed significant customer contracts and achieved a record-high order book. Our consulting and managed services businesses declined in a market with weaker demand. We continue our focus on efficiency to remain resilient across all businesses, with the biggest profitability improvement in the second quarter seen in Tietoevry Tech Services. As announced on 1 July, the strategic review of Tietoevry Tech Services is progressing with an active sales process ongoing. As a company, we are in the middle of a multi-year strategic transformation, which we embarked on with our specialization strategy at the beginning of 2022. We are making consistent progress in our ambition of repositioning Tietoevry as a leading software and digital engineering company. During the quarter, we launched a new unified operating model for Tietoevry Create to realize its global scale, competitive offerings and efficiency. The software businesses further expanded their footprint with customer wins, SaaS models and AI-enabled products. As an example, in healthcare we have co-created with our customers AI-augmented diagnosis and treatment solutions for patient-centred care. Our hearts and minds remain with our colleagues and people in Ukraine as the devastating situation in the country continues. We are also proud of the progress in our sustainability agenda - we remain focused on climate action, ethical conduct and social impact as outlined in our Sustainability Pledge launched in March. Tietoevry was recognized as one of Europe’s Climate Leaders 2024 in a listing by the Financial Times and as one of the World’s Most Sustainable Companies of 2024 by Time Magazine - both compiled in partnership with Statista. We also continue to have diversity and inclusion in focus, demonstrated, for example, by our long-term participation in Pride.” Financial performance by segment Revenue, Revenue, Growth, Organic Adjusted Adjusted Adjusted Adjusted % growth, operating operating operating operating EUR EUR % million million profit, profit, margin, % margin, % EUR EUR million million 4–6/2024 4–6/2023 4–6/2024 4–6/2023 4–6/2024 4–6/2023 Tietoevry 213.9 204.8 4 -2 24.3 24.4 11.4 11.9CreateTietoevry 148.2 139.8 6 5 14.7 14.8 9.9 10.6BankingTietoevry 58.6 58.2 1 1 15.3 17.0 26.2 29.1CareTietoevry 67.3 63.8 5 5 10.1 9.4 15.1 14.7IndustryTietoevry 256.1 265.4 -4 -4 19.8 13.1 7.7 4.9TechServicesEliminations -29.2 -37.0 — — -6.0 -5.7 — —andnon-allocatedcostsGroup total 715.0 695.2 3 1 78.3 72.9 11.0 10.5 For further information, please contact: Tomi Hyryläinen, Chief Financial Officer, tel. +358 50 555 0363, tomi.hyrylainen (at) tietoevry.com Tommi Järvenpää, Head of Investor Relations, tel. +358 40 576 0288, tommi.jarvenpaa (at) tietoevry.com A teleconference for analysts and media will be held on 23 July 2024 at 10.00 a.m. EEST (09.00 a.m. CEST, 08.00 a.m. UK time). Kimmo Alkio, President and CEO, and Tomi Hyryläinen, CFO, will present the results online in English. The presentation  can be followed on Tietoevry's website . To take part in the questions and answers session after the presentation you will need to dial in by phone. You can access the teleconference by registering on this link . After the registration you will be provided phone numbers, user ID and a conference ID to access the conference. The event is recorded and it will be available on demand later during the day. Tietoevry publishes its financial information in English and Finnish. Tietoevry Corporation DISTRIBUTION Nasdaq Helsinki Nasdaq Stockholm Oslo Børs Principal Media Tietoevry creates purposeful technology that reinvents the world for good. We are a leading technology company with a strong Nordic heritage and global capabilities. Based on our core values of openness, trust and diversity, we work with our customers to develop digital futures where businesses, societies, and humanity thrive. Our 24 000 experts globally specialize in cloud, data, and software, serving thousands of enterprise and public-sector customers in more than 90 countries. Tietoevry’s annual turnover is approximately EUR 3 billion and the company’s shares are listed on the NASDAQ exchange in Helsinki and Stockholm, as well as on Oslo Børs. https://www.tietoevry.com

GiG further extends UK growth with Betzone partnership for iGaming platform with enhanced compliance solution

Gaming Innovation Group Inc. (GiG) has extended its footprint in the UK with the announcement of a long term agreement to power the Betzone brand with its revolutionary iGaming platform, CoreX, and powerful workflow automation tools LogicX and DataX, as GiG continues the execution of its strategic growth plans for the region. The second UK deal to be announced for GiG in as many weeks, the agreement stands as further evidence of GiG’s ability to attract ambitious new partners looking for sustainable growth in complex regulated markets, leveraging the competitive advantage its suite of leading technology and solutions carries for the localised UK market. With compliance and responsible gaming (RG) being key parts of the agreement, Betzone will benefit from GiG’s comprehensive compliance innovation. This solution integrates multiple systems to deliver a seamless risk assessment and management tool. By incorporating big data into GiG’s platform and using the advanced LogicX and DataX technologies, the system dynamically adjusts player interactions based on their risk levels. This allows operators to tailor marketing communications and financial checks to individual player profiles, ensuring responsible gaming and compliance with anti-money laundering (AML) regulations. Its effectiveness and adaptability have already been proven to power positive results with an existing partner in another complex regulated market. Online gaming in the UK continues to offer one of the largest and most established regulated markets around the world, with an estimated revenue of £11 billion (€13 billion). Andrew Cochrane, Chief Business Officer at GiG, commented, "The partnership with the team at Betzone is another exciting opportunity to showcase our strength at powering growth in regulated markets, with the UK a prominent market for our expansion. The combination of pioneering technology and our commitment to innovation, as perfectly demonstrated with our new and advanced compliance solution, means we are able to deliver a suite of products that provide the most comprehensive and secure springboard for sustained revenue growth. The UK will continue to be a market of considerable opportunity for GiG over the years to come." Adam Joseph, Chief Operations Officer at Betzone added: “We are delighted to announce this partnership with GiG. Their proven technology track record, customer centric tools and industry leading compliance and RG solutions make GiG the perfect partner to scale the Betzone brand, supporting our plans for rapid growth and exciting new business opportunities in a sustainable and responsible manner." For further information, contact: Richard Carter, CEO Platform & Sportsbook, richard.carter@gig.com About Gaming Innovation Group (GiG)Gaming Innovation Group is a leading iGaming technology company, providing solutions, products and services to iGaming Operators. Founded in 2012, Gaming Innovation Group’s vision is ‘To be the industry-leading platform, sportsbook and media provider delivering world-class solutions to our iGaming partners and their customers.  GiG’s mission is to drive sustainable growth and profitability of our partners through product innovation, scalable technology and quality of service. Gaming Innovation Group operates out of Malta and is dual-listed on the Oslo Stock Exchange under the ticker symbol GIG and on Nasdaq Stockholm under the ticker symbol GIGSEK. www.gig.com  

The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. CEO Kjell Stenberg comments “Several important advances have recently been made for both T20K and rabeximod, laying a solid foundation for future studies and activities. I am enthusiastic and optimistic as I return to the Company and look forward to the future with great confidence. I will prioritize and continue the development of rabeximod and its new formulation. In parallel, we will also develop a clear plan to optimize the value of our exciting T20K project. To continue our development, we intend to raise capital to advance our efforts with both T20K and rabeximod in preclinical and clinical studies and to find strategic partners. Strategic collaborations in these clinical stages – especially in indications such as rheumatoid arthritis, where further clinical development would involve significant costs for a small company like Cyxone – are common. We are confident that with a well-executed preclinical and early clinical study data package for rabeximod, we will be in an excellent position to reach strategic agreements and create increased value for the compound.” Background and motive Despite advances in the treatment of rheumatoid arthritis (“RA”) and multiple sclerosis (“MS”), there is still a need for safer and more effective treatments for both indications. Cyxone's product portfolio currently consists of two candidates – rabeximod and T20K. Rabeximod, a drug candidate for the treatment of moderately to severely active RA, has a favorable safety profile and is in clinical phase II. T20K is in preclinical development, ready for clinical development, for MS. Both candidates have mechanisms for growth in other indications; rabeximod can treat other autoimmune diseases and T20K can treat central nervous system (“CNS”) diseases. The Company's goal is to offer new, effective, safe and easy-to-use medicines for autoimmune inflammatory conditions to improve patients' quality of life. Cyxone also aims to collaborate with established pharmaceutical companies in clinical phases to finance, develop and launch rabeximod globally. For the next 12 months, the Company is in need of additional working capital. In order to continue development with rabeximod and T20K, the board has decided to carry out the Rights Issue. The primary purpose of the Rights Issue is to finance development programs with exploratory studies with the drug candidate rabeximod for patients who do not respond well to TNFa inhibitors, as well as to finance development of T20K and the overall operational activities. Provided that the Rights Issue is fully subscribed, the Company has the resources to finance the operations and development plans for the Q3 2025. If the Company through the Rights Issue does not obtain the necessary capital to finance the operations for a period of at least 12 months ahead, the Company intends to evaluate alternative financing solutions. Objectives Below is a selection of the Company's objectives for the years 2024-2026. · Initiation of collaboration with world-leading clinical experts for the treatment of RA in patients unresponsive to anti-TNK alpha therapy. · Preclinical studies to explore details of rabeximod's mechanism of action to guide prioritization of future clinical studies. · Preclinical studies to investigate T20K's ability to halt the progression of MS symptoms in early, middle and late stages of development. · Explore combinations of T20K and a kappa opioid receptor agonist (“KOR agonist”) to optimize efficacy versus safety in the EAE model. · Preclinical studies to explore the potential use of rabeximod in other diseases where the pathophysiological processes are likely to be inhibited by rabeximod. · Initiate partnership discussions in mid-late 2025 for rabeximod and/or T20K, depending on the results of the preclinical studies. · Obtain advice from regulatory authorities and conduct a pre-IND program with a combination of T20K and a KOR agonist results from preclinical studies of T20K. Investigate the potential of T20K alone or in combination with KOR agonist in disease. · Identify pharmaceutical partners that can fund clinical trials for T20K and/or rabeximod. Terms for the Rights Issue The board has today, with the support an authorization from the Annual General Meeting, decided on the implementation of an issue of a maximum of 575,802,760 shares, corresponding to approximately SEK 23 million. Cyxone's existing shareholders have preferential rights to subscribe for shares in proportion to their existing shareholdings. The general public also has the right to subscribe for shares in the Rights Issue. One (1) existing share in the Company on the record date of 30 July 2024 entitles to one (1) subscription right. Three (3) subscription rights entitle the holder to subscribe for eight (8) shares. The subscription price in the Rights Issue has been set at SEK 0.04 per share. Subscription for shares must take place during the subscription period that runs from and including 1 August 2024 to and including 15 August 2024. Subscription rights that are not used during the subscription period become invalid and lose their value. Trading in subscription rights is expected to take place on the Nasdaq First North Growth Market from and including 1 August 2024, to and including 12 August 2024. Trading in BTA (Paid Subscribed Share) is expected to take place during the period from and including 1 August 2024, until that the rights issue has been registered with the Swedish Companies Registration Office, estimated around 4 September 2024. The Rights Issue will initially increase the share capital by a maximum of SEK 23,032,110.40, from SEK 8,637,041.44 to SEK 31,669,151.84 and the total number of shares will increase by a maximum of 575,802,760 shares, from 215,926,036 shares to 791,728,796 shares. Existing shareholders who choose not to participate in the Rights Issue will be recognized with a dilution effect corresponding to approximately 72.7 percent of the votes and capital, calculated on the number of shares in the Company after the Rights Issue has been fully subscribed. Shareholders who choose not to participate in the Rights Issue have the opportunity to partially compensate themselves for the financial dilution effect by selling their subscription rights no later than 12 August 2024. Pre-subscription commitments The Rights Issue is secured in writing by members of the board and management to a total of approximately 1.1 percent (equivalent to approximately SEK 260,000) through pre-subscription commitments. The commitments are not secured by bank guarantee or similar arrangements. Indicative timeplan for the Rights Issue · Last day for trading in shares incl. right to receive subscription rights: 26 July 2024. · First day for trading in shares excluding the right to receive subscription rights: 29 July 2024. · Record date for participation in the Rights Issue: 30 July 2024. · Subscription period: 1-15 August 2024. · Trading in subscription rights: 1-12 August 2024. · Trading with BTA: from 1 August 2024 until the Rights Issue has been registered with the Swedish Companies Registration Office, estimated around 4 September 2024. The last day for trading in BTA will be announced through a separate press release after the rights issue has been completed. · Press release on the outcome of the Rights Issue: around 16 August 2024. Memorandum and teaser Memorandum and teaser about the Rights Issue will be made available via the Company's (www.cyxone.com) and Hagberg & Aneborn Fondkommission AB's (www.hagberganeborn.se) websites at the latest when the subscription period begins. Advisors In connection with the Rights Issue, Sedermera Corporate Finance AB assists the Company with project management, Markets & Corporate Law Nordic AB with legal advice and Hagberg & Aneborn Fondkommission AB with issuing services. For more information about the Rights Issue, please contact: Sedermera Corporate Finance ABPhone: +46 (0)40 615 14 10E-mail: cf@sedermera.sewww.sedermera.se For more information about the Company, please contact: Kjell Stenberg, CEOPhone: +46 (0)70 781 88 08E-mail: kjell.g.stenberg@cyxone.comwww.cyxone.com This information is information that Cyxone AB is obliged to make public according to the EU's Market Abuse Regulation (MAR). The information was provided, through the contact person below, for publication on 23 July 2024. Important information This press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants, subscription rights, BTA’s or other securities in Cyxone AB investors should not subscribe for or acquire any securities other than on the basis of the information in the information document that will be made public before the start of the subscription period in the Rights Issue. No action has been taken and no action will be taken to permit an offer to the public in any jurisdiction other than Sweden. This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or in any other jurisdiction where the distribution of this press release would be unlawful. Nor does this press release constitute an offer to sell new shares, warrants, subscription rights, BTA’s or other securities to any person in a jurisdiction where it would not be permitted to make such an offer to such a person or where such action would require prospectus, additional registration or other measures than under Swedish law. The information document, the application form and other documents relating to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires measures referred to in the previous sentence or where they would be contrary to the rules of such country. Actions contrary to this instruction may constitute a violation of applicable securities laws. Neither shares, warrants, subscription rights, BTA’s nor any other securities have been or will be registered under the United States Securities Act of 1933 in its current wording (the "Securities Act") or the securities laws of any state or other jurisdiction in the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States. This press release may contain certain forward-looking statements that reflect the Company's current views on future events and financial and operational development. Words such as "intends", " estimates", "expects", "may", "plans", "believes", " anticipates" and other expressions that imply indications or predictions of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By nature, forward-looking statements involve known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments and actual outcomes may differ materially from those expressed in forward-looking statements. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or the rules of First North Growth Market. About Cyxone Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com

UPM Half-Year Financial Report 2024: Comparable EBIT increased by 60% in Q2, UPM Paso de los Toros reached full capacity

UPM-Kymmene CorporationStock Exchange Release (Half-Year Financial Report)23 July 2024 at 09:30 EEST UPM Half-Year Financial Report 2024:Comparable EBIT increased by 60% in Q2, UPM Paso de los Toros reached full capacity Q2 2024 highlights · Sales totalled EUR 2,546 million (2,558 million in Q22023) · Comparable EBIT increased by 60% to EUR 182 million, 7.2% of sales (114million, 4.5%) · Operating cash flow was EUR 204 million (459million) · Moderate recovery in many product markets · UPM Paso de los Toros pulp mill reached nominal capacity before its first maintenance shutdown in June · Unusually high maintenance activity with three pulp mills and all nuclear power plant units having scheduled maintenance H1 2024 highlights · Sales decreased by 3% to EUR 5,186 million (5,345 million in H12023) · Comparable EBIT increased by 10% to EUR 515 million (470million), and was 9.9% (8.8%) of sales · Operating cash flow was EUR 539 million (1,173million) · Net debt increased to EUR 2,763 million (2,557 million) and the net debt to EBITDA ratio was 1.64 (1.07) · Cash funds and unused committed credit facilities totalled EUR 3.3 billion at the end of Q2 2024 · Sale of the Steyrermühl site, Austria in January · CDP recognised UPM with double ‘A’ score for transparency on climate change and forest Key figures Q2/2024 Q2/2023 Q1/2024 Q1–Q2/2024 Q1– Q1– Q2/2023 Q4/2023Sales, EURm 2,546 2,558 2,640 5,186 5,345 10,460Comparable EBITDA, 359 255 489 848 732 1,573EURm% of sales 14.1 10.0 18.5 16.3 13.7 15.0Operating profit, 50 108 354 404 426 608EURmComparable EBIT, EURm 182 114 333 515 470 1,013% of sales 7.2 4.5 12.6 9.9 8.8 9.7Profit before tax, 28 96 332 360 336 464EURmComparable profit 163 101 311 474 445 934before tax, EURmProfit for the 33 77 279 312 261 394period, EURmComparable profit for 131 77 258 389 358 755the period, EURmEarnings per share 0.05 0.15 0.51 0.56 0.48 0.73(EPS), EURComparable EPS, EUR 0.23 0.15 0.47 0.70 0.66 1.40Return on equity 1.1 2.5 9.6 5.5 4.2 3.2(ROE), %Comparable ROE, % 4.6 2.5 8.9 6.9 5.8 6.2Return on capital 1.6 3.0 9.6 5.7 4.5 3.5employed (ROCE), %Comparable ROCE, % 5.2 3.1 9.1 7.2 5.8 6.4Operating cash flow, 204 459 335 539 1,173 2,269EURmOperating cash flow 0.38 0.86 0.63 1.01 2.20 4.25per share, EUREquity per share at 20.10 21.24 21.42 20.10 21.24 20.93the end of period,EURCapital employed at 14,590 15,322 15,028 14,590 15,322 14,916the end of period,EURmNet debt at the end 2,763 2,557 2,312 2,763 2,557 2,432of period, EURmNet debt to EBITDA 1.64 1.07 1.46 1.64 1.07 1.55(last 12 months)Personnel at the end 16,776 17,571 16,132 16,776 17,571 16,573of period UPM presents certain measures of performance, financial position and cash flows, which are alternative performance measures in accordance with the guidance issued by the European Securities and Markets Authority (ESMA). The definitions of alternative performance measures are presented in » UPM Annual Report 2023  Massimo Reynaudo, President and CEO, comments on the results: “In Q2, our comparable EBIT increased by 60% on last year, in line with our expectations. The continued improvement was sustained by a moderate recovery in our product markets as well as a greater contribution from the UPM Paso de los Toros pulp mill in Uruguay. Our Q2 performance was held back by an exceptional amount of maintenance at our pulp mills and nuclear power plant units. The shutdowns were successful, and our assets are now in an excellent position to serve our customers in the second half of the year, operating at full capacity. Our Q2 sales were EUR 2,546 million and our comparable EBIT was EUR 182 million. Our operating cash flow was EUR 204 million and our net debt increased slightly to EUR 2,763 million. During the quarter we paid out the first instalment of dividends for the previous financial year, totalling EUR 400 million. In UPM Fibres, pulp demand was good, and prices continued to increase. A very important milestone was reached in the UPM Paso de los Toros pulp mill in Uruguay, where production reached nominal capacity for a full month already before the first maintenance shutdown in June. The quarter was impacted by maintenance at both pulp mills in Uruguay and at UPM Pietarsaari, Finland. UPM Specialty Papers delivered good results despite higher pulp prices. In UPM Raflatac, global demand for self-adhesive label materials recovered from last year’s lows. Both businesses implemented successful margin management actions. UPM Communication Papers’ profitability decreased due to delivery volumes that were impacted by lower demand after the restocking in Q1, and the political strikes in Finland. Margins in Q2 were burdened as fibre cost increases materialised more quickly than price increases. In May, we announced plans to close the Hürth newsprint mill in Germany and to shut down one fine paper machine (PM3) at Nordland Papier, also in Germany. Tight margin management and productivity improvements will be the key focus in the second half of the year. UPM Energy had a weak quarter of seasonally lower electricity prices and prolonged maintenance activities at Olkiluoto nuclear power plant units. UPM Plywood continued its steady performance in a seasonally good quarter with all plywood mills running at full capacity. EU anti-dumping measures on the imports of birch plywood from Russia entered into force and had a positive impact on the European market. In Other operations, the European market for advanced renewable fuels continued to be soft and the performance of our biofuels business remained at the level of the previous quarter. We have made further progress with the design for the potential biofuels refinery in Rotterdam and completed a major part of the basic engineering. The plan includes new proprietary technology related to processing the desired UPM integrated feedstocks, which we have validated at a demonstration scale. Before the potential investment decision, our focus will be on testing the new technologies on flexible feedstock options at a larger scale and securing the feedstock supply. This will be essential to ensure differentiation and support the long-term competitiveness of the business case. We expect this work to take approximately two years. We remain confident that the future growth in demand for advanced renewable fuels is attractive. The recent market turmoil only confirms our view that a differentiated, competitive and sustainable feedstock range will be the key to ensuring profitability over market cycles and potential regulatory developments. Our entry to the highly attractive biochemicals market is approaching. The UPM Biochemicals refinery in Leuna, Germany, is moving steadily towards the start of production by the end of the year. Commissioning continued in Q2 and the commercial interest for wood-based products remained strong. In June, we announced an exciting partnership with Nokian Tyres, a leading manufacturer of premium tyres, which will start using UPM BioMotion™ renewable functional fillers in its production. During the quarter, we struck five new business-specific collective labour agreements in Finland in good co-operation with employee representatives. These mutually beneficial agreements support our long-term competitiveness and ability to serve our customers. For the second half of the year, we anticipate strong run and improving results. Our biggest investment ever, the UPM Paso de los Toros pulp mill, has moved from ramp-up to regular production. With our competitive Uruguay platform operating at scale, we expect the increased pulp deliveries to improve our second-half results. With our portfolio of competitive businesses in expanding markets, UPM is set to perform well while we prepare for the next phase of growth.” Outlook for 2024 UPM’s full-year 2024 comparable EBIT is expected to increase from 2023, supported by higher delivery volumes, the ramp-up and optimisation of the UPM Paso de los Toros pulp mill, and lower fixed costs. Demand for many UPM products is expected to gradually improve as the destocking seen in 2023 is over. The market conditions for renewable fuels are expected to be weaker than last year. UPM continues to manage margins and take actions to reduce variable and fixed costs. In H2 2024, comparable EBIT is expected to be higher than in H1 2024. This improvement is expected to come especially from UPM Fibres, with the full pulp capacity available and pulp price levels starting at a higher level than at the start of the year. There are no major maintenance shutdowns scheduled for the company in H2 2024, whereas H1 2024 was impacted by unusually high maintenance activity and political strikes in Finland. The timing of the annual energy-related refunds is expected to support the result in Q4. Invitation to UPM’s webcast on half year financial report 2024 A webcast and a conference call for analysts and investors will start at 13:15 EEST. The half year report will be presented in English by President and CEO Massimo Reynaudo and CFO Tapio Korpeinen. Participants can follow the webcast online via this link . Participants wishing to ask questions after the presentation must register for the conference call. To participate in the conference call, please register here . After registering. you will be provided with telephone numbers, a user ID and a conference ID to access the conference. To ask a question, press *5 on your telephone keypad to join the queue. The webcast will be available at www.upm.com  for 12 months after the call. * It should be noted that certain statements herein, which are not historical facts, including, without limitation, those regarding expectations for market growth and developments; expectations for growth and profitability; and statements preceded by "believes", "expects", "anticipates", "foresees", or similar expressions, are forward-looking statements. Since these statements are based on current plans, estimates and projections, they involve risks and uncertainties which may cause actual results to materially differ from those expressed in such forward-looking statements. Such factors include, but are not limited to: (1) operating factors such as continued success of manufacturing activities and the achievement of efficiencies therein including the availability and cost of production inputs, continued success of product development, acceptance of new products or services by the Group's targeted customers, success of the existing and future collaboration arrangements, changes in business strategy or development plans or targets, changes in the degree of protection created by the Group's patents and other intellectual property rights, the availability of capital on acceptable terms; (2) industry conditions, such as strength of product demand, intensity of competition, prevailing and future global market prices for the Group's products and the pricing pressures thereto, financial condition of the customers and the competitors of the Group, the potential introduction of competing products and technologies by competitors; and (3) general economic conditions, such as rates of economic growth in the Group's principal geographic markets or fluctuations in exchange and interest rates. The main earnings sensitivities and the group’s cost structure are presented on pages 178–179 of the Annual Report 2023. Risks and opportunities are discussed on pages 34–35, and risks and risk management are presented on pages 133–137. * UPM, Media RelationsMon-Fri 9:00–16:00 EESTtel. +358 40 588 3284media@upm.com UPMWe deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Fibres, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility, we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 16,600 people worldwide and our annual sales are approximately EUR 10.5 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils.www.upm.com Follow UPM onX |LinkedIn |Facebook |YouTube |Instagram | #UPM #biofore #beyondfossils

Diamyd Medical receives positive feedback from FDA on potential Accelerated Approval for Diamyd® in Type 1 Diabetes

In a recent in-person Type C Meeting the FDA acknowledged that C-peptide could be used by Diamyd Medical as a surrogate endpoint reasonably likely to predict the clinical benefit of preservation of endogenous insulin production. As such, Accelerated Approval could be sought based on a demonstration of significant treatment-related benefits on C-peptide levels in response to Diamyd[®] administration.  Diamyd Medical has and will continue to have ongoing discussions with the FDA to determine the requirements for a Biologics License Application (BLA) under an Accelerated Approval pathway, including a potential earlier readout of stimulated C-peptide from the ongoing Phase 3 trial DIAGNODE-3. “Aligning with the FDA on the pathway for Accelerated Approval for Diamyd represents a significant step towards making this treatment available to patients with type 1 diabetes," says Ulf Hannelius, CEO of Diamyd Medical. "The potential of using C-peptide as a surrogate endpoint for accelerated approval marks an important milestone. We are committed to working closely with the FDA to diligently advance on this pathway and to obtain regulatory approval as soon as possible for this promising therapy.”  Professor Mark Atkinson, PhD, Diamyd Medical Board Member and an investigator with four decades of efforts seeking attempts to prevent and reverse type 1 diabetes, noted, “I left this FDA meeting with an extreme sense of optimism that a pathway for approval is feasible for Diamyd.  The need for such a therapy clearly exists, and the real winners of any such decision, if afforded, will be those living with type 1 diabetes, and perhaps even those who have yet to be diagnosed.” About Accelerated Approval and Surrogate EndpointsThe FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint.  A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. About Diamyd MedicalDiamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd[®] is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company’s prospective European Phase IIb trial, where Diamyd[®] was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymphnode can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd[®]. Diamyd Medical also develops the GABA-based investigational drug Remygen[®] as a component in the treatments of metabolic diseases. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB. Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

UPM Raflatac accelerates its growth in Graphics by acquiring Grafityp

(UPM Raflatac, Helsinki, 23 July 2024 at 10:00 EEST) – UPM Raflatac has acquired Grafityp, a Belgian-based company to further accelerate its growth in graphics solutions. Merging UPM Raflatac’s existing Graphics business with Grafityp will strengthen UPM Raflatac’s overall competitive positioning in this attractive product segment, expand its portfolio and give access to high-value new technologies. Both parties have agreed not to disclose the purchase price or other transaction details. Grafityp is a well-established company with more than 50 years of history and a pioneer in developing and manufacturing self-adhesive graphics solutions. Today it is known for its strong brands and product portfolio consisting of colour films, print films for large format colour printing, laminates and wrapping films for various end-uses. The company has approximately 100 employees and has a manufacturing site in Houthalen, Belgium and a distribution centre in the UK. Grafityp’s manufacturing site in Houthalen, Belgium. “We are committed to become a full product and service provider in graphics solutions. Merging Grafityp with UPM Graphics business accelerates our growth. Grafityp is a leading, innovative Graphics company with lot of know-how. We look forward to growing together and offering an even stronger product portfolio to our current and new customers,” says Timo Kekki, Senior Vice President, UPM Raflatac Films and Specials. “This acquisition presents significant opportunities to accelerate growth and enhance business value through the expansion of our customer base, production facilities and innovative product offering. The UPM Group shares our commitment to human values and sustainability. The complementary nature of our two organizations is truly remarkable, and we anticipate considerable synergies arising from this partnership. This agreement accelerates our ambitious growth plans. We eagerly anticipate the promising future this collaboration will bring,” says Herman Bosman, Owner of Grafityp. UPM Graphics is a new strategic self-adhesive business unit within UPM Raflatac. The business was established after acquiring AMC AG and its graphics business in 2022. UPM Raflatac’s strategy is to grow its graphics business through organic and possibly inorganic measures to give it a significant weight in the company’s product portfolio. Typical graphics applications can be found e.g. in indoor and outdoor advertising, signage and vehicle wrapping. For further information please contact: Timo Kekki, Senior Vice President, Films and Specials SBU¸ UPM Raflatac Media contacts coordinated by UPM Media Relations, tel. +358 40 588 3284, media@upm.com Juuli Räsänen, Director, Graphics Business Unit, Films and Specials SBU, UPM Raflatac Media contacts coordinated by UPM Media Relations, tel. +358 40 588 3284, media@upm.com Herman Bosman, Chairman of the Board, Grafityp, tel. +32 11 600 851 Patrick Nijs, CEO, Grafityp, tel. +32 11 600 851 Photographs for media: https://materialhub.upm.com/l/WzQbVc9hbfpC UPM, Media Relations Mon-Fri 9:00-16:00 EEST tel. +358 40 588 3284 media@upm.com UPM Raflatac UPM Raflatac offers high-quality self-adhesive paper and film products including label materials, graphics solutions and removable self-adhesive products. We operate 12 factories and deliver our innovative and sustainable products through our global network of distribution terminals.We are one of UPM’s growth businesses and employ around 3,100 people. Our sales reached almost EUR 1.5 billion (USD 1.6 billion) in 2023. Find out how we are labeling a smarter future beyond fossils atwww.upmraflatac.com. Follow UPM Raflatac on LinkedIn  | Facebook  | YouTube  | Instagram  UPMWe deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Fibres, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility, we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 16,600 people worldwide and our annual sales are approximately EUR 10.5billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils. www.upm.com Follow UPM onX |LinkedIn |Facebook |YouTube |Instagram | #UPM #biofore #beyondfossils Grafityp We have been developing films and laminates for more than 50 years with brands that stick. Family Bosman has been running Grafityp since the establishment and is still actively today. Our speciality is developing, producing and selling self-adhesive foils and films for various end uses. Our strategy is based on customer intimacy and operational excellence. We want to be leading in sustainability based on the three Ps – people, planet and profit and we are very proud on solutions we provide there related. Our goal is to reduce CO2 emissions by 40% by 2030. Find out more www.grafityp.com Follow us on LinkedIn  | Facebook  | YouTube  | Instagram  #grafityp #grafitypselfadhesivefilms #letssticktogether #grafitypmakesyoustick

Japan Laser Becomes New Distributor for OptoFidelity in Japan

The cooperation enables OptoFidelity to locally serve the growing Japanese Augmented Reality (AR) market with its testing systems for waveguide R&D and manufacturing 11 JULY 2024 – TAMPERE, Finland — We are pleased to announce that Japan Laser has been appointed as the new distributor for OptoFidelity's AR products and services in Japan. “OptoFidelity considers the Japanese market a key player in waveguide manufacturing and global AR supply chain,” commented Pekka Laiho, Chief Business Officer at OptoFidelity. “Japan Laser has a rich history of introducing the latest optical technologies to the market by fostering mutually beneficial industry and customer relationships. Drawing from this extensive experience, they are well-equipped to showcase OptoFidelity's advanced test systems for the manufacturing of AR waveguides.” Since its establishment in 1968, Japan Laser has been a trusted provider of laser and electro-optics products. Over the years, the company has cultivated strong partnerships and served a wide range of customers, from academia to various industrial sectors. As Japan's oldest and most experienced trading firm specializing in lasers and electro-optics, Japan Laser's expertise and commitment to quality make it an ideal partner for OptoFidelity. “We are excited to announce our new partnership with OptoFidelity. Together, we aim to set the optical metrology standards for Augmented Reality in Japan. We look forward to leveraging our combined strengths to contribute to expanding the AR technologies to the masses,” said Tatsuya Uzuka, President at Japan Laser. “We will work closely with OptoFidelity's team, following up on opportunities to become fully familiar with their technology, strategy, and philosophy. Our goal is to build a strong partnership within this year,” added Mr. Uzuka. Japan Laser will focus on reselling all of OptoFidelity's AR/VR products and services. Its engineering team, which currently services traditional laser and optical technology systems, will be involved in supporting customers with the operation and maintenance of OptoFidelity's products. This collaboration is expected to raise OptoFidelity's presence in Japan and penetrate deeper into the Japanese AR/VR market. For more information, please contact Japan Laser at [meas@japanlaser.co.jp]. About Japan Laser Japan Laser has been providing state-of-the-art optical technology products and solutions since 1968, serving a wide range of customers from academia to industry. With a global network of manufacturers, Japan Laser continues to lead the market in lasers and electro-optics in Japan. For more information, visit: https://www.japanlaser.co.jp About OptoFidelity OptoFidelity provides advanced testing systems that help smart device manufacturers bring innovative products faster to the market. Our optical metrology products and solutions are renowned for their precision, repeatability, and traceability. They minimize the risks and offer our customers a clear view of their product development and manufacturing quality. OptoFidelity is defining the standards for assessing the quality of AR/VR/MR waveguides and devices, setting a new benchmark for image excellence, and paving the way for XR technologies to become a part of our everyday lives. OptoFidelity is trusted by technology leaders, including Google, Samsung, MagicLeap, Lenovo, poLight, and XReal. For further information, visit OptoFidelty online . Press contact Arlinda Sipilä | Growth Marketing Director, OptoFidelity arlinda.sipila@optofidelity.com | +358 50 362 3571 <ends>

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release July 23, 2024 at 3:20 p.m. Nokian Tyres has received an announcement from Société Générale SA (SG SA) on July 22, 2024, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, Société Générale SA’s holding through financial instruments and total holding in Nokian Tyres shares and voting rights exceeded the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on July 18, 2024. The holding through financial instruments of Société Générale SA (SG SA) in Nokian Tyres amounted to 11,567,821 shares, corresponding to 8.32% of Nokian Tyres’ shares and voting rights and total holding amounted to 11,617,032 shares, corresponding to 8.36% of Nokian Tyres’ shares and voting rights. Total positions of person(s) subject to the notification obligation: +----------------+----------+------------------+-----+----------------------+| |% of |% of shares and |Total|Total number of shares|| |shares and|voting rights |of |and voting rights of || |voting |through financial |both |issuer || |rights |instruments (total|in % | || |(total |of B) |(A+B)| || |of A) | | | |+----------------+----------+------------------+-----+----------------------+|Resulting |0.04 |8.32 |8.36 |138,921,750 ||situation on the| | | | ||date on | | | | ||which threshold | | | | ||was crossed or | | | | ||reached | | | | |+----------------+----------+------------------+-----+----------------------+|Position of |0.01 |3.11 |3.12 | ||previous | | | | ||notification | | | | |+----------------+----------+------------------+-----+----------------------+ Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rights: +------------+------+-----------------+----------------+-----------------+|Class/type |Number |% of shares ||of shares |of |and voting rights ||ISIN code  |shares | || |and | || |voting | || |rights | |+------------+------+-----------------+----------------+-----------------+| |Direct|Indirect  |Direct (SMA 9:5)|Indirect  || |(SMA |(SMA 9:6 and 9:7)| |(SMA 9:6 and 9:7)|| |9:5) | | | |+------------+------+-----------------+----------------+-----------------+|FI0009005318|49,211| |0.04% | ||Ordinary | | | | ||shares | | | | |+------------+------+-----------------+----------------+-----------------+|Subtotal A |49,211 |0.04% |+------------+------+-----------------+----------------+-----------------+ B: Financial instruments according to SMA 9:6a: +--------------+----------+----------+-----------+-----------------+-----------+|Type of |Expiration|Exercise/ |Physical or|Number of shares |% of shares||financial |date |Conversion|cash |and voting rights|and voting ||instrument | |Period |settlement | |rights |+--------------+----------+----------+-----------+-----------------+-----------+|Listed Call |03/01/2033|Until |Cash |276,858 |0.20% ||Warrant on | |03/01/2033| | | ||Basket | | | | | |+--------------+----------+----------+-----------+-----------------+-----------+|OTC Call |03/01/2033|Until |Cash |282,561 |0.20% ||Option on | |03/01/2033| | | ||Basket | | | | | |+--------------+----------+----------+-----------+-----------------+-----------+|OTC Call |03/01/2033|Until |Cash |1,059,775 |0.76% ||Option | |03/01/2033| | | |+--------------+----------+----------+-----------+-----------------+-----------+|OTC Put Option|03/01/2033|Until |Cash |4,419,290 |3.18% || | |03/01/2033| | | |+--------------+----------+----------+-----------+-----------------+-----------+|Listed Call |03/01/2033|Until |Cash |1,051,877 |0.76% ||Warrant | |03/01/2033| | | |+--------------+----------+----------+-----------+-----------------+-----------+|Listed Put |03/01/2033|Until |Cash |4,419,290 |3.18% ||Warrant | |03/01/2033| | | |+--------------+----------+----------+-----------+-----------------+-----------+|Contract for |N/A |N/A |Cash |58,170 |0.04% ||difference | | | | | |+--------------+----------+----------+-----------+-----------------+-----------+| | | |Subtotal B |11,567,821 |8.32% |+--------------+----------+----------+-----------+-----------------+-----------+ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:   +-------------+------------------+---------------------+----------------+|Name |% of shares |% of shares and |Total of both, %|| |and voting rights |voting rights through| || | |financial instruments| |+-------------+------------------+---------------------+----------------+|Société |0.04% |4.18% |4.22% ||Générale S.A.| | | |+-------------+------------------+---------------------+----------------+|Société |0.00% |4.14% |4.14% ||Générale | | | ||Effekten Gmbh| | | |+-------------+------------------+---------------------+----------------+ Further information:Päivi AntolaSVP, Communications, Investor Relations and BrandTel. +358 10 401 7327, IR@nokiantyres.com Nokian Tyres develops and manufactures premium tires for people who value safety, sustainability and predictability. Inspired by our Scandinavian heritage, we craft innovative products for passenger cars, trucks and heavy machinery that give you peace of mind in all driving conditions. Our Vianor chain provides tire and car services. In 2023, our net sales totaled EUR 1,174 million. At the end of 2023 we employed over 3,400 professionals. Nokian Tyres is listed on Nasdaq Helsinki. Further information: www.nokiantyres.com 

Heimdal Integrates with Autotask PSA to Elevate MSP Operations and Drive Market Expansion

This new integration is poised to significantly enhance support ticket creation and management, driving productivity and unlocking new commercial opportunities for Heimdal customers and partners. Driven by high customer demand and the need to address complex operational challenges, this integration reinforces Heimdal's commitment to providing scalable, efficient solutions that cater to the evolving needs of Managed Service Providers (MSPs) and Managed Security Service Providers (MSSPs). By integrating with Autotask PSA, Heimdal positions itself to reach a broader market, offering a compelling value proposition that attracts and retains partners globally. Jesper Frederiksen, CEO of Heimdal, commented on the announcement: "The integration with Autotask PSA is a transformative step in our strategy to elevate cybersecurity as the cornerstone of MSP and MSSP operations. By empowering our partners to respond more effectively to cybersecurity threats and deliver superior protection, we are positioning Heimdal at the forefront of a rapidly evolving market.” “As RMM and PSA tools become more integrated, our focus on cybersecurity ensures that our partners can provide unparalleled service and security to their clients, driving growth and expanding market reach." "We're very excited to add Heimdal to the growing list of integration partners on the Autotask Integration Hub, continuing to ensure Autotask is the most integrated PSA solution in the world,” said Nadir Merchant, general manager, IT Operations Suite, Kaseya. Key benefits of integration include: · Automated Ticket Creation - Customers and partners using Autotask PSA can now automate support ticket creation and management for various operational and cybersecurity alerts, including CPU, Memory, Disk, Microsoft updates, Next-Gen AV, DNS poisoning, Firewall issues, REP, PEDM, VectorN Detection, and Zero-Trust Execution Protection. · Consolidated Customer View for Partners - Partners now have a centralized view of all corporate customers, enabling them to efficiently monitor operational notifications and cyber alerts. This consolidated view enhances the ability to manage multiple clients, improving service delivery and customer satisfaction, and ultimately driving business growth. For further details about the Heimdal and Autotask PSA integration, visit: Heimdal Assistance and Support . To learn more or join Heimdal's global partner program, visit Heimdal Partner NEXUS . About Autotask PSA Autotask is a cloud-based Professional Services Automation (PSA) solution that centralizes business operations to improve insights, accuracy, productivity, service levels, and profitability. Autotask PSA is developed by Datto, a Kaseya company and the leading global provider of AI-powered cybersecurity and IT management software solutions purpose-built for Managed Service Providers (MSPs). Datto’s integrated platform helps its extensive network of MSP partners serve over one million businesses globally, offering proactive detection, prevention, and rapid recovery solutions to minimize downtime and data loss. For more information, visit Datto . About Heimdal Established in Copenhagen in 2014, Heimdal empowers CISOs, security teams, and IT administrators to improve their security operations, reduce alert fatigue, and implement proactive measures through a unified command and control platform. Heimdal's award-winning cybersecurity solutions span the entire IT estate, addressing challenges from endpoint to network levels, including vulnerability management, privileged access, Zero Trust implementation, and ransomware prevention. For more information, visit: Heimdal . Media Contact Madalina Popovici Media Relations Manager mpo@heimdalsecurity.com

Stardeus Receives Its Biggest Update Yet

Today Paradox Arc and Kodo Linija released a major update for their game, Stardeus, which is currently available in Steam Early Access. Stardeus is a deep colony simulation set aboard a damaged starship, crewed by drones and hibernating human survivors. As the game's immortal AI, players will command drones to repair the starship, make critical decisions about the human crew, and explore a procedurally generated universe filled with complexity. The latest update, named Bioverse, is the most substantial since Stardeus entered Early Access in 2022 and adds onto the games replayability and storytelling.  See the trailer here . The new update includes a comprehensive overhaul of many core systems, significantly improving the game's AI and combat mechanics, and introducing an entirely new body part system. This anticipated feature allows humans, robots, and animals to have multiple body parts, each contributing specific stats. These parts can be removed or replaced, and their absence can lead to impaired functionality or even… death. In addition to these major changes, the update also introduces new systems for health, stats, and conditions, enhancing the overall gameplay experience. Players will also find new content, including a scenario, devices, materials, and species, further deepening the sim experience. An overview of what’s new: · Revamped AI system · Enhanced combat mechanics · Innovative body part system, including new health, stats, conditions, and abilities system · New content: Additional scenario, new devices, materials, species and more · New trade system · Twitch Integration Download assets here . For more information about the game and the Bioverse update, please visit: https://store.steampowered.com/app/1380910/Stardeus/

(Reminder) Invitation to Kongsberg Automotive's Q2 2024 Earnings Call

Kongsberg, July 24, 2024: Kongsberg Automotive (KA) will release its Q2 results on Thursday August 8, 2024 at approximately 07:00 CET. President & CEO Linda Nyquist-Evenrud and CFO Christian Johansson will present the results during a webcast at 09:00 CET and will host a Q&A session after the presentation. The event is open to the public and will be webcasted live. The link: Kongsberg Automotive Q2 Earnings release (royalcast.com)  will give you access to the webcast. The earnings release and presentation will be published on www.newsweb.no and on KA's website www.kongsbergautomotive.com. The recording of the event will be made available on the company`s website shortly after the presentation.   Investor Relations contact:Mads Langaard - Head of Investor Relationsinvestor.relations@ka-group.com+47 905 81 264 Media and Communications contact:Therese Sjöborg Skurdal - Director Corporate Communicationstherese.skurdal@ka-group.com+47 982 14 059 About Kongsberg Automotive ASAKongsberg Automotive provides cutting-edge technology to the global vehicle industry. We drive the global transition to sustainable mobility by putting engineering, sustainability, and innovation into practice. Our product portfolio includes driver and motion control systems, fluid assemblies, and industrial driver interface products. Find more information at:kongsbergautomotive.com https://www.kongsbergautomotive.com

Stora Enso appoints a new CFO and a new EVP Packaging Solutions division

Stora Enso has appointed Niclas Rosenlew Group Chief Financial Officer. He will replace Seppo Parvi, who has previously announced that he will leave Stora Enso to continue his career outside the Company. Stora Enso has also appointed Carolyn Wagner Executive Vice President, Packaging Solutions division. She will replace Ad Smit who will retire. They will join Stora Enso latest in January 2025 and be members of Stora Enso’s Group Leadership Team.Niclas Rosenlew is currently Group CFO at the Swedish stock-listed industrial company SKF, a position held since 2019. Prior to his current role, he held a CFO position at Basware, and senior finance positions at Microsoft and Nokia. Niclas holds a Master of Science degree in Finance.“I am delighted to welcome Niclas Rosenlew to the role as Stora Enso’s new CFO. Niclas has extensive experience in leading, developing and reshaping large international organisations. His solid background in CFO and other senior positions in listed companies will be immensely valuable in Stora Enso’s continued growth transition, value creation and in reaching our financial targets. I would like to express our utmost gratitude to our current CFO Seppo Parvi for his dedicated service over the past decade and wish him success in his new professional role,” says Stora Enso’s President and CEO Hans Sohlström.Carolyn Wagner is currently Divisional CEO of the Packaging Division at the German Klingele Paper & Packaging Group. Prior to her current role, she has held senior positions at other European corrugated packaging companies, amongst others, DS Smith and SCA. Carolyn holds a degree of Graduate Engineer Packaging Technology.“Carolyn’s strong packaging industry insight will be important in developing and advancing our packaging solutions business. I would like to thank Ad Smit for his key role in integrating De Jong Packaging Group into our existing packaging solutions business after the acquisition, and wish him all the best for the future,” Sohlström says.“I am thrilled about the opportunity to join Stora Enso and, as part of the team, contribute to its success,” says Niclas Rosenlew.“It is with great pleasure that I take up my new position in Stora Enso. With exciting opportunities ahead, our goal is to lead the industry, enhance sustainable growth, and offer superior global products and services,” says Carolyn Wagner.Part of the global bioeconomy, Stora Enso is a leading provider of renewable products in packaging, biomaterials and wooden construction, and one of the largest private forest owners in the world. Stora Enso has approximately 20,000 employees and our sales in 2023 were EUR 9.4 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors   STORA ENSO OYJ

Kindred Group plc – Interim report: January – June 2024 (unaudited)

Kindred Group plc – Interim report: January – June 2024 (unaudited) Second quarter 2024 · Total revenue was GBP 327.6 (307.3) million, an increase of 7 per cent. · Gross winnings revenue (B2C) increased by 6 per cent to GBP 317.2 (298.3) million. · Underlying EBITDA increased by 32 per cent to GBP 73.6 (55.7) million. · Profit before tax was GBP 55.6 (33.1) million. · Profit after tax was GBP 44.5 (27.7) million. · Profit after tax includes a loss from discontinued operations of GBP 1.7 (6.9) million and profit from continuing operations of GBP 46.2 (34.6) million. · Earnings per share were GBP 0.21 (0.13). · Free cash flow amounted to GBP 41.6 (3.0) million. · Number of active customers increased by 12 per cent to 1,749,611 (1,561,444). First half 2024 · Total revenue was GBP 635.3 (613.7) million, an increase of 4 per cent. · Gross winnings revenue (B2C) increased by 3 per cent to GBP 614.8 (595.6) million. · Underlying EBITDA increased by 26 per cent to GBP 132.9 (105.1) million. · Profit before tax was GBP 95.4 (63.5) million. · Profit after tax was GBP 75.9 (53.3) million. · Profit after tax includes a loss from discontinued operations of GBP 2.7 (14.9) million and profit from continuing operations of GBP 78.6 (68.2) million. · Earnings per share were GBP 0.35 (0.25). · Free cash flow amounted to GBP 65.3 (32.0) million. · As a result of the closure of the Group’ s locally licensed North American operations, the presentation of the Group’s condensed consolidated financial statements has been updated to present continuing and discontinued operations separately (as required by the relevant accounting standards). Refer to the appendix on page 27 for further information. All commentary within this report related to the condensed consolidated income statement refers to the total Group numbers shown on pages 28 to 31 (in line with total Group numbers previously reported). CEO Nils Andén comments on the second quarter of 2024 “Building on our solid start to 2024, I am pleased to present a very positive set of second-quarter results for Kindred. We continue to demonstrate our resilience and strategic execution, which is reflected in our strong performance across our market portfolio. The vast majority of our top markets have grown year-on-year, which is very encouraging.” “Total revenue for the second quarter was GBP 327.6 million, marking a 7 per cent increase compared to the same period last year (8 per cent in constant currency). Excluding North America, total revenue increased by 9 per cent for the same period. Underlying EBITDA came in at GBP 73.6 million, reflecting a significant 32 per cent increase year-over-year, and representing a margin of 22 per cent. This highlights the scalability of our business model and accelerated top-line growth while maintaining a stable cost base.” “Our development in locally regulated markets has been particularly strong, with year-on-year Gross winnings revenue from locally regulated markets growing 10 per cent (12 per cent excluding North America).” “The second quarter contained strong sportsbook activity throughout, with Euro 2024 boosting customer engagement towards the end of the period. Favourable results, in combination with a record share of Bet Builder activity, delivered a historic high sportsbook margin of 12.1 per cent. This is considerably higher than the long-term average margin of 9.9 per cent and we expect to see some normalisation in the second half of 2024.” “The KSP project remains firmly on track, with key features and functionality being released ahead of our planned market rollout, starting later this year. Live customers from selected test markets are already using the platform and providing valuable feedback and insight for the Product and Development teams.” Trading update up to and including 21 July 2024 The average daily Gross winnings revenue for the Group, up to and including 21 July 2024, was GBP 3.28 million, 10 per cent higher (11 per cent in constant currency) compared to the daily average for the full third quarter of 2023. Closure of the North American operations distort the comparatives, the growth in Gross winnings revenue for the Group excluding North America is 12 per cent (14 per cent in constant currency) for the same period. The sports betting margin after free bets for the above period was 10.6 per cent, which is ahead of the Group long-term average of 9.9 per cent and the 9.4 per cent across the full third quarter of 2023. Kindred Group’s presentation of the interim report Kindred Group’s CEO Nils Andén and Interim CFO Patrick Kortman will host a web presentation in English at 10.00 (CEST) which is webcasted live on https://www.kindredgroup.com/Q22024.   To access the telephone conference in connection with the presentation, please register at https://conference.financialhearings.com/teleconference/?id=50047081. After registration you will be provided a phone number and a conference ID to access the conference. Please call in well in advance for registration. There will be an opportunity to ask questions after the presentation.

Loomis Interim Report January – June 2024

Loomis delivered solid financial results for the second quarter. Revenue exceeded SEK 7.6 billion, which is a new record for us. This positive performance was driven by organic growth across most business lines, except for international where we are still experiencing cyclical headwinds. Notably, our automated solutions experienced double-digit organic growth in both regions. The acquisition of CIMA also contributed positively to the results. The operating income (EBITA) of SEK 887 million is our highest ever and we increased our operating margin to 11.6 percent (10.6). Operating cash flow surpassed SEK 1.1 billion for the quarter, representing a strong 126 percent conversion rate relative to operating income (EBITA). Comments on Quarter 2 · Revenue for the second quarter was SEK 7,639 million (7,072). Revenue grew by 8.0 percent (13.8) of which organic growth was 7.0 percent (7.7) and acquisitions contributed with 3.0 percent (0.6). Exchange rate effects on revenue was –1.9 percent (5.4). · Operating income (EBITA) 1) for the quarter was SEK 887 million (752). The operating margin (EBITA) was 11.6 ­percent (10.6). · Items affecting comparability in the quarter amounted to SEK –97 million (–13) and relates to costs for further restructuring within Segment Europe and Latin America and the provision for the administrative fine from the Swedish Financial Supervisory Authority that was communicated in June. · Operating income (EBIT) before items affecting comparability for the quarter was SEK 834 million (709) and operating margin (EBIT) before items affecting comparability was 10.9 percent (10.0). · Net financial expenses for the quarter were SEK –186 million (–144). · Income before taxes for the quarter was SEK 550 million (552) and net income was SEK 396 million (357). · Earnings per share before dilution for the quarter were SEK 5.65 (5.02) and after dilution were 5.64 (5.01). · Cash flow from operating activities2) amounted to SEK 1,113 million (310) in the quarter, equivalent to 126 percent (41) of operating income (EBITA). The cash flow was partially positively impacted by a reversal of the temporary build-up of foreign currency stock over the quarter end in Q1. · Loomis AB has cancelled 4,279,829 treasury shares and repurchased 758,908 shares during the second quarter. The Board of Directors has resolved to continue to repurchase own shares during the third quarter 2024. 1)        Earnings Before Interest, Taxes, Amortization of acquisition-related intangible fixed assets, Acquisition-related costs and revenue and items affecting comparability. 2)        Cash flow from operating activities is exclusive of impact from IFRS 16. This press release is also available on the company's website, www.loomis.com. For more information, please contact: Jenny Boström Head of Sustainability and IR jenny.bostrom@loomis.com +46 79 006 45 92 Loomis offers secure and effective comprehensive solutions for managing payments, including the distribution, handling, storage and recycling of cash and other valuables. Loomis’ customers are mainly financial institutions and retailers.  Loomis operates through an international network of around 400 branches in more than 20 countries. Loomis employs around 25,000 people and had revenue in 2023 of more than SEK 28 billion. Loomis is listed on Nasdaq Stockholm Large-Cap list. This information is information that Loomis AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 07.30 a.m. CEST on July 24, 2024.

Interim report Q2 2024: Growth in Automotive premium steel in a weak market

Comments by the CEO SSAB’s operating result for the second quarter of 2024 amounted to SEK 2,969 (4,963) million. The decrease compared to a year earlier was primarily due to lower US heavy plate prices. The market in Europe continued to be relatively weak, whereas the market for high-strength steel was more resilient. Compared to the first quarter, the operating result was somewhat lower, whereas operating cash flow increased by more than SEK 1 billion. SSAB Special Steels had an operating result of SEK 1,659 (2,003) million and an operating margin of 21% (23%) during the quarter. SSAB Special Steels’ unique offering provides added value for our customers and this in turn translates into more stable prices than for standard products. SSAB Americas’ operating result for the second quarter decreased to SEK 1,204 (2,642) million and the operating margin was 19% (34%), as prices weakened. SSAB Europe had an operating result of SEK 400 (764) million and an operating margin of 3% (6%). The market was weak and the political strikes in Finland had a negative effect of around SEK 125 million, while shipments to the car industry (Automotive Advanced High Strength Steels) reached a record level, supported by SSAB’s advanced products as well as our leading position in emission-free steels. Safety performance continued to improve and LTIF decreased to 0.64 (1.01) during the quarter. The market in Europe was relatively weak during the second quarter and the US heavy plate market weakened. During the third quarter, SSAB will carry out planned maintenance at most production sites and this will be reflected in lower output. SSAB Americas will bring forward the maintenance stop at the Montpelier mill. Demand is seasonally lower in the third quarter, especially in Europe, and the assessment is for a more pronounced decrease than normal. The market is challenging for Tibnor and Ruukki Construction but measures to reduce costs had a positive effect in the second quarter. The transformation to fossil-free steelmaking continues with a focus on the conversion of Oxelösund and the planning of the state-of-the-art, highly-effective mini-mill in Luleå. The new mill in Luleå will reduce Sweden’s carbon dioxide emissions by 7% in addition to the 3% reduction from the conversion of the mill in Oxelösund. SSAB’s updated targets to reduce greenhouse gas emissions were approved by the Science Based Targets initiative (SBTi) during the second quarter. Approval means that the targets are scientifically based and in line with the SBTi's raised requirements for companies to deliver on the goal of limiting global warming to 1.5°C. In conjunction with the above, SSAB launched a new combined Green and Sustainability-Linked Finance Framework that will support SSAB’s transformation to fossil-free steelmaking and investments in more efficient and flexible production systems. The combined framework provides SSAB with an opportunity to issue both green and sustainability-linked financing instruments as well as a combination of the two. SSAB invites you to a presentation of the Q2 2024 report at 9.30am CEST on Wednesday, July 24, 2024. The report will be presented by SSAB’s President and CEO Martin Lindqvist, and CFO Leena Craelius. The press conference will be held in English and live webcast on SSAB’s website www.ssab.com. Link to webcast: https://edge.media-server.com/mmc/p/3yfsbz9x  You can also participate in the briefing by telephone. Click on the link below and complete the online registration form. You can choose if you want to dial in or click “Call Me” for a call-back. Link to teleconference: https://register.vevent.com/register/BI605cd258717c41c187d7d7e5b8dd7a34 For further information, please contact:Per Hillström, Head of Investor Relations, per.hillstrom@ssab.com, phone: +46 702 95 29 12Viktoria Karsberg, Head of Corporate Identity and Group Communications,viktoria.karsberg@ssab.com, phone: +46 72 233 5288 This information is inside information that SSAB AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and information that SSAB AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7.30am CEST on July 24, 2024.

Stora Enso Oyj Half-year Report 2024: Continued profit improvement with strengthened leverage ratio

Q2/2024 (year-on-year) •     Sales decreased by 3% to EUR 2,301 (2,374) million; however, continuing operations grew by 1%. •        Adjusted EBIT increased to EUR 161 (37) million. •        Adjusted EBIT margin increased to 7.0% (1.6%). •        Operating result (IFRS) was EUR 99 (-253) million. •        Earnings per share (EPS) were EUR 0.06 (-0.29) and EPS excl. fair valuations (FV) was EUR 0.07 (-0.27). •        The value of the forest assets increased to EUR 8.7 (8.1) billion, equivalent to EUR 11.06 per share. •        Cash flow from operations amounted to EUR 323(146) million. Cash flow after investing activities was EUR 86 (-70) million. •        Net debt increased by EUR 466 million to EUR 3,497 (3,030) million, mainly due to the board investment at the Oulu site. •        The net debt to adjusted EBITDA (LTM1) ratio was 3.5 (1.7). The target to keep the ratio below 2.0 remains. H1/2024 (year-on-year) •        Sales were EUR 4,466 (5,095) million. •        Adjusted EBIT was EUR 317 (271) million. •        Operating result (IFRS) was EUR 247 (5) million. •        Earnings per share (EPS) were EUR 0.16 (-0.05) and EPS excl. fair valuations (FV) was EUR 0.16 (-0.04). •        Cash flow from operations amounted to EUR 592(400) million. Cash flow after investing activities was EUR -18 (-69) million. •        Adjusted ROCE excluding the Forest division (LTM1) decreased to 1.3% (10.7%), the target being above 13%. Key highlights •     The value creation programmes, centred on sourcing, operational and commercial efficiencies, are making good progress across all divisions. •     In addition, the profit improvement programme focusing on fixed costs, initiated in the first quarter 2024, targeting EUR 120 million has continued to progress well. This has supported an improvement in the earnings trend due to enhanced efficiencies and cash flow, and strengthened the leverage ratio: net debt to EBITDA. •     Operating working capital decreased by EUR 576 million year-on-year to an all-time low, driven by our continued focus to improve working capital efficiency. •     Stora Enso secured a EUR 435 million long-term loan, on 11 July, from the European Investment Bank to fund its EUR 1 billion investment in the Oulu mill, Finland. Loan repayment extends until 2036, improving and lengthening the Group’s debt maturity profile. The loan is currently undrawn. •     The consumer board investment at the Oulu site in Finland is progressing on schedule. Production is expected to start in the first half of 2025, with full capacity estimated to be reached during 2027. •     The plan to divest the Beihai site in China is in process. The site has been classified as assets held for sale from the end of 2023. GuidanceOn 15 May, Stora Enso raised its guidance for the full year 2024 adjusted EBIT, due to successful implementation of profit improvement actions and more favourable market conditions. The new guidance is: Stora Enso's full year 2024 adjusted EBIT is expected to be significantly higher than for the full year 2023, EUR 342 million. OutlookMarket and business outlookStora Enso anticipates a gradual market recovery in 2024. The positive forecast is supported by successful initiatives to increase profitability, which have contributed to the earnings trend over the past three quarters and helped reduce the Group's net debt to EBITDA ratio. Despite this, high wood costs will continue to pressure margins. Market uncertainties, including high inflation, potential strikes, and demand and price fluctuations, are expected to continue through the end of the year.Packaging MaterialsThe outlook for Q3 is slightly positive, supported by strong order books and an improving price outlook. Price increases announced during Q2 in both the consumer and containerboard segments are expected to contribute positively to the results, mainly in the second half of this year. The liquid and food service board segments show improved stability and demand, while carton board demand remains stable following a strong recovery. Kraftliner and testliner segments are recovering, supported by stable demand and three rounds of price increases announced during H1 this year. However, high fiber costs and seasonally higher fixed costs due to annual shutdowns in virgin fiber containerboard units will impact the second half of the year. Paper demand is expected to continue its steady, gradual decline.Packaging SolutionsDemand for Q3 is expected to remain stable with seasonal fluctuations. In Western Europe, volumes are anticipated to normalise post weather-related delays in the fresh-produce season. Asia usually experiences a downturn in Q3, with improvements expected in Q4. Central, Northern, and Eastern Europe should see consistent demand. Market challenges continue due to overcapacity.BiomaterialsLooking ahead in Q3, overall pulp demand in Europe and China is projected to remain stable. The European softwood pulp market remains balanced, with no signs of demand improvement. In China, demand is stable. Demand for fluff pulp in hygiene and tissue products continues to be stable, supported by global inventories which are at or below the 5-year average.Wood ProductsQ2 experienced a seasonal surge in volumes of classic sawn products. However, sales and volumes are projected to decrease sequentially in Q3 due to the holiday season. Building permits are anticipated to fall below 2023 levels and are expected to slightly decline in Western Europe in the foreseeable future. Meanwhile, wood costs are forecast to remain elevated.ForestIn Q3, wood market activity is expected to remain strong in Finland, Sweden, and the Baltics, with tight conditions driven by increasing demand for industrial wood (pulpwood and sawlogs).Long-term growth opportunitiesStora Enso holds leading positions in markets and segments poised for long-term growth, particularly in sustainable packaging, wood construction, and innovative biomaterials. The Group stands to benefit from sustainability trends and regulatory advancements which favour its offerings, thereby supporting its market presence and facilitating development.Key figures EUR Q2/24 Q2/23 Change Q1/24 Change Q1 Q1 Change 2023million % % -Q2/24 -Q2/23 % Q2/24–Q Q2/24–Q Q1 -Q2/24– 2/23 1/24 Q1 -Q2/23Sales 2,301 2,374 -3.0% 2,164 6.3% 4,466 5,095 -12.4% 9,396Adjusted 312 198 57.4% 298 4.9% 610 597 2.2% 989EBITDAAdjusted 161 37 n/m 156 2.8% 317 271 17.2% 342EBITAdjusted 7.0% 1.6% 7.2% 7.1% 5.3% 3.6%EBITmarginOperating 99 -253 139.2% 148 -33.2% 247 5 n/m -322result(IFRS)Result 50 -304 116.5% 101 -50.4% 152 -76 299.3% -495beforetax(IFRS)Net 42 -257 116.4% 84 -49.9% 126 -72 276.2% -431resultfor theperiod(IFRS)Forest 8,725 8,065 8.2% 8,626 1.1% 8,725 8,065 8.2% 8,731assets1Adjusted 2.8% 8.1% 1.9% 2.8% 8.1% 2.4%return oncapitalemployed(ROCE),LTM2Adjusted 1.3% 10.7% 0.0% 1.3% 10.7% 1.0%ROCEexcl.Forestdivision,LTM2Earnings 0.07 -0.27 125.3% 0.09 -23.5% 0.16 -0.04 n/m -0.73pershare(EPS)excl. FV,EUREPS 0.06 -0.29 119.4% 0.11 -48.2% 0.16 -0.05 n/m -0.45(basic),EURNet debt 3.5 1.7 4.0 3.5 1.7 3.2toLTM2adjustedEBITDAratioAverage 19,469 21,171 -8.0% 19,412 0.3% 19,465 21,182 -8.1% 20,822number ofemployees(FTE) 1 Total forest assets value, including leased land and Stora Enso's share of Tornator.2 LTM=Last 12 months Stora Enso’s President and CEO Hans Sohlström comments on the second quarter 2024 results:I am encouraged by the fact that our Q2 performance met our expectations, reinforcing our recently upgraded 2024 guidance. Advances in our profitability and cash flow improvement initiatives, coupled with more favourable market conditions in some segments, have supported an improved earnings trend for the third consecutive quarter. Additionally, this has strengthened our leverage ratio in the quarter despite record high growth investments. This positive development is a testament to our team's dedication and sets a strong foundation for future success.Our year-on-year Group sales dipped slightly, by 3.0%, to 2,301 million euro due to structural changes; however, our continuing operations grew by 1%. Increasing volumes in all divisions and favourable pricing in the Biomaterials and Forest divisions contributed positively. Our adjusted EBIT rose significantly to 161 million euro from 37 million euro a year ago, with the margin improving to 7.0% from 1.6%. The result was driven by higher volumes and reduced fixed and chemical costs, despite challenges such as rising wood costs and political strikes in Finland.While we managed to improve our net debt to adjusted EBITDA ratio to 3.5 from 4.0 in Q1 this year, it remains above our target of 2.0 and has increased compared to the 1.7 ratio in Q2 last year. This highlights the need for further profitability improvement and working capital reduction actions, which remain our priority. The stable valuation of our forest assets at 8.7 billion euro, or 11 euro per share, continues to provide a solid foundation for our future growth and value creation.Our value creation programmes, centred on sourcing, operational and commercial efficiencies, are making good progress across all divisions, thanks to an analytical and structured approach. These efforts have had a significant impact on profits and cost competitiveness, with about 1,900 identified improvement initiatives led by approximately 500 project owners. Additionally, our profit improvement programme, which aims for an annual fixed cost saving of 120 million euro, is advancing successfully. Together, these initiatives are contributing to sustained enhancements in profitability and competitiveness. Furthermore, we have reduced operating working capital by 576 million euro year-on-year, reaching an unprecedented low, driven by ongoing efforts to enhance working capital efficiency and release capital.The plan to divest the Beihai operation in China is proceeding. We are diligently moving forward with the process, and although it is lengthy, achieving the right value for our assets is most crucial. Ultimately, the value of the deal takes precedence over the timing.Our decentralised operating model is firmly in place and progressing well towards achieving a more focused customer and business oriented structure. I am delighted with the strides we have made, and we are already witnessing the advantages of a more efficient and agile framework. This not only benefits our strategic execution, but also enhances the service we provide to our customers.In the quarter, we conducted an Employee Engagement pulse survey across three of our five divisions. The results indicate that the level of employee engagement has remained consistently high and has even shown a slight increase in these divisions. This is particularly encouraging given the challenging circumstances in which we have been operating.We increased our outlook for the adjusted EBIT for the full year 2024 on 15 May, projecting it to be significantly higher than the profits of 342 million euro achieved last year. We remain on track to deliver on that guidance, supported by our value creation and profit improvement actions, as well as improved market conditions in some of our key segments.We are intensifying our focus on capital allocation and asset strategy in growing market segments, laying the groundwork for improved competitiveness and profitable growth across the Group. Looking ahead, we anticipate further advancements this year. We remain committed to investing in both human and capital resources to provide exceptional service to our customers and create robust shareholder value growth. Webcast for analysts, investors, and mediaAnalysts, investors, and media are invited to participate in the webcast with a teleconference today at 11:00 am EEST (10:00 CEST, 9:00 BST, 4:00 EDT). The results will be presented by President and CEO Hans Sohlström and CFO Seppo Parvi. The presentation can be followed live via the link: https://stora-enso-oyj-q2-earnings-presentation-2024.open-exchange.net/registrationDuring the webcast presentation, analysts and investors will also have the possibility to ask questions. To participate in the teleconference, please choose the “Teleconference” option on the homepage of the webcast. Recording of the webcast will be available shortly after the event at the same address and at storaenso.com/en/investors/interim-report Media representatives who wish to ask questions after the publication of the report may contact Carl Norell, SVP Corporate Communications at Stora Enso on +46 72 241 0349.This release is a summary of Stora Enso’s Half-year Report 2024. The complete report is attached to this release as a pdf file. It is also available on the company website at storaenso.com/en/investors/interim-report . Media enquiries:Carl NorellSVP Corporate Communicationstel. +46 72 241 0349Investor enquiries:Anna-Lena ÅströmSVP Investor Relationstel. +46 70 210 7691Part of the global bioeconomy, Stora Enso is a leading provider of renewable products in packaging, biomaterials, and wooden construction, and one of the largest private forest owners in the world. Stora Enso has approximately 20,000 employees and our sales in 2023 were EUR 9.4 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in the USA on OTC Markets (OTCQX) as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors STORA ENSO OYJ

Rottneros interim report January-June 2024

NET TURNOVER increased by 4 percent to 711 (681) MSEK. Compared to the first quarter of 2024, turnover rose by 3 percent due to higher market prices. THE LIST PRICE of NBSK pulp was 16 percent higher compared with the second quarter of 2023. Compared with the first quarter of 2024, the list price rose 13 percent. The market price of CTMP rose by 1 percent compared with the second quarter of 2023 and decreased by 2 percent from the first quarter of 2024. PRODUCED VOLUME amounted to 91.0 (93.2) thousand tonnes, which is 2 percent lower than in the corresponding quarter of 2023. VOLUME SOLD rose to 88.6 (82.8) thousand tonnes, an increase of 7 percent. EBIT (operating profit) was 30 (41) MSEK. Compared with the corresponding quarter of 2023, selling prices were lower while volumes were higher. EBIT increased from the first quarter of 2024 as a result of rising prices and higher production volumes. NET PROFIT for the quarter amounted to 22 (34) MSEK. Earnings per share totaled 0.15 (0.22) SEK. THE BALANCE SHEET remains strong. The equity/assets ratio was 64 (65) percent. Available liquidity amounted to 298 (714) MSEK. Net debt was 112 MSEK. INVESTMENTS in the ongoing investment plan amounted to 216 (65) MSEK for the first half of the year. ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ Statement by the CEO After starting the year with production-related challenges, we delivered a better result than in the first quarter thanks to stable production and good cost control. At the same time, there are identified areas for improvements that will be addressed going forward. The pulp market continued to move in the right direction with clear price increases. In general, this year has been marked by a high pace of investment in our business, with all projects progressing as planned. Our strong focus on meeting customer needs and growing long-term niches, along with our solid financials, provides us with an excellent starting point. Safety, high availability and efficiency in the mills remain our top priorities. Unfortunately, a serious workplace accident occurred in June at Rottneros Mill, where two people were seriously and one slightly injured while working on a transformer. The incident is deeply regrettable and something we view with great concern. The safety of our employees is, of course, always at thetop of our agenda. The cause of the accident is now being thoroughly investigated. Net turnover grew by 4 percent compared with the same quarter last year, to 711 MSEK, as a result of increased deliveries combined with higher pulp prices. Earnings improved compared with the previous quarter, which was negatively impacted by production disruptions. EBIT totaled 30 MSEK, which is 11 MSEK lower than the second quarter of 2023. A slight decline in production and higher prices and deliveries also affected the trend. Production for the Group as a whole decreased by 2 percent as a result of a slightly lower rate at Vallvik Mill. Rottneros Mill continued to perform well, with a 1 percent increase in production. We continue to have a good supply of pulp wood, in part due to our long-term efforts to build close relationships with our suppliers. However, the steady increase in competition for wood causes prices to keep rising, albeit at a slower pace. We have secured the supply of pulp wood for the expanded production capacity at Rottneros Mill, which will come online in the final quarter of the year. Intense investment activity, all projects proceeding according to planThis year, we have a fast pace of ongoing maintenance investments to guarantee reliable and stable production. In parallel, we are preparing for the future with our major investment projects, including expanded CTMP capacity and solar cells with associated battery storage at Rottneros Mill and the tall oil plant at Vallvik. The projects are proceeding according to plan, with start-ups scheduled for the summer and autumn. Investments will total approximately 430 MSEK for the year as a whole. Investments for the quarter totaled 134 MSEK. Pulp market remains stableThe market for spruce and pine-based chemical pulp based continued to show steady growth.A favorable supply-demand balance caused prices to continue rising during the quarter to around1,600 USD per tonne of bleached chemical longfiber pulp at the end of June, up about 150 USD since the end of March. Inventory levels were relatively low, while demand grew in both Europe and North America. Overall, our customers are interested in increasing volumes, particularly in our niche segments such as e-pulp and filters. Rottneros Packaging project on track, strong interest in our climate-smart packagingInterest in our fossil-free and climate-friendly packaging solutions continues to be strong and is on the rise. Our investment project for large-scale production of molded fiber trays in Poland together with Arctic Paper is progressing as planned, with production expected to begin in the third quarter. The production lines will be installed after the summer. A strong balance sheet ensures freedom of actionWe are maintaining our strong balance sheet despite the high pace of investment this year. It is a key element in our long-term efforts to develop and grow our business. The equity ratio at the end of the quarter was 64 percent, while available liquidity was 298 MSEK. In conclusion, I would like to express my gratitude to all employees for their strong commitment to Rottneros. I would also like to thank our customers, suppliers, shareholders and the Board of Directors for their close and fruitful cooperation. Lennart Eberleh, President and CEO (For full report, see attached pdf) This information is such information that Rottneros AB is required to disclose in accordance with the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication on 24 July, 2024 at 08.00 by the contact person below. This report has been prepared in both a Swedish and an English version. In the event of deviations between the two, the Swedish version shall prevail. __________________________________________________________________________________________________________________________________________________________ Reminder; Invitation to Rottneros’ presentation of interim report Q2 2024 All participants can follow the presentation via the web link at 12.00 CET 24 July 2024. Rottneros – Q2 Presentation 2024 - Finwire  The presentation will be held in English. Questions can be asked in English or Swedish, via the link in advance or during the presentation.You can also watch the presentation afterwards via Rottneros'  Youtube channel  and website: Rapporter & presentationer | Rottneros  For further information please contact:Lennart Eberleh, President and CEO, Rottneros AB,+46 (0) 270 622 65, lennart.eberleh@rottneros.com Monica Pasanen, CFO, Rottneros AB,+46 (0) 270 622 70, monica.pasanen@rottneros.com

Metso’s Half-Year Report for January-June 2024

Figures in brackets refer to the corresponding period in 2023, unless otherwise stated. Second quarter 2024 in brief · Customer activity remained at the previous quarter's level with continued delayed decision-making · Orders received declined 14% to EUR 1,162 million (EUR 1,344 million), equipment-23% and services -6% · Sales declined 13% to EUR 1,214 million (EUR 1,396 million), equipment -21% and services -6% · Adjusted EBITA was EUR 205 million, or 16.9% of sales (EUR 238 million, or 17.1%) · Operating profit was EUR 195 million, or 16.1% of sales (EUR 222 million, or 15.9%) · Cash flow from operations improved to EUR 152 million (EUR 62 million) January-June 2024 in brief · Orders received declined 11% to EUR 2,523 million (EUR 2,829 million) · Sales declined 11% to EUR 2,431 million (EUR 2,729 million) · Adjusted EBITA declined 10% to EUR 405 million, or 16.7% of sales (EUR 449 million, or 16.5%) · Operating profit declined to EUR 383 million, or 15.8% of sales (EUR 416 million, or 15.2%) · Earnings per share were EUR 0.30 (EUR 0.34) and for continuing operations EUR 0.31 (EUR 0.34) · Cash flow from operations improved to EUR 309 million (EUR 173 million) President and CEO Pekka Vauramo: We maintained robust profitability during the second quarter, thanks to our focused actions. However, market dynamics evolved as anticipated: customer decision-making remained slow in Minerals, and Aggregates faced challenges in the North American mobile equipment market. Consequently, our total order intake declined by 14% year-on-year, primarily due to a decrease in equipment orders. Although the services businesses remained more stable, the aforementioned issues led to a slight decline in services orders, which were further affected by exchange rates. Our income statement for the quarter closely resembles that of the first quarter. Lower equipment backlogs and the timing of deliveries led to reduced sales compared to the same period last year, but the Group’s sales were sequentially at the same level. Thanks to a healthy gross margin, supported by ongoing cost management and a higher proportion of services in the sales mix, we achieved an adjusted EBITA margin of 16.9% for the quarter. This confirms that we are making progress in fortifying our financial performance against cyclicality. Another positive development was in the cash flow from operations, which improved to EUR 152 million. The Aggregates segment sales declined 14% compared to the previous year, primarily due to reduced orders in the preceding quarters. Despite this decrease in volume, the segment achieved a solid adjusted EBITA margin of 16.6%, underscoring the effectiveness of efforts made to enhance business resilience. In May, we launched the Lokotrack EC range, bringing a new diesel-electric power line to the aggregates market. Designed with modularity in mind, these units can adapt to customers’ future requirements and run on interruptible renewable energy. Furthermore, the process functions in these mobile units operate entirely on electricity, significantly reducing the use of hydraulic oil in crushing operations. Additionally, in June, we committed to investing EUR 150 million in a state-of-the-art aggregates technology center in Tampere, Finland. The production of track-mounted Lokotrack crushing plants is scheduled to commence at the new site in the third quarter of 2027, with plans to eventually relocate all our existing Tampere operations to this modern facility. Minerals experienced a 13% decline in sales, primarily due to reduced equipment backlog and delivery timing. However, the segment demonstrated increased resilience, reporting an adjusted EBITA margin of 17.3%. This positive performance can be attributed to the favorable impact of effective cost management and sales mix on the gross margin. Notably, during the quarter, we received a substantial order from India for recycling electronic waste. Our e-scrap solutions offer compelling opportunities for customers by enabling the recovery of valuable metals from waste. We anticipate that customer decision-making in Minerals will gain momentum during the second half of the year, driven by favorable copper prices. Additionally, Minerals services are poised for sustained demand, thanks to robust mine production volumes. However, in Aggregates, activity is expected to continue at a lower level year-on-year. This can be attributed to the surplus of distributor inventories in the North American mobile equipment market. Internally, we have successfully maintained strong profitability, and our focus remains on cost control and cash flow, while delivering value-added products and services to our customers. Market outlook Metso expects that the market activity in both Minerals and Aggregates will remain at the current level. In its previously published outlook, Metso expected that the market activity in both Minerals and Aggregates will remain at the current level. According to the company's disclosure policy, Metso’s market outlook describes the expected sequential development of market activity, adjusting for seasonality, during the following six-month period using three categories: improve, remain at the current level, or decline. Key figures EUR million Q2/202 Q2/202 Change Q1–Q2/2 Q1–Q2/2 Change 2023 4 3 % 024 023 %Orders received 1,162 1,344 -14 2,523 2,829 -11 5,252Orders received by 701 742 -6 1,516 1,597 -5 2,955services business% of orders received 60 55 – 60 56 – 56Order backlog 3,091 3,311 -7 2,951Sales 1,214 1,396 -13 2,431 2,729 -11 5,390Sales by services 690 734 -6 1,417 1,423 0 2,891business% of sales 57 53 – 58 52 – 54Adjusted EBITA 205 238 -14 405 449 -10 887% of sales 16.9 17.1 – 16.7 16.5 – 16.5Operating profit 195 222 -12 383 416 -8 805% of sales 16.1 15.9 – 15.8 15.2 – 14.9Earnings per share, 0.16 0.18 -11 0.31 0.34 -9 0.65continuing operations,EURCash flow from 152 62 143 309 173 79 550operationsGearing, % 40.6 35.5 – 40.6 35.5 – 33.8Personnel at end of 17,105 16,836 2 17,134period Audiocast and conference call details   An audiocast and a conference call for analysts and investors will be arranged today at 1:00 p.m. EEST. The audiocast can be followedat the company’s website . A recording and a transcript will be available at the same webpage after the event has finished.The teleconference can be accessed by registering on the link below. https://palvelu.flik.fi/teleconference/?id=50048707  The complete Half-Year Report for January-June 2024 is available as an attachment to this release.Further information, please contact:  Juha Rouhiainen, Vice President, Investor Relations, Metso Corporation, tel. +358 20 484 3253, email: juha.rouhiainen(a)metso.com (juha.rouhiainen@metso.com)   Distribution:  Nasdaq Helsinki Ltd Main media www.metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and process expertise. We are the partner for positive change. Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial

ZKTeco and Zwipe Announce Collaboration to Deliver High-Security Access Solutions in Europe

OSLO, NORWAY and MADRID, SPAIN – 24 July 2024 – ZKTeco, a globally recognized leader in access control solutions, is proud to announce a partnership with Zwipe, a leader in biometric technology for cards used in identification, access control, and payment. Together, they aim to deliver cutting-edge, high-security access solutions in Europe. This collaboration leverages the strengths of both companies to offer advanced, reliable and user-friendly security systems designed to meet the growing demand for high-level security across various sectors. This partnership integrates the Zwipe Access Biometric Smart Card with the ARMATURA access control system. It is the ideal solution for companies requiring a high security level. This partnership will enable businesses to benefit from a centralized and unified security management solution. “We are pleased to partner with Zwipe, a leading company in this market sector,” says Samuel Muñoz, Integrations Manager at ZKTeco Europe. ARMATURA, a high security and cybersecurity brand, showcases its expertise in access control security products and solutions in collaboration with ZKTeco. Robert Puskaric, President and CEO of Zwipe, commented, “We are thrilled to partner with ZKTeco. We look forward to developing and strengthening biometric-enabled access control solutions with ZKTeco. Combined, our technologies will provide enhanced security access control for organizations worldwide.” About ZKTeco Europe ZKTeco is a multinational enterprise, specializing in the manufacture and development of advanced CCTV, Time & Attendance, and Access Control technology. With over 30 years of experience in the global market, ZKTeco benefits from a highly qualified team of over 4.100 employees worldwide with its own manufacturing plants that, together with its R&D and engineering departments, ensure complete inhouse production of all aspects of its hardware, firmware, and software. One of the pioneers in multibiometric and RFID technology, ZKTeco’s products are present around the world, with over 180 million users worldwide. About Zwipe Zwipe believes the inherent uniqueness of every person is the key to a safer future. We work passionately across networks of international organizations, industries, and cultures to make convenience safe and secure. We pioneer next-generation biometric card technology for payment, physical and logical access control, and identification solutions. We promise our customers and partners deep insight and frictionless solutions, ensuring a seamless user experience with our innovative biometric products and services. Zwipe is headquartered in Oslo, Norway, with a global presence. To learn more, please visit http://www.zwipe.com/.

Wyld Networks launches the AT452 Satellite Tracker for GPS location data for asset tracking

The Wyld Connect AT452 Satellite Tracker is a comprehensive solution for location-based tracking utilising the power of low earth orbiting satellites to provide global network coverage. In a World-first, following successful trials in South America of this unique solution, Wyld is commencing deployment, starting with Brazil. If your business needs to know the location of assets in transit, of assets that are on the move continuously, regularly or in frequently then the AT452 Satellite Tracker with low power consumption can deliver your asset location data to your end application. Here are the key features and benefits: 1.No Additional Ground Infrastructure Needed: The data transmitted via the AT452 Satellite Tracker is received directly through the satellite constellation, eliminating the need for extra ground-based infrastructure. 2.Simplified Global Deployments: By exploiting satellite networks, vast areas of otherwise uncovered land and at sea are now reachable, removing the complexities of managing multiple country service contracts and roaming fees, providing a single, simple solution. 3.Cost-Effective IoT Connectivity: By leveraging Wyld Networks IoT satellite network, the AT452 Satellite Tracker offers a low-cost, reliable one-way data communication solution ideal for the asset tracking market. The AT452 Satellite Tracker streamlines the process of adding satellite IoT GPS data capabilities to assets in remote locations, offering a reliable, cost-effective, and globally applicable solution for asset tracking. Use cases are multifarious but will include deployments with containers, pallets, unmanned floating platforms, buoys, agricultural equipment and more. "The new AT 452 Satellite Tracker solves a major known business challenge across multiple vertical markets. How to collect GPS data on the 85% of the earth's surface that has no cellular coverage," said Alastair Williamson, CEO Wyld Networks. "This solution solves this issue and will enable other sensor data such as temperature, pressure and humidity to be related to location." For further information, please contact: Alastair Williamson, CEO Wyld NetworksE-mail: alastair.williamson@wyldnetworks.com Tel: +44 7 824 997689 About Wyld Networks AB Wyld Networks develop and sell innovative wireless technology solutions that enable affordable connectivity anywhere in the World, addressing the problems for businesses and people regarding the lack of global mobile network coverage. The solutions are mainly targeted to wireless connectivity for the Internet of Things (IoT) and people. Wyld Networks Ltd was formed in Cambridge, UK in 2016 and is a wholly owned subsidiary of Wyld Networks AB. The Wyld Networks share (WYLD) is traded on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB (tel +46 8-5030 1550, email ca@mangold.se). Read more on www.wyldnetworks.com

Wärtsilä electrification solutions to support CSL with emission reduction targets

Technology group Wärtsilä will supply a hybrid-electric propulsion system for an 11,000 dwt Limestone Carrier. The vessel was contracted by Montreal-based CSL Group (“CSL”) with CCCC Shanghai Equipment Engineering and Jingjiang Nanyang Shipbuilding. The order with Wärtsilä was booked in Q1 2024. The order reflects CSL’s focus on reducing its emissions profile via a comprehensive decarbonisation strategy. Wärtsilä has been closely involved in developing the concept for the hybrid-electric propulsion system  selected to optimise the engine and battery loading for the ship’s operating conditions. The system will provide redundancy when operating in confined waters to improve safety, while at the same time improving efficiency and reducing fuel consumption. “We require an electrically integrated hybrid-powered propulsion solution from a single-source supplier capable of providing lifecycle support. Wärtsilä was selected for our newbuild project because of their proven ability, experience and track record in delivering high-quality electrification and hybridisation systems,” says Frédéric Jauvin, CSL’s Vice-President, Global Technical Services. The Limestone Carrier, when delivered in 2026, will be the world’s first fully electric battery-capable self-unloading vessel. It will initially run on a hybrid diesel and battery system, with 50% of total battery capacity installed replacing diesel with electric power. By 2031, the aim is to run the ship entirely on electric power, further reducing carbon emissions to less than 10%. “Wärtsilä is committed to making decarbonised shipping possible, so we are delighted to be supporting CSL with solutions that enhance the sustainability of their fleet,” comments Torsten Büssow, Director, Electrical & Power Systems Business Wärtsilä Marine. “This is a short sea shipping vessel that will operate with a lot of manoeuvring and variable load profiles, and electrification and hybridisation systems are the most efficient for such vessels.” For this vessel, Wärtsilä will supply the whole hybrid electric propulsion system, including generators, DC hub, Energy and Power Management System, main propulsion e-motors, bow thruster e-motors, and the battery solution. Delivery is scheduled for early 2025. Media contact for more information on this release: Isabella Alder Positioning and Strategic Communications Manager, Wärtsilä Marine Tel: +44 (0) 7792 681 757  marine.media@wartsila.com  (marine.media@wartsila.com%C2%A0) Image caption: Example image of a ship electrification ecosystem. © Wärtsilä Corporation   All Wärtsilä releases are available at https://www.wartsila.com/media/news-releases and at http://news.cision.com/wartsila-corporation where also the images can be downloaded. Use of the image(s) is allowed only in connection with the contents of this press release. Wärtsilä images are available at https://www.wartsila.com/media/image-bank .Wärtsilä Marine in briefWärtsilä Marine is a global pioneer in power, propulsion and lifecycle solutions for the marine market. We develop industry-leading technologies, advancing maritime's transition to new fuels. We support building an end-to-end digital ecosystem where all vessels and ports are connected. Ultimately, Wärtsilä Marine is driving the shipping industry forward on its journey towards a decarbonised and sustainable future through our broad portfolio of engines, propulsion systems, hybrid technology, exhaust treatment, shaft line solutions and digital technologies, as well as integrated powertrain systems. Our offering, which is underpinned by our performance-based agreements, upgrades, lifecycle solutions, decarbonisation services, as well as an unrivalled global network of maritime expertise, delivers the efficiency, reliability, safety, and environmental performance needed to support a safe and sustainable future for our customers, our communities and our planet. www.wartsila.com/marine Wärtsilä in briefWärtsilä is a global leader in innovative technologies and lifecycle solutions for the marine and energy markets. We emphasise innovation in sustainable technology and services to help our customers continuously improve environmental and economic performance. Our dedicated and passionate team of 17,800 professionals in more than 280 locations in 79 countries shape the decarbonisation transformation of our industries across the globe. In 2023, Wärtsilä’s net sales totalled EUR 6.0 billion. Wärtsilä is listed on Nasdaq Helsinki.  www.wartsila.com

CS MEDICA Receives "Intention To Grant" for European Patent Application Concerning CANNASEN® Psoriasis Gel, Reinforcing Leadership in CBD-infused Dermatological Innovations

CS MEDICA is proud to announce the receipt of an "Intention To Grant" for its patent application from the European Patent Organization (EPO), which has 39 member states[1]. This achievement enhances the protection of its innovative product, CANNASEN® Psoriasis Gel, which contains CBD. This patent discloses a novel treatment approach for psoriasis symptoms such as pain, itch, redness, scaling, and inflammation, along with the specific composition of the psoriasis gel. Psoriasis, an immune-mediated disorder, affects over 125 million people globally, manifesting in painful symptoms such as itchiness, redness, scaling, and inflammation due to excessive skin cell production triggered by an overactive immune system. Of these, approximately 80% experience mild to moderate symptoms, while 20% suffer from severe forms of the disease. Notably, 50% of all psoriasis patients are actively seeking alternative treatments[2] to avoid the side effects commonly associated with traditional therapies. Cannabidiol (CBD) is widely acknowledged by scientists and patients for its therapeutic benefits, which include analgesic, anti-inflammatory, immunosuppressive, antiproliferative, and antioxidant properties. Additionally, CBD is known to reduce itching and act as a homeostatic regulator. CANNASEN® Psoriasis Gel represents a dermatological care breakthrough, harnessing CBD's therapeutic potential. As one of the first compliant substance-based treatments with CBD for psoriasis to achieve patent protection, this marks a significant milestone in dermatological care. The patent approval follows a PCT international application, confirming the company's innovative approach and the effectiveness of its product. "We are delighted by the 'Intention To Grant' status for our European patent application," stated Lone Henriksen, CEO of CS MEDICA. "This validation underscores our commitment to pioneering innovations that meet stringent regulatory standards, including MDR, MHRA, FDA, and TGA, ensuring our product's compliance and efficacy." Following the “mention of grant” of the patent application by the EPO, CS MEDICA will initiate the process for national validations for relevant European countries. Securing patent protection is crucial for a MedTech company like CS MEDICA, as it not only safeguards its intellectual property but also significantly enhances the valuation of the product portfolio. While generating sales in existing markets is vital, obtaining patent protection for innovations like CANNASEN® Psoriasis Gel ensures long-term competitive advantage and opens up additional revenue streams through potential licensing and partnerships. This strategic move underscores the commitment to delivering value to shareholders by protecting and capitalizing on groundbreaking technologies. "We believe that securing patent protection not only validates our novel approach but also sets a precedent for CBD-infused therapies in dermatology," added Lone Henriksen. Looking ahead, CS MEDICA expects to obtain patent protection for CANNASEN® Psoriasis Gel across key global markets, including the USA, Canada, India, China, and Australia. CS MEDICA remains committed to transforming the treatment landscape for people with psoriasis, offering hope for improved quality of life through innovative, safe, and clinically validated solutions.   [1] https://www.epo.org/en/applying/european/unitary/unitary-patent [2] Source:  6.1 https://www.psoriasis.org/psoriasis-statistics/ - 6.2 https://www.fortunebusinessinsights.com/industry-reports/psoriasis-treatment-market-100600 - 6.3 https://globalranetwork.org/ project/disease-info/- 6.4 Rheumatoid Arthritis marked- https://www.globenewswire.com/news-release/2022/01/28/2374912/28124/en/The-Worldwide-Rheumatoid-Arthritis-Drugs-Industry-is-Expected-to-Reach-34-3-Billion-by-2027.html -6.5 https://onlinelibrary.wiley.com/doi/full/10.1111/resp.13838 -6.6 https://www.alliedmarketresearch.com/sleep-aids-market - 6.7 https://www.prnewswire.com/news-releases/global-alopecia-market-size-to-reach-usd-13-80-billion-in-2028--says-reports-and-data-301500078.html- 6.8 https://www.blueweaveconsulting.com/report/global-hair-care-products-market-bwc19130 -6.9 https://soft-ox.com/chronic-wounds/- 6.10 https://www.fortunebusinessinsights.com/wound-care-market-103268 -6.11 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201926/ -6.12 https://www.alliedmarketresearch.com/pain-management-therapeutics-market6.13 https://www.aafa.org/ allergy-facts/- 6.14 https://www.alliedmarketresearch.com/allergy-treatment-market -6.15 https://www.who.int/news/item/08-06-2018-recognizing-neglected-skin-diseases-who-publishes-pictorial-training-guide -6.16 https://www.bccresearch.com/market-research/pharmaceuticals/skin-disease-treatment-technologies-markets-report.html   

Archer Limited: Archer secures contract worth USD 40 million in Brazil

Archer Limited: Archer secures contract worth USD 40 million in Brazil Hamilton Bermuda, (July 24, 2024) Archer has been awarded a two-year contract for platform drilling services for Equinor in Brazil.  The estimated firm contract value is USD 40 million. The contract will commence in November 2024 in direct continuation of Archer’s current contract for drilling operations and maintenance on Equinor’s Peregrino A & B platforms and includes an optional two-year extension period. Alexander Olsson, EVP Platform Operations comments: ‘’We are proud that Equinor has chosen to continue their relationship with Archer in Brazil where we have been the partner of choice since the start of drilling operations in 2008. This contract reflects our client’s confidence in our ability to maintain safe and efficient operations across both their platforms. It is testament to the hard work and dedication of our teams who have supported both the Peregrino A & B assets for over fifteen years. This contract is an important part of Archer’s strategy to increase and strengthen operations in key regions and gives us visibility to continue our international growth”. For additional information please contact: Espen Joranger, Chief Financial Officer | Mobile: +47 982 06 812 | Email: espen.joranger@archerwell.com Joachim Houeland, Manager Treasury & Investor Relations | Mobile: +47 482 78 748 | Email: joachim.houeland@archerwell.com This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act).

Valmet’s Half Year Financial Review 2024: Orders received remained at the previous year's level and amounted close to EUR 1.3 billion and Comparable EBITA decreased to EUR 141 million in Q2

Valmet’s Half Year Financial Review January 1 – June 30, 2024: Orders received remained at the previous year's level and amounted close to EUR 1.3 billion and Comparable EBITA decreased to EUR 141 million in the second quarter Valmet Oyj’s stock exchange release onJuly24, 2024 at 2:00 p.m. EEST Figures in brackets, unless otherwise stated, refer to the comparison period, i.e., the same period of the previous year. April–June 2024: Orders received remained at the previous year's level •         Orders received remained at the previous year’s level and amounted to EUR 1,283 million (EUR 1,268 million). –        Orders received increased in the Services segment, remained at the previous year's level in the Automation segment, and decreased in the Process Technologies segment. –        Orders received increased in EMEA (Europe, Middle East and Africa), North America and China, and decreased in Asia-Pacific and South America. •         Net sales decreased 7 percent to EUR 1,324 million (EUR 1,417 million). –        Net sales remained at the previous year's level in the Automation and Services segments and decreased in the Process Technologies segment. •         Comparable earnings before interest, taxes and amortization (Comparable EBITA) decreased 8 percent to EUR141 million (EUR 153 million). –        Comparable EBITA remained at the previous year's level in the Services and Automation segments and decreased in the Process Technologies segment. •         Comparable EBITA margin was 10.6 percent (10.8%). •         Earnings per share (EPS) were EUR 0.31 (EUR 0.54). EPS decreased mainly due to lower operating profit and higher net financial expenses. Adjusted EPS was EUR 0.43 (EUR 0.60). Adjusted EPS decreased mainly due to lower EBITA and higher net financial expenses. •         Items affecting comparability amounted to EUR -9 million (EUR 2 million). •         Cash flow provided by operating activities totaled EUR 128 million (EUR -37 million). January–June 2024: Orders received amounted to EUR 2,333 million •         Orders received decreased 17 percent to EUR 2,333 million (EUR 2,821 million). –        Orders received remained at the previous year's level in the Services segment and decreased in the Process Technologies and Automation segments. –        Orders received remained at the previous year's level in EMEA and decreased in China, South America, Asia-Pacific and North America. •         Net sales decreased 7 percent to EUR 2,536 million (EUR 2,738 million). –        Net sales remained at the previous year's level in the Services and Automation segments and decreased in the Process Technologies segment. •         Comparable EBITA decreased 9 percent to EUR262 million (EUR 286 million). –        Comparable EBITA remained at the previous year's level in the Automation and Services segments and decreased in the Process Technologies segment. •         Comparable EBITA margin was 10.3 percent (10.5%). •         EPS was EUR 0.62 (EUR 0.92). Adjusted EPS was EUR 0.84 (EUR 1.11). •         Items affecting comparability amounted to EUR -16 million (EUR 0 million). •         Cash flow provided by operating activities totaled EUR 267 million (EUR 172 million). Guidance for 2024 Valmet reiterates its guidance issued on June 13, 2024, in which Valmet estimates that net sales in 2024 will remain at the previous year's level in comparison with 2023 (EUR 5,532 million) and Comparable EBITA in 2024 will increase in comparison with 2023 (EUR 619 million). Short-term market outlook Valmet estimates that the short-term market outlook for pulp has increased to satisfactory (previously weak) and that the short-term market outlook for board and paper has increased to satisfactory (previously weak/satisfactory, in which weak referred to customer activity and satisfactory to Valmet's capacity utilization). Furthermore, Valmet estimates that the short-term market outlook for energy has decreased to satisfactory (previously good). Valmet reiterates the good short-term market outlook for services, flow control and automation systems, and the satisfactory short-term market outlook for tissue. The short-term market outlook is given for the next six months from the end of the reported period. It is based on customer activity (50%) and Valmet’s capacity utilization (50%), and the scale is ‘weak–satisfactory–good’. President and CEO Pasi Laine: Orders received remained at the previous year's level and amounted close to EUR 1.3 billion in the second quarter "Valmet’s orders received remained at the previous year’s level and amounted close to EUR 1.3 billion in the second quarter. Orders received increased in Services, remained at the previous year’s level in Automation and decreased in Process Technologies. Orders received in Valmet’s stable business totaled close to EUR 3.1 billion during the last four quarters, representing 69% of Valmet’s orders received. This is a clear change in the company compared to 2014, when stable business represented 34% of orders received. Valmet’s order backlog amounted to EUR 3.8 billion at the end of the quarter. Valmet’s net sales amounted to EUR 1.3 billion. Net sales remained at the previous year’s level in Services and Automation, and decreased in Process Technologies. Comparable EBITA margin was 16.9% in Services, 16.5% in Automation and 3.0% in Process Technologies. Comparable EBITA totaled to EUR 141 million and amounted to EUR 80 million in Services, EUR 58 million in Automation and EUR 15 million in Process Technologies. Valmet’s short-term market outlook remains good for Services and Automation segments. Today, we have increased Process Technologies' short-term market outlook for pulp, and for board and paper to satisfactory. The short-term market outlook for energy was decreased to satisfactory. The market activity overall has improved compared to the end of Q1/2024 and we have a good starting point in terms of market activity going into the second half of the year. During the quarter, Valmet revised upwards its Comparable EBITA guidance for 2024. In the new guidance, Valmet estimates that net sales in 2024 will remain at the previous year's level in comparison with 2023 and Comparable EBITA in 2024 will increase in comparison with 2023. I have been working in different positions at Valmet and its predecessors for several decades and as Valmet’s President and CEO since Valmet became an independent company in 2013. Since 2013, Valmet has created approximately EUR 5 billion in total shareholder value, taking the full dividend for 2023 into account. I am extremely proud of this and many other important milestones that we have achieved together as Valmeteers during these years. As I prepare to step down from my role, I am confident that the foundation we have built positions Valmet well for continued success in the future. I wish to extend my deepest thanks to our customers and partners for the good cooperation we have enjoyed over the years, to our shareholders for your trust, and to all my colleagues at Valmet for your hard work, dedication and passion." Chair of the Board Mikael Mäkinen "This interim review is the last one under Pasi Laine’s leadership as the President and CEO of Valmet. The Board of Directors gratefully thank Pasi for his contribution in developing Valmet into a strong and unique company. Valmet has a solid foundation to continue its excellent performance path also in the future", says Mikael Mäkinen, Chair of the Board, Valmet. Thomas Hinnerskov to start as the President and CEO of Valmet as of August 12, 2024 On February 19, 2024, Valmet’s Board of Directors appointed Thomas Hinnerskov as the President and CEO of Valmet. He will start in the position on August 12, 2024. Thomas Hinnerskov succeeds Pasi Laine, who will continue as the President and CEO of Valmet until August 11, 2024. Key figures1 EUR million, or as Q2/202 Q2/202 Change Q1–Q2/ Q1–Q2/ Changeindicated 4 3 2024 2023Orders received 1,283 1,268 1% 2,333 2,821 -17%Order backlog2 3,828 4,414 -13% 3,828 4,414 -13%Net sales 1,324 1,417 -7% 2,536 2,738 -7%Comparable EBITA 141 153 -8% 262 286 -9%% of net sales 10.6% 10.8% 10.3% 10.5%EBITA 132 155 -15% 245 286 -14%% of net sales 9.9% 11.0% 9.7% 10.5%Operating profit 103 136 -24% 189 232 -18%(EBIT)% of net sales 7.8% 9.6% 7.5% 8.5%Profit before 84 129 -35% 157 220 -29%taxesProfit for the 58 99 -41% 114 170 -33%periodEarnings per 0.31 0.54 -42% 0.62 0.92 -33%share, EURAdjusted earnings 0.43 0.60 -28% 0.84 1.11 -24%per share, EUREquity per share, 13.21 12.93 2% 13.21 12.93 2%EUR2Cash flow provided 128 -37 267 172 55%by operatingactivitiesCash flow after -14 -71 -81% 95 104 -8%investingactivitiesComparable return 14% 15%on capitalemployed(Comparable ROCE)before taxes (LTM)Return on capital 13% 15%employed (ROCE)before taxes (LTM)Return on equity 13% 15%(ROE) (LTM)Net debt to EBITDA 1.63 0.77ratio3Gearing2 45% 23%Equity to assets 40% 45%ratio2 1  The calculation of key figures is presented on page 60 2  At end of period 3  Last twelve months' EBITDA LTM = Last twelve months Segment key figures Orders received, EUR million Q2/2024 Q2/2023 Change Q1–Q2/ Q1–Q2/ Change 2024 2023Services 497 430 15% 1,024 1,007 2%Automation 352 340 4% 681 732 -7%Flow Control 195 211 -7% 389 427 -9%Automation Systems 157 130 21% 291 304 -4%Process Technologies 434 497 -13% 628 1,082 -42%Pulp and Energy 187 277 -32% 243 489 -50%Paper 247 221 12% 385 593 -35%Total 1,283 1,268 1% 2,333 2,821 -17% Net sales, EUR million Q2/2024 Q2/2023 Change Q1–Q2/ Q1–Q2/ Change 2024 2023Services 473 457 4% 880 846 4%Automation 351 338 4% 659 642 3%Flow Control 201 202 0% 389 389 0%Automation Systems 150 136 10% 271 252 7%Process Technologies 500 623 -20% 997 1,251 -20%Pulp and Energy 221 263 -16% 447 549 -19%Paper 279 360 -23% 550 702 -22%Total 1,324 1,417 -7% 2,536 2,738 -7% Comparable EBITA, EUR million Q2/2024 Q2/2023 Change Q1–Q2/ Q1–Q2/ Change 2024 2023Services 80 80 0% 140 142 -2%Automation 58 61 -5% 109 110 -1%Process Technologies 15 30 -50% 36 59 -40%Other -12 -17 -26% -23 -26 -11%Total 141 153 -8% 262 286 -9% Comparable EBITA, % of net sales Q2/2024 Q2/2023 Q1–Q2/ Q1–Q2/ 2024 2023Services 16.9% 17.5% 15.9% 16.8%Automation 16.5% 17.9% 16.5% 17.2%Process Technologies 3.0% 4.8% 3.6% 4.7%Total 10.6% 10.8% 10.3% 10.5% EBITA, EUR million Q2/2024 Q2/2023 Change Q1–Q2/ Q1–Q2/ Change 2024 2023Services 78 81 -4% 134 143 -7%Automation 58 63 -8% 107 107 0%Process Technologies 9 29 -67% 31 61 -50%Other -13 -16 -20% -27 -25 6%Total 132 155 -15% 245 286 -14% News conference and webcast for analysts, investors and media Valmet will arrange a news conference in English as a live webcast at https://valmet.videosync.fi/q2-2024 on Wednesday, July 24, 2024, at 3:00 p.m. Finnish time (EEST). President and CEO Pasi Laine and CFO Katri Hokkanen will be presenting the results. Recording of the webcast will be available shortly after the event at the same address. It is possible to take part in the news conference through a conference call by registering through the link below: https://palvelu.flik.fi/teleconference/?id=50048301 After the registration you will be provided phone numbers and a conference ID to access the conference. If you wish to ask a question during the conference, please dial *5 to enter the question queue. All questions should be presented in English. The event can also be followed on social media platform X at www.x.com/valmetir. Further information, please contact: Pekka Rouhiainen, VP, Investor Relations, Valmet, tel. +358 10 672 0020 VALMET Katri Hokkanen CFO Pekka Rouhiainen VP, Investor Relations DISTRIBUTION: Nasdaq Helsinki Major media www.valmet.com Valmet is a leading global developer and supplier of process technologies, automation and services for the pulp, paper and energy industries. With our automation systems and flow control solutions we serve an even wider base of process industries. Our more than 19,000 professionals around the world work close to our customers and are committed to moving our customers’ performance forward – every day. The company has over 220 years of industrial history and a strong track record in continuous improvement and renewal. Valmet’s net sales in 2023 were approximately EUR 5.5 billion. Valmet’s shares are listed on the Nasdaq Helsinki and the head office is in Espoo, Finland.  Follow us on valmet.com  | X |X (IR) |LinkedIn |Facebook |YouTube |Instagram | Processing of personal data 

Neste’s newly-commissioned terminal capacity in Houston, Texas expands availability of Neste’s sustainable aviation fuel at airports in the central and eastern parts of the U.S.

Neste Corporation, News, 24 July 2024The news was updated on 25 July 2024 at 12.30 p.m. (EET)** Photo: ONEOK Galena Park Terminal in Houston, Texas. Courtesy of ONEOK.Neste has commissioned terminal capacity at ONEOK’s terminal in Houston, Texas for blending and storing Neste MY Sustainable Aviation Fuel ™. This is a major step in further expanding the availability of Neste’s SAF to airlines also operating from airports east of the Rocky Mountains all the way to the East Coast.The new capacity at ONEOK’s terminal in Houston provides Neste with storage capacity of up to 100,000 tons (around 33.5 million gallons) and is directly connected to the energy pipeline infrastructure in the eastern part of the U.S. Already in 2022, Neste demonstrated its ability to supply SAF to New York’s LaGuardia Airport  using existing fuel distribution infrastructure. In September 2023, Neste also expanded its capability to supply renewable fuels to customers on the West Coast, commissioning terminal capacity in Los Angeles, California.“Neste is fully committed to supporting the U.S. aviation industry in its efforts to decarbonize. This expansion of our SAF supply capabilities working together with partners such as ONEOK along the fuel supply chain, underlines this commitment. It provides a reliable basis for supplying SAF to domestic and visiting airlines at airports across the eastern part of the country as well as a solid base for supporting policies on state, federal, and local levels in the U.S.,” says Alexander Kueper, Vice President, Renewable Aviation Business at Neste.”ONEOK is excited to deliver the energy products the world needs today, while innovating for tomorrow. As a valued partner providing critical energy to the aviation industry, we’re proud to utilize our extensive infrastructure platform to facilitate growth within the sustainable fuels markets,” said Greg Lusardi, senior vice president, corporate development at ONEOK, one of the largest diversified energy infrastructure companies in the U.S.Sustainable Aviation FuelSustainable aviation fuel is a renewable aviation fuel providing a more sustainable alternative to conventional, fossil-based jet fuel. Using Neste MY Sustainable Aviation Fuel ™ reduces greenhouse gas emissions by up to 80%* over the fuel’s life cycle, compared to using conventional jet fuel. Neste’s SAF is made from sustainably sourced, 100% renewable waste and residue raw materials, such as used cooking oil and animal fat waste. SAF is blended with conventional jet fuel before use and works seamlessly with existing aircraft engines and fueling infrastructure. *) When used in neat form (i.e. unblended) and calculated with established life cycle assessment (LCA) methodologies, such as CORSIA methodology**) The original news release stated that Neste demonstrated its ability to supply SAF to New York’s LaGuardia Airport already in 2021. This has been corrected to 2022.

Departing CEO of ADDvise divests shares of series A to a major shareholder of ADDvise

The departing CEO Rikard Akhtarzand has agreed with Kenneth Lindqvist, one of the major shareholders of ADDvise, to divest 2,500,000 shares of series A to Kenneth Lindqvist, privately and through companies. The total purchase price for the shares amounts to SEK 37,500,000. The divestment of the shares is subject to approval by the Swedish Inspectorate of Strategic Products (ISP) pursuant to the Screening of Foreign Direct Investments Act (2023:560), and will be completed after the obtaining of such approval. Upon completion of the transaction, Rikard Akhtarzand’s holdings, privately and through companies, will amount to 120,416 shares of series A and 8,728,493 shares of series B. The transaction will be reported to the Swedish Financial Supervisory Authority upon completion of the transaction. For further information, please contact: Rikard Akhtarzand, CEO +46 (0) 76-525 90 71 Rikard.Akhtarzand@addvisegroup.se Important information This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on July 24, 2024, at 15:50 CEST. About ADDvise ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.

Russia-Linked Brute-Force Campaign Targets EU via Microsoft Infrastructure

This aligns with European leaders’ belief that Russia is waging a ‘shadow war’ to unsettle Europe.  At the NATO summit in July, leaders claimed Russia was behind cyberattacks, disinformation, sabotage, and other disruptive actions. Danish Prime Minister Mette Frederiksen stated, “Russia is trying to destabilize all of us, using various measures.” She urged that countries “take it more seriously.” The investigation into the Russian brute-force campaign has revealed several critical insights: · Attackers are aiming for High-Value Targets (HVTs) · Key infrastructure cities like Edinburgh and Dublin have been frequently targeted · Over half of the attack IP addresses are linked to Moscow, targeting major cities in the UK, Denmark, Hungary, and Lithuania · The rest of the investigated attack IPs can be traced back to Amsterdam and Brussels · Major ISPs like Telefonica LLC and IPX-FZCO were significantly abused Heimdal’s data shows these attacks date back to May 2024 but may have been happening even longer. Prevalent Infiltration and Attack Techniques The attackers primarily target administrative accounts using various case combinations and language variants. Over 60% of attack IPs are new, with approximately 65% recently compromised and the rest previously abused, revealing a constantly evolving threat. The threat actors employ known attack principles such as SMBv1 crawlers, RDP crawlers, and RDP alternative port crawlers, exploiting weak or default credentials through password guessing, spraying, and stuffing. Additionally, their use of legitimate Microsoft infrastructure broadens the attack surface and complicates detection and response. Data shows that attackers have actively exploited Microsoft infrastructure from the Netherlands and Belgium to increase their attack range and success odds. Russia Leveraging State-Owned Networks to Propagate Attack Major ISPs like Telefonica LLC and IPX-FZCO are significantly abused, with the former accounting for 27.7% of attacks from Russia. The attackers also leveraged resources from Russian allies, including Indian telecom companies Bharat Sanchar Nigam Limited and Bharti Airtel Limited, both of which have faced recent data breaches. Scope of Brute-Force Campaign Russia’s motivation behind these cyberattacks is multifaceted. The reasons for these actions likely include aims to destabilize and disrupt critical infrastructure in Europe, extract sensitive data, gain financial advantage to fuel ongoing cyber-war efforts, or deploy malware. The threat actors’ mandates can span multiple types of subversive cyber-warfare ops, including seek-and-destroy, disruption of critical assets, and sabotage. A Wake Up Call for the European Union This persistent threat underscores the need for cybersecurity measures within EU countries, including strengthening cloud security, enforcing multi-factor authentication, conducting regular security audits, and educating employees. Morten Kjaersgaard, founder of Heimdal, said: This data shows that an entity in Russia is waging a hybrid war on Europe, and may have even infiltrated it. The threat actors are aiming to extract as much data or financial means as possible, leveraging Microsoft infrastructure to do so. Whoever is responsible, whether it’s the state or another nefarious group, they have no shame in using Russia’s allies to commit these crimes. The exploitation of Indian infrastructure is a strong example. The data also proves these attackers have strong ties with China. Paul Vixie, co-founder of SIE Europe, added: The data that Heimdal has uncovered is explosively evil, and SIE Europe data clearly shows how well built these Russian Wasp nests are and they show no signs of stopping. SIE Europe does not ever traffic in Personally Identifiable Information, and this case shows the investigative power of public information once cooperatively assembled. Read the full investigation here: Russia-Linked Brute-Force Campaign Targets EU via Microsoft Infrastructure (heimdalsecurity.com) . About Heimdal Established in Copenhagen in 2014, Heimdal empowers CISOs, security teams, and IT administrators to improve their security operations, reduce alert fatigue, and implement proactive measures through a unified command and control platform. Heimdal®'s award-winning cybersecurity solutions span the entire IT estate, addressing challenges from endpoint to network levels, including vulnerability management, privileged access, Zero Trust implementation, and ransomware prevention. For further press information: Maria Madalina PopoviciMedia Relations Manager Email: mpo@heimdalsecurity.com

Interim report April–June 2024

Second quarter · Revenue amounted to €509.4m (€424.7m), an increase of 20.0% with an organic growth of 16.5%. · Operating profit (EBIT) was €21.3m (€13.2m), an increase of 61.4%, representing an operating margin of 4.2% (3.1%). · Net profit amounted to €5.9m (€7.2m), which represents a margin of 1.2% (1.7%). · EBITDA was €70.6m (€58.3m), an increase of 21.1%. EBITDA margin was 13.8% (13.7%). · EBITDAaL amounted to €43.3m (€33.9m), an increase by 27.9%, corresponding to an EBITDAaL margin of 8.5% (8.0%). · Net cash flow from operating activities was €47.4m (€43.6m). · Basic/diluted earnings per share were €0.042 (€0.037). First half · Revenue amounted to €1,008.2m (€844.0m), an increase of 19.5% with an organic growth of 15.5%. · Operating profit (EBIT) was €40.3m (€23.9m), representing an operating margin of 4.0% (2.8%). · Net profit amounted to €12.4m (€9.3m), which represents a margin of 1.2% (1.1%). · EBITDA was €137.8m (€112.6m), an increase by 22.4%. EBITDA margin was 13.7% (13.3%). · EBITDAaL amounted to €83.9m (€64.5m), corresponding to an EBITDAaL margin of 8.3% (7.6%). · Net cash flow from operating activities was €125.4m (€105.0m). · Basic/diluted earnings per share were €0.084 (€0.047). REVENUE AND EARNINGS []€ millions Q2 Q2 Variance 6M 6M Variance LTM[1)] FY(€m) 2024 2023 2024 2023 2023Revenue 509.4 424.7 20% 1,008.2 844.0 19% 1,910.6 1,746.4Operating 21.3 13.2 61% 40.3 23.9 69% 77.8 61.4profit(EBIT)Operating 4.2% 3.1% 4.0% 2.8% 4.1% 3.5%profitmarginNet 5.9 7.2 -16% 12.4 9.3 34% 21.5 18.4profitNet 1.2% 1.7% 1.2% 1.1% 1.1% 1.1%profitmarginBasic/dilu 0.042 0.037 14% 0.084 0.047 79% 0.155 0.118tedearningspershare, €EBITDA 70.6 58.3 21% 137.8 112.6 22% 269.0 243.8EBITDA 13.8% 13.7% 13.7% 13.3% 14.1% 14.0%marginAdjusted 74.4 61.1 22% 144.5 118.5 22% 279.9 253.9EBITDAAdjusted 14.6% 14.4% 14.3% 14.0% 14.6% 14.5%EBITDAmarginEBITDAaL 43.3 33.9 28% 83.9 64.5 30% 164.3 144.9EBITDAaL 8.5% 8.0% 8.3% 7.6% 8.6% 8.3%marginAdjusted 47.1 36.7 28% 90.6 70.4 29% 175.2 155.0EBITDAaLAdjusted 9.2% 8.6% 9.0% 8.3% 9.2% 8.9%EBITDAaLmarginEBITA 26.2 18.6 41% 50.0 34.6 45% 98.0 82.6EBITA 5.1% 4.4% 5.0% 4.1% 5.1% 4.7%margin Definition and reconciliation of alternative performance measures are available at www.medicover.com/financial-information. [1)] LTM: last twelve months (1 July 2023-30 June 2024) CEO Statement We continue to deliver strong organic revenue growth and see continued strong momentum in our core markets, with high demand across divisions and geographies, especially in Poland. The margin expansion and strong operating cash generation we saw in the first quarter have continued in the second quarter, which is tangible proof of the operational leverage as we scale volume in our medical infrastructure.  Revenue for the quarter was up 20.0% to €509.4m (€424.7m), with an organic growth of 16.5%. Fee-For-Service and other services (FFS) increased by 16.1% in the quarter, now representing 56% of total revenue. EBITDA in the quarter increased by 21.1% to €70.6m (€58.3m), representing an EBITDA margin of 13.8% (13.7%). Healthcare Services revenue grew by a very strong 20.6% to €352.6m (€292.5m), with an organic growth of 16.4%, whereof price representing around half. At the end of the quarter, the division had 1.8 million members, growing by 35 thousand new members in the quarter. FFS increased by 18.6% in the quarter and represented 52% of divisional revenue. EBITDA grew by 22.0% in the quarter to €54.6m (€44.8m), an EBITDA margin of 15.5% (15.3%), driven by most businesses but especially apparent in our Polish platform. We continue to see improving profit impact from our India facilities becoming more mature. However, this was slightly offset by the hospital in Romania opened in late Q2 2023 and new immature units in India. These are, on the other hand, important initiatives for long-term growth and profitability, and after the end of the quarter, we have opened two new greenfield hospitals in India. In the near term, our primary focus in India is to mature our hospitals to keep driving margin improvement. Diagnostic Services revenue amounted to €162.9m (€138.1m), an increase of 17.9%, with an organic growth of 16.0%, with price representing approximately 2.3pp of this growth. This quarter, too, we saw strong volume growth in the laboratory business. The laboratory test volume increased by 19.4%, and 34.7 million tests were performed in the quarter (29.1 million). Germany continues to drive large volumes, while we continue to grow in our important FFS markets. FFS increased by 11.2% in the quarter, now representing 66% of divisional revenue. EBITDA amounted to €26.4m (€20.3m), an increase of 29.8%, and an EBITDA margin of 16.2% (14.7%) – primarily an effect of our growing FFS revenue. These are comforting signs as we still have additional margin-accretive initiatives to implement across the Division. We are continuing to demonstrate that we can grow well organically and improve margins, and this makes me confident that we are on a good path to achieving the medium-term financial targets for the period 2023-2025. Financial targets by year-end 2025: · organic revenue should exceed €2.2bn · an adjusted organic EBITDA in excess of €350m · loans payable net of cash and liquid short-term investments/adjusted EBITDAaL ≤3.5x Fredrik RågmarkCEO This report has not been subject to review by the Company’s auditor. This is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through the agency of the contact person set out below at 7.45 (CEST) on 25 July 2024. This interim report and other information about Medicover is available at medicover.com . Financial calendarInterim report July-September                                                                    30 October 2024, 7.45 CET For further information, please contact:Hanna Bjellquist, Head of Investor RelationsPhone: +46 70 303 32 72E-mail: hanna.bjellquist@medicover.com Conference call: A conference call for analysts and investors will be held today at 09.30 CEST. To listen in please register here . To ask questions please register here . Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland, Germany, Romania and India. In 2023, Medicover had revenue of €1,746 million and more than 45,000 employees. For more information, go to www.medicover.com

Invitation to a press and analyst conference call for the presentation of Concentric’s Second Quarter 2024 Report

Concentric's Interim Report for Q2 2024 (January-June 2024), will be published on the 31 of July 2024, at 08.00 CET. At 10.00 CET media, investors and analysts are invited to participate/join via webcast/telephone conference for a presentation of the report. President & CEO Martin Kunz and CFO Marcus Whitehouse will host the presentation, which will be held in English and is followed by a Q&A-session. We look forward to your participation. Please see the below detailed information to join in: Press and analysts conference at 10.00 CET (09:00 UK TIME) 1. Access the webcast: https://edge.media-server.com/mmc/p/w94jf78h · Please press the play button or refresh your browser if your webcast video does not load automatically. 2. Telephone conference · Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial In Numbers, and a unique Personal PIN. · In the 10 minutes prior to the call start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number. Telephone conference Online Registration: https://register.vevent.com/register/BIeab942f474174447aff5342f2406aebc For further information, please contact Gregory Asante at Tel: +44 121 445 6545 or E-mail: info@concentricab.com

Kemira expands sodium chlorate capacity in South America to cater for growing pulp and paper market opportunities

Kemira expands sodium chlorate capacity in South America to cater for growing pulp and paper market opportunities [SUB] Bleaching production capacity to increase over 10% Kemira today announced an investment to expand the capacity of its sodium chlorate manufacturing facility in Ortigueira, Brazil. The investment, a strategic priority for Kemira’s Pulp & Paper business, will enable Kemira to respond to the continued growth of the bleached pulp market in South America where Brazil is the leading producer in the region. The capacity increase of over ten percent will be operational in the last quarter of 2024. Sodium chlorate is the main component used in the production of chlorine dioxide, which is produced on-site at pulp mills. It is the primary bleaching agent for pulp, preserving pulp yield and providing superior strength compared to other oxidants. Kemira manufactures sodium chlorate using a proprietary process and renewable energy. Harri Eronen, President, Pulp & Paper segment, Kemira: “This investment strongly indicates our commitment to our pulp and paper customers in the region. They trust Kemira because of our strong know-how in fiber processing and bleaching applications, which produce strong, bright and clean pulp for paper, board and tissues.” The interest towards molded fiber increasing Increasingly, industries are transitioning away from depending on fossil-based raw materials for everyday items such as packages and single use items, offering a significant opportunity for pulp and paper manufacturers. “An application area that is particularly exciting for our customers is molded fiber. That’s because the transition from single-use plastics to renewable alternatives is driving a need for safe and cost-efficient molded packaging produced from renewable resources. It’s exciting to play a critical role in helping to realize a more sustainable and circular future with our partners through our chemistry.” Cellulosic fiber, the renewable and abundant raw material, plays a key role in the circular economy. Kemira’s chemistry know-how enables a wide range of traditional and new end products, from recyclable paper, board and molded fiber packaging, to tissue products and textiles. For more information, please contact:   Investor inquiries: Mikko Pohjala, Vice President, Investor RelationsTel. +358 40 838 0709mikko.pohjala@kemira.com  Media inquiries: Greg Morrison, Director CommunicationsTel. +31 6 21 62 87 23 greg.morrison@kemira.com   Kemira is a global leader in sustainable chemical solutions for water-intensive industries. Our customers include industrial and municipal water treatment operators, and pulp & paper industry among others. We provide the best-suited products and services to improve our customers’ product quality, process, and resource efficiency. Our focus is on water treatment, renewable solutions and digital services. In 2023, Kemira had annual revenue of around EUR 3.4 billion and around 5,000 employees. Kemira shares are listed on the Nasdaq Helsinki Ltd. www.kemira.com  

Invitation to attend Systemair AB (publ)’s Annual General Meeting

PRESS RELEASE, 25 JULY 2024  Shareholders in Systemair AB (publ), reg. no. 556160-4108 (“Systemair” or the “Company”) are hereby invited to attend the Company’s Annual General Meeting (the “AGM”) at 3.00 p.m. on Thursday 29 August 2024 in the Lecture Hall (Aulan) at Systemair Expo, Skinnskatteberg, Sweden. Registration at the AGM will open at 2.00 p.m. Coffee and sandwiches will be served. For those wishing to participate, there will be a tour of the Technology Centre and Systemair Expo prior to the AGM. Those wishing to participate should assemble at 1.00 p.m. at Systemair’s Expo, Skinnskatteberg. In accordance with the provisions of Chapter 7, Section 4a of the Swedish Companies Act and the Company's Articles of Association, the Board of Directors has decided that, as an alternative for shareholders who do not attend the meeting in person, postal voting will be possible. Shareholders can therefore choose to exercise their voting rights at the AGM by attending in person, by proxy or by postal vote. Right to attend the AGM and application of intention to take part Shareholders wishing to participate in the AGM must be entered in the share register maintained by Euroclear Sweden AB on the record day, Wednesday, 21 August 2024, and must notify the Company of their intention to participate no later than Friday, 23 August 2024. Registration should be done either via the form at https://group.systemair.com/registration, by phone +46 (0)222-440 00, or by post to Systemair AB, Reception, 739 30 Skinnskatteberg, Sweden. Applications shall include details of name, civic registration number/corporate registration number, address, telephone number, any assistants (no more than two) and number of shares. Shareholders represented by a proxy must issue a dated power of attorney for the proxy. The maximum period of validity for the power of attorney shall be five (5) years from the date of issue. A power of attorney form is available on the Company’s website, https://group.systemair.com/registration or may be requested by writing to the address above. Anyone representing a legal entity must present a registration certificate, or equivalent document, confirming the person’s authority to sign for the organisation. Powers of attorney, registration certificates and other authorisation documents must be available at the AGM and should, in order to facilitate admission to the AGM, be received by the Company no later than on Friday, 23 August 2024. The original copy of the power of attorney document must be shown. To be entitled to participate in the AGM, a shareholder who has had his/her shares registered in the name of a nominee must arrange for the nominee to re-register the shares in the shareholder’s name so that the shareholder is entered in the share register on the record day, Wednesday, 21 August 2024. Such registration may be temporary (“voting registration”) and is requested from the nominee in accordance with the nominee's procedures at such time in advance as the nominee determines. Voting registrations requested by shareholders in time for the registration to be made by the nominee by no later than Friday 23 August 2024 will be taken into account in the production of the share register. Postal voting Shareholders may exercise their voting rights at the AGM by postal voting. A special form must be used for postal voting. The form is available on the Company's website https://group.systemair.com/registration and may also be provided by mail to shareholders who request it. Postal votes must be received by the Company no later than Friday, 23 August 2024. Completed forms, including any attachments, are to be emailed to agm@systemair.se. Alternatively, the original voting document(s), completed, are to be sent by post to Systemair AB, “Årsstämma”, Industrivägen 3, SE-739 30 Skinnskatteberg, Sweden. Submission of the form is valid as notification to participate in the AGM. If the shareholder is a legal entity, a copy of the entity’s registration certificate or equivalent authorisation document for the legal entity should be attached to the form. The same applies to postal voting by a proxy on behalf of the shareholder. Shareholders may not attach special instructions or conditions to their postal vote. If they do so, their vote will be declared invalid in its entirety. Further instructions are provided on the postal voting form. Proposed agenda 1)       Declare the meeting open and elect a chairman for the AGM. 2)       Prepare and approve the list of voters. 3)       Elect one or two persons to verify the minutes. 4)       Determine whether the AGM has been duly convened. 5)       Approve the agenda. 6)       Report on the work of the Board of Directors and its committees. 7)       Presentation of the annual accounts and the consolidated accounts, followed by the CEO’s report on the business. 8)       Presentation of audit report and audit report on the consolidated accounts, as well as auditor’s statement of opinion on compliance with the guidelines on remuneration to senior executives, which have applied in the period since the preceding AGM. 9)       Resolutions on: a)       adoption of the income statement and balance sheet, along with the consolidated income statement and the consolidated balance sheet for the 2023/24 financial year; b)       disposition of the Company’s profit or loss according to the balance sheet adopted; c)        discharge from liability to the Company for the CEO and the members of the Board. 10)    Resolution on the number of members of the Board. 11)    Resolution on fees to the Board and auditor. 12)    Election of Board of Directors, Chairman and auditor. 13)    Decision on the approval of the remuneration report. 14)    Resolution on the Board’s proposal for guidelines on remuneration and other terms of employment for senior executives. 15)    Resolution on a) establishment of an incentive programme (LTIP 2024) and b) hedging arrangements relating thereto. 16)    Resolution on the Board’s proposal for authorisation to decide on acquisition and transfer of the Company’s own shares. 17)    Resolution on the Board’s proposal to issue warrants within LTIP 2022. 18)    Closing of the meeting. Proposed resolutions: Shareholders, together representing 53,52 percent of the voting rights of all shares in the Company, have notified the Company that they support the proposals under items 1, 9, 10, 11, 12, 13, 14, 15, 16 and 17 below. 1. Declare the AGM open and elect a chairman for the meetingThe Nominating Committee for the AGM 2024, consisting of Chairman Lennart Francke, appointed by Swedbank Robur Fonder, and members Gerald Engström, appointed by Färna Invest AB, and Magnus Tell, appointed by Alecta, proposes that Gerald Engström be elected Chairman of the AGM. 9. b Appropriation of profitThe Board of Directors proposes a dividend of SEK 1.20 per share. Monday, 2 September 2024 is proposed as the record day for the dividend. If the AGM resolves in accordance with the proposal, it is estimated that Euroclear Sweden AB will be able to pay the dividend on Thursday 5 September 2024. 10. Number of Board membersThe Nominating Committee proposes that during the next mandate period the Board shall consist of five regular members elected by the AGM and no deputies. 11. Resolution on fees to the Board and auditorThe Nominating Committee proposes that the remuneration to the Board of Directors shall be SEK 870,000 (830,000) to the Chairman of the Board, SEK 590,000 (560,000) to the Vice Chairman and SEK 365,000 (350,000) to each of the other members elected by the AGM. Remuneration to the Audit Committee is proposed to remain unchanged at SEK 110,000 (110,000) to the Chairman of the Committee and SEK 55,000 (55,000) to the other member. Remuneration to the Remuneration Committee is proposed to remain unchanged at SEK 30,000 (30,000) to the Chairman of the Committee and SEK 20,000 (20,000) to the other member. The total remuneration to the members elected by the AGM shall amount to SEK 2,770,000 (2,655,000). It is proposed that the auditor’s fees shall be paid according to approved invoices. 12. Election of Board of Directors, Chairman and auditorThe Nominating Committee proposes the re-election of Board members Carina Andersson, Gerald Engström, Patrik Nolåker, Gunilla Spongh and Niklas Engström. Gerald Engström is proposed for re-election as Chairman of the Board. Patrik Nolåker is proposed for re-election as Vice Chairman of the Board. In accordance with the recommendation of the Audit Committee, it is proposed that Ernst & Young AB, auditors, be re-elected as the Company’s auditor for a period of one year. Ernst & Young intends to appoint Authorised Public Accountant Johan Holmberg as auditor in charge. 13. Decision on the approval of the remuneration report The Board of Directors proposes that the Annual General Meeting approves the Board of Directors' report on remuneration pursuant to Chapter 8. Section 53a of the Companies Act for the financial year 2023/24. 14. Board’s proposal for guidelines on remuneration and other terms of employment for senior executivesThe Board of Directors proposes that the AGM resolves on the following guidelines for the determination of salary and other remuneration to senior executives. The Board's proposal, to be applied as from the AGM 2024, is broadly consistent with the guidelines applicable as of the AGM 2023. Remuneration to senior executives shall – based on the conditions in the market in which the Company operates and the environment in which the particular executive works – be competitive, enable the recruitment of new executives and help to ensure that senior executives remain with the Company. “Senior executives” refers to the CEO and other members of Group Management. The system of remuneration shall consist of a fixed salary and pension but may also include variable salary and benefits such as a company car. In addition to the above, special incentive programmes approved by the AGM may apply. Fixed salary and benefits shall be determined individually based on the aforementioned criteria and the specific competence of the particular executive. Variable pay is based on the Company's performance with the aim of promoting the Company's strategy, long-term value creation and sustainability. The variable portion is paid as a proportion of the fixed salary and may amount to no more than 40 percent of the annual salary for the CEO, 25 percent for other senior executives and 15 percent for key individuals. As a principle, pensions shall be premium-based and shall not exceed 35 percent of the wage base. The size of the pension shall adhere to the same criteria as above. The Board shall be authorised to depart from the guidelines if there are special reasons for doing so in individual cases. Notice of termination and severance payments The CEO’s employment may be terminated with twelve (12) months’ notice by the Company or six (6) months’ notice by the CEO. For other Senior executives, the period of notice is as stated in the applicable collective bargaining agreement or is no more than twelve (12) months from the Company or six (6) months from the employee. No other agreements entitle the CEO or other Senior executives to severance pay Share-based and share-price-based incentive programmes In 2023 the AGM resolved to issue warrants within the framework of the incentive program LTIP 2023. During the financial year Systemair issued a total of 362,500 warrants for Systemair shares to Senior executives within the Company. Transfer of the warrants to the participants has been made at a price corresponding to their market value according to an external independent valuation with the application of an accepted valuation model (Black-Scholes). LTIP 2023 runs over four years and the last day for subscription is 30 September 2027. In 2021, 592,500 warrants were subscribed for by Senior executives within LTIP 2021 and in 2022, 520,740 warrants were subscribed within LTIP 2022. These programmes also run over four years and the last day for subscription is 30 September 2025 and 2026 respectively. The subscription prices amount to SEK 98,20 for LTIP 2021, SEK 58,30 for LTIP 2022 and SEK 77,50 for LTIP 2023 Shareholders' views and significant changes in the guidelines As mentioned above the proposed guidelines to be presented at the AGM 2024 do not entail any material changes to the Company's existing remuneration guidelines. The Company has not received any material comments from shareholders on the existing guidelines for the remuneration of Senior executives. 14. Resolution on a) establishment of an incentive programme (LTIP 2024) and b) hedging arrangements relating thereto A) Establishment of the Programme The Board of Directors proposes that the AGM resolve to implement a long-term share-based and performance-related incentive programme (the “Programme” or “LTIP 2024”). The Programme is aimed at senior executives (including the CEO) and employees of the Systemair Group and shall be implemented as soon as practicable following approval of the Board’s proposals to that effect by the Systemair AGM 2024. The Board wishes to encourage senior executives and employees to make investments in the Company. On that basis, participation in the Programme requires the Participant to make an investment in the Company with their own funds. The Board believes that the Programme will positively impact the Company’s development going forward, and will thus benefit both Systemair and its shareholders. It is proposed that the Programme should target a maximum of 70 permanent employees at the Systemair Group, within the following three categories: President & CEO (1 person) (“Group 1”), Group Management (7 persons) (“Group 2”) and other employees (62 persons) (“Group 3”). The participants in Groups 1–3 are collectively referred to as the “Participants” and individually as the “Participant”. In order to participate in the Programme, the Participants are offered the opportunity to invest their own funds in shares in Systemair at market price (in an amount corresponding to approximately 8–12 percent of the Participants’ annual salaries), such shares then being allocated to the Programme (“Investment Shares”). For each Investment Share, the Participants have the opportunity to be allocated a maximum of five (5) shares in Systemair (“Performance Shares”) free of charge, either by Systemair or by a designated third party, in accordance with the terms and conditions set out below for the financial years 2024/2025, 2025/2026 and 2026/2027 (the “Measurement Period”). Allocation of Performance Shares will take place after the end of a vesting period, which runs from the start of the Programme up to and including the date of publication of the interim report for the period May–July 2027 (“Vesting Period”). The right to receive Performance Shares is not transferable. Notification and information to the Participants in the Programme will be provided during August 2024, with the Programme to subsequently be launched as soon as practicable after the AGM 2024 (although the Board shall be entitled to postpone this date for individual Participants if justified for particular reasons, but to no later than 31 March 2025). The Participants may choose to invest in no more than the following number of Investment Shares, which, depending on target achievement, may generate allocation of the maximum number of Performance Shares as follows: Category Participant Maximum number of Maximum number of Investment Shares per Performance Shares Participant that may be allocated (excluding any Performance Shares as compensation for dividends)1 President and 6,000 30,000 CEO (1 Participant)2 Group 3,000 15,000 Management (7 Participants)3 Other 1,500 7,500 employees (62 Participants)Total (70 120,000 600,000Participants): “Performance share A”: One (1) Performance Share A per Investment Share will be allocated if the total shareholder return on Systemair’s shares (“TSR”), over a period of ten (10) trading days beginning on the first trading day after the day of publication of the year-end report on the period May 2023–April 2024, compared with the corresponding period after the year-end report on the period May 2026–April 2027, exceeds fifteen (15.0) per cent.[1] ”Performance share B”: A maximum of one and a half (1.5) Performance Shares B per Investment Share will be allocated if the average organic annual increase in net sales amounts to or exceeds five percent (5.0) during the Measurement Period. Achievement of the performance target is measured on a financial year basis with an equal allocation for each financial year, whereby the final allocation will be based on the overall achievement of the individual financial year targets during the Measurement Period. “Performance share C”: A maximum of two (2) Performance Shares C per Investment Share will be allocated if the average annual operating margin (EBIT margin) amounts to or exceeds ten percent (10.0) during the Measurement Period. Achievement of the performance target is measured on a financial year basis with an equal allocation for each financial year, whereby the final allocation will be based on the overall achievement of the individual financial year targets during the Measurement Period. “Performance share D”: A maximum of half (0.5) a Performance Share D per Investment Share will be allocated if no less than two thirds (2/3) of the annual ESG targets set by the Board have been met or exceeded in each financial year during the Measurement Period. Achievement of the performance target is measured on a financial year basis with an equal allocation for each financial year, whereby the final allocation will be based on the overall achievement of the individual financial year targets during the Measurement Period. At the time of establishing the Programme, the Board has adopted the following ESG targets: i) Increase the proportion of women managers, ii) Reduce Scope 1 and 2 emissions intensity, iii) Reduce the rate of injuries leading to sick leave by 15 percent annually In allocating Performance Shares A–D, each target achievement is assessed separately and so for maximum allocation in LTIP 2024, all targets stated above must be achieved. The period for Participants to invest in Investment Shares shall be 2–27 September 2024. However, the Board shall be entitled to extend (or postpone) the period for investment, in the event for example that any circumstance should arise during the period preventing acquisition by the Participants, or in the event that any ‘closed’ or other similar period in which insider information in the company exists should apply, although up to no later than 31 March 2025. Performance Shares A–D may normally not be allocated until after the end of the Vesting Period. In order for a Participant, where applicable, to be allotted Performance Shares A–D, the Participant must, with certain exceptions, have been permanently employed in the Systemair Group during the entire Vesting Period and the Participant must have retained, until the end of the Vesting Period, the Investment Shares invested within the scope of the Programme. Investment Shares sold prior to the end of the Vesting Period shall not be included in the calculation to determine the allocation of Performance Shares A–D. The Board shall be entitled to formulate and resolve on the detailed terms and conditions of the Programme and shall be entitled to make reasonable adjustments to meet specific regulatory or market conditions abroad, such as waiving the requirement to invest in Investment Shares and/or offering cash settlement to Participants. In this context, the Board shall be authorised to implement an alternative incentive solution for employees in countries where participation in LTIP 2024 is not appropriate, in which case the terms and conditions for any such alternative solution shall, as far as practicable, correspond to those of LTIP 2024. Participation in the Programme is subject to such participation being legally permissible in the jurisdictions concerned. In the event that, in the opinion of the Board, a Participant cannot be allocated Performance Shares A–D at reasonable cost or with reasonable administrative efforts, or in order to facilitate the payment of tax on benefits, the Board shall be authorised to approve a cash settlement for such Participant. A further condition for participation in the Programme is that Participants enter into an agreement with the Company regarding the full terms and conditions of the Programme. The Board, or person designated by the Board, is authorised to draw up and conclude such agreements with the Participants. In order to align the interests of the Participants and the shareholders, Systemair will compensate for dividends and other transfers of value to the shareholders during the Vesting Period by increasing the number of shares that each Performance Share A–D entitles the Participant to receive. The Programme shall comprise a maximum of 640,000 shares in Systemair, represented by no more than 600,000 shares based on allocation of Performance Shares A–D (excluding Investment Shares), and no more than 40,000 shares as compensation for any dividends. [1] TSR shall be understood as meaning the return to shareholders in the form of share price appreciation and reinvestment of any dividends during the Measurement Period. TSR is calculated by comparing the average closing price of the Company’s share over a period of ten (10) trading days beginning on the first trading day after the day of publication of the year-end report on the period May 2023–April 2024, compared with the corresponding period after the year-end report on the period May 2026–April 2027. Costs of the Programme etc. The costs of the Programme, which are recognised in the income statement, have been calculated in accordance with the IFRS 2 accounting standard, along with provision for anticipated social security contributions, and are reported as accrued over the Vesting Period. The calculation is based on the closing price for Systemair shares on 3 July 2024, i.e. SEK 77.70 per share, and the following assumptions: (i) an annual dividend yield of approximately 1.7 per cent, (ii) annual employee turnover of 10 percent, (iii) an average achievement of 100 percent of the Performance Condition for Performance Shares A and D, and of 50 percent for Performance Shares B and C and (iv) a maximum of a total 600,000 Performance Shares A–D available for allocation excluding dividend compensation. In addition to what follows from the above, the costs for the Programme have been based on the assumptions that the Programme comprises 70 Participants, that each Participant takes up their maximum investment entitlement and that all Investment Shares remain in place at the end of the Vesting Period. In total, the costs of the Programme, calculated in accordance with IFRS 2 are estimated at around SEK 18.5 million, excluding social security contributions (SEK 32.2 million assuming an average achievement of 100 percent of all performance conditions). The costs of social security contributions are estimated at approximately SEK 6.4 million, based on the above assumptions, and an assumed annual share price increase of 10 percent over the term of the Programme and a tax rate of 25 per cent (SEK 11.2 million at an average of 100 percent achievement of the Performance Condition) for social security contributions. The expected annual costs of SEK 8.5 million, including social security contributions, represent approximately 0.4 percent of the Systemair Group’s total personnel costs for the financial year 2023/2024. Impact of the Programme on key performance indicators and dilution Upon maximum allocation of Performance Shares A–D, and assuming that no corporate events (other than dividend compensation) necessitating recalculation occur during the Vesting Period, the number of Systemair shares to be allocated free of charge in the Programme totals 640,000, representing approximately 0.31 per cent of the share capital and votes (calculation based on the number of shares in Systemair outstanding on 20 June 2024). The impact on key performance indicators and earnings per share is marginal Hedging and dilution To enable implementation of the Programme in a cost-efficient and flexible manner, the Board has considered different methods for delivery of shares in the Programme. These include repurchase and transfer of treasury shares to Programme Participants, the issuance, repurchase and subsequent transfer of shares to Programme Participants, and “equity swap” agreements with third parties. The Board has also taken into account the fact that delivery of shares in the Programme shall be effected no earlier than during 2027. The Board proposes that the Meeting resolves, as a main option, that the Company’s obligations arising from LTIP 2024 should be fulfilled through repurchase and transfer of treasury shares as described in sections B.1 and B.2 below. In the event that the majority required for sections B.1 and B.2 below cannot be achieved, the Board proposes that Systemair should be able to enter into an equity swap agreement with a third party, as described in section B.3 below. None of the hedging options will result in an increase in the number of shares in the Company and therefore will not result in any dilutive effect regarding the number of shares issued to existing shareholders. B) Hedging measures in connection with the Programme 1. Proposal to authorise the Board of Directors to resolve upon acquisition of treasury shares via the stock exchange for the purposes of LTIP 2024 To ensure Performance Shares are delivered to Participants in both LTIP 2024 and any future incentive programmes, the Board proposes that the AGM should resolve to authorise the Board to resolve upon acquisition of a maximum of 640,000 shares in the Company as follows: a) The shares shall be acquired on Nasdaq Stockholm in accordance with Nasdaq Stockholm’s regulations in force at any given time. b) Acquisitions may be made at a price within the price range prevailing at any given time, that is, within the range between the highest bid price and the lowest ask price published on an ongoing basis by Nasdaq Stockholm. c) Acquisitions shall be made on a cash payment basis. d) The authorisation may be exercised on one or more occasions prior to the AGM 2025. 2) Proposal for resolution as to transfer of treasury shares to Participants in LTIP 2024 To ensure delivery of Performance Shares to the Participants in LTIP 2024, the Board proposes that the AGM resolve to transfer a maximum of 640,000 treasury shares as follows: a) The Participants shall be entitled to receive shares, whereby each Participant shall be entitled to receive the number of shares to which they are entitled in LTIP 2024. b) Shares shall be transferred free of charge to Participants in LTIP 2024 at the time and on the terms and conditions applying to LTIP 2024. c) The number of Performance Shares that may be transferred shall be recalculated as a result of any bonus issue (resulting in the issuance of new shares), share split, rights issue and/or other standard corporate event conducted during the Vesting Period, as described in the terms and conditions for LTIP 2024. d) The reason for the waiver of the preferential rights of shareholders in connection with the transfer of shares is to enable shares in the Company to be delivered in LTIP 2024, and the Board considers it to be in the interests of the Company and the shareholders that Participants in the Programme should be offered the opportunity to become shareholders in the Company in accordance with the terms and conditions of LTIP 2024. Since LTIP 2024 is not expected to give rise to a need for cash settlement or payment of social security contributions until such time as Performance Shares are allocated, the Board does not propose that the AGM should also resolve on transfers of treasury shares via the stock exchange in order to secure such payments in terms of liquidity. Before any Performance Shares are transferred to Participants in LTIP 2024, the Board may propose that a subsequent AGM should resolve that transfers of treasury shares may be performed via the stock exchange in order to secure such payments. 3) Equity swap agreements with third parties The Board proposes that the AGM, in the event that a sufficient majority as stated in sections B.1 and B.2 above cannot be achieved, should resolve to hedge the financial exposure that is expected to arise via LTIP 2024 by enabling Systemair to enter into “equity swap agreements” with third parties on market terms, according to which the third party shall be able in its own name to acquire and transfer shares in Systemair to the Participants in LTIP 2024. Specific authorisation The Board proposes that the Board, or person designated by the Board, shall be authorised to undertake any minor adjustments to the above-mentioned draft resolutions as may be required by formal requirements. If major changes take place in the Systemair Group or in the market that in the Board’s view would result in the conditions for allocation of Performance Shares no longer being considered reasonable, the Board shall be authorised to make adjustments to LTIP 2024, including inter alia the right to resolve that the number of Performance Shares allocated should be reduced or that no Performance Shares whatsoever should be allocated. Preparation of the proposal The proposed Programme and related hedging measures have, under guidelines issued by Systemair’s Board of Directors, been prepared by Systemair’s Remuneration Committee, with the assistance of external advisors. The Remuneration Committee has presented its work to the Board, whereupon the Board has decided to propose that the Programme and related hedging measures be adopted at the AGM 2024. Neither the CEO nor any other person who may be eligible for inclusion in LTIP 2024 has participated in the Board’s preparation of or resolution on the proposal. Earlier incentive programmes at Systemair For an account of the Company’s other ongoing incentive programmes, see Note 11 of the 2023/2024 Annual Report and the Board of Directors’ 2023/2024 Remuneration Report. Other than these programmes, the Company is not operating any other long-term incentive programmes. Rules on majority voting The resolution of the AGM as per section A., above, requires a majority of more than half of the votes cast. In order for a resolution as per the proposal in section B.1 above to be valid, it must be supported by shareholders representing no less than two thirds of both the votes cast and the shares represented at the AGM. In order for a resolution as per the proposal in section B.2 above to be valid, it must be supported by shareholders representing no less than nine tenths of both the votes cast and the shares represented at the AGM. In order for a resolution as per section B.3 above to be valid, it must be supported by a majority of more than half of the votes cast at the AGM. 16. Resolution on the Board’s proposal for authorisation to decide on acquisition and transfer of the Company’s own sharesThe Board proposes proposes that the AGM resolve to authorise the Board to decide, on one or more occasions during the period until the next AGM, on the acquisition of shares in the Company. a) Maximum number of shares may be repurchased so that the Company's holding at any time does not exceed five (5) per cent of all shares in the Company. b) The shares shall be acquired on Nasdaq Stockholm at a price within the price range prevailing at any given time, that is, within the range between the highest bid price and the lowest ask price published on an ongoing basis by Nasdaq Stockholm. c) Acquisitions shall be made on a cash payment basis. The Board has issued a statement in accordance with Chapter 19, Section 22 of the Swedish Companies Act. The Board of Directors further proposes that the AGM resolve to authorise the Board to decide, on one or more occasions during the period until the next AGM, on the transfer of shares in the Company. a) The shares shall be transferred on Nasdaq Stockholm at a price within the price range prevailing at any given time, that is, within the range between the highest bid price and the lowest ask price published on an ongoing basis by Nasdaq Stockholm. b) Transfer of shares may be made with deviation from the shareholders' preferential rights. The purpose of the authorisations is to allow the Board to adjust the capital structure in order to create increased value for the Company’s shareholders. Rules on majority voting In order for the AGM’s decision to be valid, the proposal must be supported by shareholders representing no less than two thirds of both the votes cast and the shares represented at the AGM. 17. Resolution on the Board’s proposal to issue warrants within LTIP 2022 The AGM 2022 resolved to implement an incentive programme referred to as “LTIP 2022”. In order to complete the LTIP 2022 registration process at the Swedish Companies Registration Office, the Board proposes that the AGM once again confirms LTIP 2022 by resolving to the issuing of warrants on the terms and conditions set out below, which are in line with the decision of the AGM2022. The issue of the warrants shall, with deviation from the shareholders' preferential rights, be directed to the wholly owned subsidiary, Kanalfläkt Industrial Service AB, registration number 556063-2530 (the "Subsidiary"). The warrants shall be issued free of charge to the Subsidiary. The right to subscribe for the warrants is vested in the Subsidiary with the right and obligation for the Subsidiary to offer employees within LTIP to acquire the warrants for consideration on the terms and conditions set out below. The reason for the deviation from the shareholders' preferential rights is that the Board of Directors believes that it is important and in the interest of all shareholders that Group management and other key persons, who are deemed important for the further development of the company, have a long-term interest in good value growth for the Company’s shares. A personal long-term shareholder commitment can be expected to contribute to an increased interest in the company's activities and performance, as well as to increase participants' motivation and affinity with the company and its shareholders. An explanation of the preparation of the proposal, the costs of the programme and the impact on key indicators is given in Appendix A. Issue of warrants to the Subsidiary The issue, which comprises a maximum of 600,000 warrants of series 2022/2026 shall be made with derogation from shareholders' preferential rights and on the following terms. 1. Number of warrants issued The Company shall issue a maximum of 600,000 warrants. Each warrant carries the right to subscribe for one (1) new share in the Company. 2. Subscription rights and allotment The right to subscribe for the warrants shall, with deviation from the shareholders' preferential rights, be exclusively vested in the Subsidiary wholly owned by the Company. 3. Issue price The warrants shall be issued free of charge to the Subsidiary. 4. Time for signing The warrants must be subscribed for within four (4) weeks from the date of the issue decision. The Board of Directors has the right to extend the subscription period. 5. Time for exercise of warrants Each warrant entitles the holder to subscribe for one (1) new share in the Company. Subscription of shares in accordance with the terms of the warrants may take place during the following periods: a) a two-week period from the day following the publication of the Company's interim report for the period 1 May to 31 July 2025/2026, but no earlier than 18 August 2025 and no later than 30 September 2025, b) a two-week period from the day following the publication of the company's interim report for the period 1 May to 31 January 2025/2026, but no earlier than 2 March 2026 and no later than 30 April 2026, and c) a two-week period from the day following the publication of the company's interim report for the period 1 May to 31 July 2026/2027, but no earlier than 17 August 2026 and no later than 30 September 2026. 6. Subscription price The subscription price for the share upon exercise of the warrant shall be an amount equal to 110 percent of the calculated volume weighted average price of the company's share on Nasdaq Stockholm during the period from 29 August 2022 to 9 September 2022. If the company has inside information during this period, the Board of Directors shall have the right to postpone the measurement period. The subscription price may not be lower than the current quota value of the share. In the event that the subscription price exceeds the quota value of the previous shares, the excess amount (the excess price) shall be recorded in the free share premium fund in the company's balance sheet. If, upon subscription of a share, the last paid price on Nasdaq Stockholm for the Company's share at the close of trading on the trading day immediately preceding the new subscription exceeds 160 per cent of the volume weighted average price of the Company's share during the period from 29 August 2022 up to and including 9 September 2022, the subscription price shall be increased by an amount equal to the amount by which the said payment price exceeds 160% of the said average price Alternative model Holders of the warrants shall have the right, upon subscription of shares with the exercise of the warrants, to request the application of an alternative exercise model in accordance with the full terms and conditions. When applying the alternative subscription model, the subscription price for each share shall be equal to the quota value of the share and the warrants shall entitle the holder to a converted number of shares, which shall be lower as a starting point. However, the warrants shall not entitle the holder to more than one (1) share per warrant, subject to any conversion in accordance with the full terms and conditions of the warrants. Assuming that the subscription price for the shares in the company for which warrants entitle to subscription is set at SEK 58.30, application of the alternative exercise model would have the following effects in the event of full new subscription with the support of all 600,000 warrants and full exercise of the alternative exercise model at the share prices for the company's shares prior to the subscription period indicated below: Illustrative calculation example based on an assumed subscription price of SEK 58.30 Share price Total dilution Total number of new sharesSEK 60 0.01% 17,071SEK 70 0.05% 100,645SEK 80 0.08% 163,260SEK 90 0.09% 177,159 7. Increase in share capital The increase in the Company's share capital, if the warrants are exercised in full, may amount to a maximum of SEK 150,000 (assuming the current quota value and that no conversion has taken place). 8. Dividend Shares subscribed for with the exercise of the warrants carry the right to a dividend for the first time on the record date for dividends that falls closest after subscription has been executed. 9. Authorisation and rules on majority voting The Board, or the person appointed by the Board, shall be authorised to make such minor amendments to the resolution as may be required for registration with the Swedish Companies Registration Office and Euroclear Sweden AB. In order for the AGM’s decision to be valid, the proposal must be supported by shareholders representing no less than two thirds of both the votes cast and the shares represented at the AGM. The full terms and conditions for the warrants are set out in Appendix B - "Terms and conditions for Systemair AB (publ) warrants 2022/2026". Among other things, section 8 of Appendix B states that the subscription price as well as the number of shares for which each warrant entitles the holder to subscribe may be recalculated in the event of a bonus issue, new issue, split, merger or in certain other cases. In the event of full subscription and full exercise of the warrants, the company's share capital may be increased by a maximum of SEK 150,000 through the issue of a maximum of 600,000 shares, each with a quota value of SEK 0.25 (after completion of the share split), subject, however, to the conversion that may be required under the terms of the warrants. These new shares, when fully exercised, represent approximately 0.29 percent of the total number of shares in the Company. Available documents and details of the number of shares outstanding in the CompanyThe annual report and audit report, auditor’s statement on compliance with the guidelines on remuneration to senior executives in force since the preceding AGM, the full text of the Board’s proposed resolutions as above and other documents as required by the Swedish Companies Act will be made available to shareholders at the Company’s offices and on the Company’s website at group.systemair.com no later than from Thursday, 8 August 2024, inclusive. The documents will be sent free of charge to any shareholders who request to receive them and who provide their postal address. The documents will also be available at the AGM. At the time of issue of this invitation, there are a total of 208,000,000 shares and votes in the Company. The Company holds no treasury shares. Information at the AGMThe Board of Directors and President shall – if any shareholder so requests and the Board considers the request may be met without significant damage to the Company – at the AGM disclose information about circumstances that may affect the judgement of an item on the agenda, circumstances that may affect judgement of the financial situation of the Company or a subsidiary and the Company’s relationship with another Group company. Anyone wishing to submit questions in advance may do so to Systemair AB, Reception, 739 30 Skinnskatteberg or by e-mail to: agm@systemair.se Processing of personal data For more information on how personal data is processed in connection with the AGM, please refer to the privacy policy available on Euroclear Sweden AB's website:https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf Skinnskatteberg, July 2024 Systemair AB (publ) Board of Directors For further information contact: Gerald Engström, Chairman of the Board + 46 70 519 00 01Roland Kasper, CEO, + 46 73 094 40 13Anders Ulff, CFO, + 46 70 577 40 09 This information was made public by the above-mentioned contacts on 25 July 2024 at 08:00. Systemair in brief Systemair is a leading ventilation company operating in 51 countries in Europe, North America, the Middle East, Asia, Australia and Africa. The company had a turnover of SEK 12.3 billion in the 2023/24 financial year and employs approximately 6,600 employees today. Systemair has reported an operating profit yearly since 1974 when the company was founded. Over the past 10 years, growth has averaged 9 percent. Systemair helps to improve the indoor climate with the help of energy-efficient and sustainable products that reduce carbon dioxide emissions. Systemair has a well-established business in growth markets. Systemair shares have been quoted on the Nasdaq OMX Nordic Exchange in Stockholm since October 2007 and are today traded on the Large Cap List. The Group comprises about 90 companies.

Neste's Half-Year Financial Report for January–June 2024

Neste Corporation, Half-Year Financial Report, 25 July 2024 at 9 a.m. (EET) Focus on operational excellence in a weak renewables marketSecond quarter in brief: · Comparable EBITDA totaled EUR 240 million (EUR 784 million)  · EBITDA totaled EUR 119 million (EUR 523 million) · Renewable Products' comparable sales margin was USD 382/ton (USD 800/ton) · Oil Products' total refining margin was USD 15.1/bbl (USD 16.7/bbl) · Cash flow before financing activities was EUR -461 million (EUR -24 million) January–June in brief: · Comparable EBITDA totaled EUR 791 million (EUR 1,614 million) · EBITDA totaled EUR 561 million (EUR 986 million) · Cash flow before financing activities was EUR -801 million (EUR -126 million) · Cash-out investments were EUR 758 million (EUR 946 million) · Comparable ROACE was 14.4% over the last 12 months (2023: 23.9%) · Solid financial position, leverage ratio 34.5% at the end of June (31.12.2023: 22.7%) · Comparable earnings per share: EUR 0.28 (EUR 1.35) · Earnings per share: EUR 0.02 (EUR 0.64) Figures in parentheses refer to the corresponding period for 2023, unless otherwise stated.President and CEO Matti Lehmus:“Our result in the second quarter reflects the significantly weaker renewables market and the Porvoo refinery major turnaround. Compared to the first quarter of the year, middle distillate prices, US bioticket and renewable credit prices as well as renewable spot premiums in Europe decreased further. At the same time, waste and residue feedstock average prices increased slightly, as increasing renewable diesel production capacity supported feedstock demand.In the midst of the very challenging renewables market environment, operational performance at our refineries was solid. We were also able to conduct the planned Porvoo major turnaround safely, on time and on budget. Following our systematic cost efficiency improvement initiatives, we were able to decrease our fixed costs year-on-year and compared to the first quarter. In Renewable Products, comparable EBITDA totaled EUR 152 (513) million in the second quarter, impacted by a clearly lower comparable sales margin of USD 382 (800)/ton. As a result of the rapidly changed market conditions, the second-quarter comparable sales margin includes a one-off valuation loss in our bioticket and credit inventories totaling EUR -36 million, equivalent to USD -40/ton in comparable sales margin. The renewables sales volume during the quarter totaled 955 (957) thousand tons, impacted by the preparation for the upcoming maintenance shutdowns at our refineries both in Rotterdam and Singapore. We continued our efforts to grow the sustainable aviation fuel (SAF) business and we expect our SAF sales to grow clearly in the third and fourth quarter. During the second quarter, the share of waste and residue inputs was 88% (96%).In Oil Products, comparable EBITDA totaled EUR 62 (239) million in the second quarter. Profitability was impacted by the planned Porvoo major turnaround. Utilization rate was 34% (86%) due to the turnaround and the total refining margin during the quarter reached 15.1 (16.7) USD/bbl. In Marketing & Services, comparable EBITDA was EUR 24 (29) million in the second quarter, impacted by lower unit margins particularly in Finland. Neste’s market shares continued to be strong.We estimate the second quarter to be the weakest quarter of the year for Neste in terms of results and cash flow to be substantially positive in the second half of the year.We continue executing our strategy with short-term priorities including growth of our SAF sales, ramp up of the new production capacity, improved cash flow and actions to improve our cost efficiency.”The Group's second-quarter 2024 resultsNeste's revenue in the second quarter totaled EUR 4,642 million (5,351 million). The revenue decreased EUR 1.6 billion due to lower sales volumes compared to the second quarter of 2023, mostly driven by the Porvoo major turnaround, whereas the sales prices had a positive impact of approximately EUR 0.5 billion. Currency exchange rates as well as higher trading volumes and prices in Oil Products increased the revenue by approximately EUR 0.3 billion.The Group’s comparable EBITDA was EUR 240 million (784 million). Renewable Products' comparable EBITDA was EUR 152 million (513 million), driven mostly by lower sales volume and lower sales margin compared to the second quarter of 2023. Oil Products' comparable EBITDA was EUR 62 million (239 million), affected by the Porvoo major turnaround. Marketing & Services comparable EBITDA was EUR 24 million (29 million). The Others segment's comparable EBITDA was EUR -1 million (0 million).The Group’s EBITDA was EUR 119 million (523 million), which was impacted by inventory valuation losses of EUR 118 million (losses 305 million), and changes in the fair value of open commodity and currency derivatives totaling EUR -4 million (38 million). Profit before income taxes was EUR -169 million (295 million), and net profit EUR -144 million (259 million). Comparable earnings per share were EUR -0.05 (0.63), and earnings per share EUR -0.19 (0.34).The Group's January–June 2024 resultsNeste's revenue in the first six months totaled EUR 9,443 million (10,649 million). The revenue decreased EUR 1.6 billion due to lower sales volumes compared to the first six months of 2023, mostly driven by the Porvoo major turnaround, whereas sales prices had a positive impact of approximately EUR 0.3 billion. Currency exchange rates as well as higher trading volumes and prices in Oil Products, increased the revenue by approximately EUR 0.2 billion.The Group’s comparable EBITDA was EUR 791 million (1,614 million). Renewable Products' six-month comparable EBITDA was EUR 394 million (928 million), clearly impacted by the weak market environment as sales margin decreased by EUR -515 million. Oil Products' comparable EBITDA was EUR 339 million (632 million), affected mostly by the Porvoo major turnaround. Marketing & Services comparable EBITDA was EUR 47 million (52 million). The Others segment's comparable EBITDA was EUR 8 million (1 million).The Group’s EBITDA was EUR 561 million (986 million), which was impacted by inventory valuation losses of EUR 246 million (losses 579 million), and changes in the fair value of open commodity and currency derivatives totaling EUR 26 million (-60 million). Profit before income taxes was EUR 20 million (571 million), and net profit was EUR 18 million (497 million). Comparable earnings per share were EUR 0.28 (1.35), and earnings per share were EUR 0.02 (0.64).One-off costs related to restructuring, totaling EUR 13 million, had an impact on the first-half results. These one-off costs have been eliminated from comparable EBITDA.OutlookMarket outlook for 2024The uncertainty in the global economic outlook and geopolitical situation continues to create market volatility. In Renewable Products, bioticket and renewable credit prices and renewable diesel price premiums are expected to remain at a low level compared to 2023 and feedstock prices are expected to remain volatile. In Oil Products, the refining market continues to be impacted by geopolitical tensions.Guidance for 2024 specifiedRenewable Products’ total sales volume is expected to increase from 2023 and to reach approximately 4.4 Mt (+/- 10%) in 2024, out of which SAF sales volume is expected to be 0.5–0.7 (previously 0.5–1.0) Mton. Renewable Products’ full-year 2024 average comparable sales margin is expected to be in the range of USD 480–580/ton (previously USD 480-650/ton).Oil Products’ total sales volume in 2024 is expected to be lower than in 2023, impacted by the Porvoo major turnaround in the second quarter. Oil Products’ full-year 2024 total refining margin is expected to be lower than in 2023.Additional informationIn Renewable Products, SAF sales are expected to continue growing toward the end of the year. Singapore refinery is scheduled to have a 6-week and Rotterdam refinery a 4-week maintenance shutdown in the third quarter. Singapore’s new line is also scheduled to have an 8-week maintenance shutdown in the fourth quarter, after which full capacity is expected to be reached. Renewable Products’ full-year sales volume is impacted by the planned maintenance shutdowns and the ramp-up timeline of Martinez Renewables joint operation (Martinez). Following the fire at the end of 2023, the Martinez facility has been operating at slightly below 50% of nameplate capacity in the first half of the year, but targeted to reach approximately 75% of nameplate capacity during the third quarter and 100% by the end of the year. Work is ongoing to proceed with repairs to ensure safe and reliable operations.In Marketing & Services the sales volumes and unit margins are expected to follow the previous years' seasonality pattern.The Group’s total fixed costs in 2024 are expected to be slightly higher than in 2023 due to the Porvoo major turnaround and the build-up of resources for the growth projects under construction. The fixed costs growth trend is expected to level out compared to 2023 due to cost saving and efficiency measures.The Group’s full-year 2024 cash-out capital expenditure excluding M&A is estimated to be approximately EUR 1.4–1.6 billion. The share of maintenance and strategic capex is expected to represent approximately 40% and 60%, respectively, as the Porvoo major turnaround increases maintenance capex for 2024.Conference callA conference call in English for investors and analysts will be held on 25 July 2024, at 3 p.m. Finland / 1 p.m. London / 8 a.m. New York. In order to receive the participant dial in numbers and a unique personal PIN, participants are requested to register using this link: https://register.vevent.com/register/BI504e0b7625e5420faee61b1a20ed1c63. The conference call can also be followed as a webcast . Further information:Matti Lehmus, President and CEO, tel. +358 10 458 11Martti Ala-Härkönen, CFO, tel. +358 40 737 6633Anssi Tammilehto, Vice President, Investor Relations, tel. +358 50 458 8436

Implantica announces continuing progress in modular PMA application to FDA for RefluxStop™

Upon completion of its review of Module 1, the first of three modules to be submitted in our PMA, FDA provided Implantica a list of deficiencies, all of which the company considers to be minor. No major issues have been identified by FDA thus far, and Implantica is in the process of addressing these comments. Based on FDA’s response, the company has decided to submit Module 2 of our PMA application once our response to FDA’s findings on Module 1 has been finalized. Based on this approach, the company does not anticipate any significant impact on the overall timeline. Implantica will provide an update within the next 1-2 months. Implantica’s CEO, Dr. Peter Forsell says, "We are passionate about the progress of our PMA submission to FDA and are pleased with the positive feedback received on our Module 1 submission. We are excited to announce that the 5-year results to be submitted in Module 2 are remarkable and consistent with the positive outcomes observed at the 1-4-year marks, which is truly rewarding.” For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 49nicole.pehrsson@implantica.com Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@fnca.se The information was sent for publication, through the agency of the contact person set out above, on July 25, 2024, at 08:30 a.m. (CET). About ImplanticaImplantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information. About RefluxStop™RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It’s unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower oesophageal sphincter’s closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit. In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower oesophageal sphincter in its original, natural position. The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux. Newsroomhttps://www.implantica.com/media/media-kit Communityhttps://ch.linkedin.com/company/implanticahttps://www.twitter.com/implantica Media Contact:Implantica AGJuanita Eberhart, VP Marketing & AdvocacyM: +1 925-381-4581juanita.eberhart@implantica.com

Sale of Gjensidige’s operations in the Baltics to ERGO International AG

This release contains inside information related to Gjensidige Forsikring ASA pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Gjensidige Forsikring ASA ("Gjensidige" or the "Company") has entered into an agreement with ERGO International AG, managing ERGO Group’s international business portfolio, for the sale of its subsidiary ADB Gjensidige ("Gjensidige Baltics"). Key information · Sale of 100 per cent of the shares in ADB Gjensidige · Agreed purchase price of EUR 80 million, representing a price to book multiple of 2.0 x for ADB Gjensidige, payable fully in cash at closing (the purchase price at closing to be adjusted for any changes in equity between signing and closing) · Closing is subject to, among other things, customary regulatory approvals Gjensidige's management will host a conference call for investors and analysts tomorrow, Friday 26 July 2024, at 10:30 CET. Please find conference call details below. “Creating a leading Nordic P&C company is a key priority for me. A strong commitment to improve profitability and growth in the Nordics has been important for me from day one. The sale of our Baltic business supports such a strategy and shows our clear Nordic market focus, which is aligned with our core competence and capabilities. The divestment of Gjensidige Baltics is a result of our strategic review. We believe that this transaction creates the best long-term value for our shareholders and enables us to focus all efforts on our core markets in the Nordics”, says CEO Geir Holmgren.   The transaction will not have a significant impact on the Gjensidige Group’s financials and the financial targets for the Group remain unchanged. The transaction is expected to result in an accounting loss of around NOK 120 million to be recognised in Q3 2024. At the same time, the transaction is expected to positively impact the Group's solvency ratio at closing by approximately 4 percentage points, based on the approved partial internal model as at 30 June 2024. Going forward ADB Gjensidige will be classified as held for sale, and the financial accounts for the company will be presented separately in the statement of financial position. ADB Gjensidige has 659 employees and offers general insurance products to private and commercial customers in Lithuania, Latvia and Estonia. Please refer to Gjensidige Forsikring Group’s Q2 2024 interim report for the latest results of the Baltic segment, and the Group’s Annual report for 2023 note 11 for Gjensidige Forsikring ASA for accounting information on ADB Gjensidige.  Both reports are available at www.Gjensidige.com/investor-relations/reports-and-presentations. Conference call details: · Date and time: 26 July 2024, 10:30 CET · Tel. nos:- USA: +1 786 697 3501- Norway: +47 21 56 33 18- UK: +44 (0) 33 0551 0200- Other locations: dial one of the numbers above · Password: Sommer24 Replay · Tel. nos:- USA: 1 866 583 1035- UK: +44 (0) 20 8196 1480- Other locations: dial one of the numbers above · Confirmation code: 3209107# This release is issued by Mitra Hagen Negård, Head of Investor Relations at Gjensidige Forsikring ASA. Date and time of publication: 14:30 CET, 25 July 2024. Contact persons Gjensidige Forsikring ASA:Head of Investor Relations, Mitra Hagen Negård, tel. +47 957 93 631Head of Communication: Øystein Thoresen, Tel: + 47 952 33 382 Gjensidige is a leading Nordic insurance group listed on the Oslo Stock Exchange. We have about 4,500 employees and offer insurance products in Norway, Denmark, Sweden and the Baltic states. In Norway, we also offer pension and savings. The Group's operating income was NOK 36 billion in 2023, while total assets were NOK 148 billion.

Cabonline Group appoints Charlotta Söderlund as President and CEO

Charlotta joined Cabonline in 2017 and has over 18 years of experience in the taxi industry. She has been a key member of Cabonline's management team and has played a crucial role in Cabonline's operational success and strategic development. - We are delighted to announce that Charlotta Söderlund is our new President and CEO. With her solid experience, deep understanding of our business, and strong leadership, we are confident that Charlotta will continue to drive Cabonline forward successfully, says Peter Viinapuu, Chairman of the Board of Cabonline Group. As COO, Charlotta has been responsible for optimising Cabonline's operational processes and strengthening core businesses. As acting CEO, Charlotta has demonstrated strong and inclusive leadership and the ability to navigate a challenging period with a continued focus on growth and development. - I am honoured to continue to lead and drive Cabonline forward into the next phase of our development and strengthen our position in the Nordic market as President and CEO. We have a great team, and I look forward to working closely with them to continue developing our business. We will focus on being relevant to our customers, travellers, riders and drivers and achieve sustainable and profitable growth. My ambition and goal is to increase our customer focus and quality by including and creating participation in our development journey ahead. I am convinced and passionate that a clear customer focus creates value for everyone, says Charlotta Söderlund. For further information, please contact:Peter Viinapuu, Chairman of the board, phone +46 ‭+46 76 641 10 06‬, peter@vgruppen.comCharlotta Söderlund, CEO, phone +46 70453 77 70‬, charlotta.weigel@cabonline.com‬‬‬ This information is information that Cabonline Group Holding AB (publ) is obliged to make public pursuantto the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:00 CET on July 25, 2024. About Cabonline: Cabonline is the leading taxi company in the Nordic region, with ~2,200 connected transporters and ~4,100 vehicles in Sweden, Norway, Finland and Denmark. Cabonline operates a series of well-known brands, such as TaxiKurir, Taxi Skåne, Umeå Taxi, Sverigetaxi, TOPCAB, Norgestaxi, Kovanen, Fixu Taxi and Flygtaxi. Through Cabonline, transporters can access attractive customer agreements, support from industry-leading technology and efficient services where shared infrastructure delivers economies of scale. In 2023, Cabonline’s revenue was approximately SEK 5.6 billion. For further information, cabonlinegroup.com/en 

EQT to sell its stake in fiber-to-the-home network Fiberklaar

EQT is pleased to announce that the EQT Infrastructure V fund (“EQT”) has signed an agreement to sell its majority stake in Fiberklaar (the "Company") to its co-shareholder Proximus, Belgium's largest telecom operator, for a purchase price of EUR 246 million. Headquartered in Ghent, Fiberklaar is Flanders' leading independent fiber-to-the-home provider, rolling out a large-scale, open access network to households and small businesses. Today, Fiberklaar has many active construction projects across Flanders and is well on track to bring fiber to households throughout the region. Fiberklaar was founded as a joint venture in 2021 by EQT and Proximus, marking EQT's first partnership with a national telecoms incumbent. Applying its experience in developing strong fiber companies in Europe and North America, EQT, alongside Proximus, has supported Fiberklaar in creating an efficient rollout engine to build a fiber network accessible to all operators. Since its formation, Fiberklaar has played an instrumental role in accelerating fiber deployment in the Flemish region, driving digital inclusion in Belgium which continues to lag other European countries in terms of fiber coverage. Having achieved significant milestones during its ownership, EQT’s exit is a natural next step for Fiberklaar. The Company now begins a new chapter in its journey to increase access to high-speed connectivity solutions in Belgium, while playing a role in Proximus’ possible future cooperation agreements to roll-out fiber in Flanders. Ulrich Köllensperger, Partner within the EQT Value-Add Infrastructure Advisory team, said: “Private capital has a huge role to play in supporting companies solving connectivity gaps and modernizing digital infrastructure. We are pleased to have helped Fiberklaar scale so quickly together with Proximus, drawing on our vast experience of multiple fiber-to-the-home rollout projects across geographies. We thank the entire Fiberklaar team for their contribution and look forward to following the Company’s journey as it continues to foster digital inclusion and contribute to the prosperity of the Flemish Region.” Guillaume Boutin, CEO Proximus, said: “Over the past three years, Fiberklaar, with full support of EQT Infrastructure and Proximus, has transformed from a start-up into a strong deployment engine. Becoming the only shareholder of Fiberklaar will allow us to work more closely together and further increase the efficiency and quality of the fiber roll-out in Flanders, while capturing the value generated by synergies.” Jo van Gorp, CEO Fiberklaar, said: “I am very grateful to EQT for their great cooperation and support and look forward to the next phase of our partnership with our sole shareholder Proximus. Fiberklaar has played an instrumental role in accelerating fiber deployment in the Flemish region, driving digital inclusion in Belgium which continues to lag other European countries in terms of fiber coverage. We have achieved many impressive milestones over the last years with our most valued employees, construction partners and suppliers. With the valuable experience and know-how of the Proximus Group and the good relations with our stakeholders, Fiberklaar is well positioned to continue its mission to further roll out its high-quality and future-proof fiber network open to all.” The closing of the transaction is expected in the coming days. ContactEQT Press Office, press@eqtpartners.com

Immunovia presents data from discovery study at 2024 PancreasFest medical conference

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed discovery study results for the company’s next-generation early detection test for pancreatic cancer at the PancreasFest 2024 Annual Meeting (abstract #P33).  PancreasFest is an annual conference of physicians and translational researchers with special interest in the pancreas who convene to find new ways to improve the care of patients with pancreatic disease, including pancreatic cancer. It is organized by the Collaborative Alliance for Pancreatic Education and Research.  Abstracts submitted to this medical conference undergo a rigorous peer-review and selection process in which only a subset of studies are chosen for presentation at the meeting. Results presented at PancreasFest reflect a detailed scientific presentation of the initial positive data the company shared in a 7 November 2023 press release. The discovery study, the most comprehensive pancreatic cancer proteomics study done to date, identified 15 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC). These protein biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. Over 3,000 proteins were evaluated in 329 blood samples from Stage 1 and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays. “We are honored to have been chosen to present the discovery study results at this important conference.  We look forward to discussing the detailed study data and receiving scientific and clinical insights from this key group of physicians and researchers who are experts in pancreatic cancer,” said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia. For more information, please contact: Jeff Borcherding CEO and President jeff.borcherding@immunovia.com Karin Almqvist Liwendahl Chief Financial Officer karin.almqvist.liwendahl@immunovia.com +46 709 11 56 08 Immunovia in brief Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit  www.immunovia.com

Konecranes Plc’s Half-year financial report, January-June 2024: Record-high comparable EBITA margin in all Business Segments

KONECRANES PLC HALF-YEAR FINANCIAL REPORT, JANUARY-JUNE 2024 JULY 26, 2024 8:30 am EEST Konecranes Plc’s Half-year financial report, January-June 2024 Record-high comparable EBITA margin in all Business Segments This release is a summary of Konecranes Plc’s Half-year financial report, January-June 2024. The complete report is attached to this release in pdf format and is also available on Konecranes’ website at www.konecranes.com. The figures presented in this report are unaudited. Figures in brackets, unless otherwise stated, refer to the same period a year earlier. Konecranes has made changes in reporting Industrial Equipment's order intake and net sales. The change also impacts Industrial Equipment's profitability. The previous year’s figures presented in this release have been restated and are fully comparable with the current year figures. SECOND QUARTER HIGHLIGHTS - Order intake EUR 967.7 million (1,092.9), -11.5 percent (-11.6 percent on a comparable currency basis), order intake increased in Service but decreased in Port Solutions and Industrial Equipment - Service annual agreement base value EUR 331.8 million (313.9), +5.7 percent (+5.9 percent on a comparable currency basis) - Service order intake EUR 406.4 million (374.5), +8.5 percent (+8.5 percent on a comparable currency basis) - Order book EUR 2,987.1 million (3,411.4) at the end of June, -12.4 percent (-12.8 percent on a comparable currency basis) - Sales EUR 1,031.5 million (913.0), +13.0 percent (+13.0 percent on a comparable currency basis), sales increased in all segments - Comparable EBITA margin 14.3 percent (10.8) and comparable EBITA EUR 147.3 million (98.3); the increase in the comparable EBITA margin was mainly driven by pricing and higher volumes, as well as good strategy execution. - Operating profit EUR 137.8 million (98.0), 13.4 percent of sales (10.7), items affecting comparability totaled EUR 1.9 million (-7.7), mainly comprising of restructuring costs - Earnings per share (diluted) EUR 1.26 (0.71) - Free cash flow EUR 21.5 million (114.0) JANUARY-JUNE 2024 HIGHLIGHTS - Order intake EUR 1,876.8 million (2,382.5), -21.2 percent (-21.0 percent on a comparable currency basis) - Service order intake EUR 794.9 million (753.3), +5.5 percent (+6.2 percent on a comparable currency basis) - Sales EUR 1,944.6 million (1,812.3), +7.3 percent (+7.8 percent on a comparable currency basis) - Comparable EBITA margin 12.8 percent (10.7) and comparable EBITA EUR 249.0 million (193.7); the comparable EBITA margin increased in all three segments - Operating profit EUR 226.9 million (183.7), 11.7 percent of sales (10.1), items affecting comparability totaled EUR 6.7 million (-5.1), mainly comprising of restructuring costs - Earnings per share (diluted) EUR 2.00 (1.38) - Free cash flow EUR 70.3 million (230.0) - Net debt EUR 437.7 million (619.8) and gearing 26.8 percent (43.2) DEMAND OUTLOOK Our demand environment within industrial customer segments has remained good and continues on a healthy level. Global container throughput continues on a high level, and long-term prospects related to global container handling remain good overall. FINANCIAL GUIDANCE Konecranes expects net sales to remain approximately on the same level or to increase in 2024 compared to 2023. Konecranes expects the full-year 2024 comparable EBITA margin to improve from 2023. KEY FIGURES +-----------+-------+-------+------+-------+-------+------+-------+-------+| | 4-6/ | 4-6/ |Change| 1-6/ | 1-6/ |Change| R12M | 1-12/ || |2024 |2023 |% |2024 |2023 |% | |2023 |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Orders |967.7 |1,092.9|-11.5 |1,876.8|2,382.5|-21.2 |3,655.8|4,161.4||received, | | | | | | | | ||MEUR | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Order book | | | |2,987.1|3,411.4|-12.4 | |3,040.8||at end of | | | | | | | | ||period, | | | | | | | | ||MEUR | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Sales |1,031.5|913.0 |13.0 |1,944.6|1,812.3|7.3 |4,098.7|3,966.3||total, MEUR| | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Comparable |168.9 |118.7 |42.4 |293.3 |236.5 |24.0 |591.8 |535.0 ||EBITDA, | | | | | | | | ||MEUR 1 | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Comparable |16.4% |13.0% | |15.1% |13.1% | |14.4% |13.5% ||EBITDA, % 1| | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Comparable |147.3 |98.3 |49.8 |249.0 |193.7 |28.6 |506.1 |450.7 ||EBITA, MEUR| | | | | | | | ||1 | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Comparable |14.3% |10.8% | |12.8% |10.7% | |12.3% |11.4% ||EBITA, % 1 | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Comparable |139.7 |90.3 |54.7 |233.6 |178.7 |30.7 |474.6 |419.7 ||operating | | | | | | | | ||profit, | | | | | | | | ||MEUR 1 | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Comparable |13.5% |9.9% | |12.0% |9.9% | |11.6% |10.6% ||operating | | | | | | | | ||margin, % 1| | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Operating |137.8 |98.0 |40.6 |226.9 |183.7 |23.5 |445.6 |402.5 ||profit, | | | | | | | | ||MEUR | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Operating |13.4% |10.7% | |11.7% |10.1% | |10.9% |10.1% ||margin, % | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Profit |131.9 |77.5 |70.3 |211.4 |149.7 |41.2 |429.3 |367.6 ||before | | | | | | | | ||taxes, | | | | | | | | ||MEUR | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Net profit |99.7 |56.6 |76.2 |159.0 |109.3 |45.5 |325.3 |275.6 ||for the | | | | | | | | ||period, | | | | | | | | ||MEUR | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Earnings |1.26 |0.71 |76.2 |2.01 |1.38 |45.5 |4.11 |3.48 ||per share, | | | | | | | | ||basic, EUR | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Earnings |1.26 |0.71 |76.2 |2.00 |1.38 |45.5 |4.09 |3.46 ||per share, | | | | | | | | ||diluted, | | | | | | | | ||EUR | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Gearing, % | | | |26.8% |43.2% | | |22.9% |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Net debt / | | | |0.7 |1.3 | | |0.7 ||Comparable | | | | | | | | ||EBITDA, | | | | | | | | ||R12M 1 | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Return on | | | | | | |19.2% |16.4% ||capital | | | | | | | | ||employed, %| | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Comparable | | | | | | |20.2% |17.7% ||return on | | | | | | | | ||capital | | | | | | | | ||employed, %| | | | | | | | ||2 | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Free cash |21.5 |114.0 | |70.3 |230.0 | |351.6 |511.4 ||flow, MEUR | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+|Average | | | |16,587 |16,477 |0.7 | |16,503 ||number of | | | | | | | | ||personnel | | | | | | | | ||during the | | | | | | | | ||period | | | | | | | | |+-----------+-------+-------+------+-------+-------+------+-------+-------+ 1) Excluding items affecting comparability, see also note 11 in the summary financial statements 2) ROCE excluding items affecting comparability, see also note 11 in the summary financial statements CEO Anders Svensson: Konecranes had an excellent Q2. Performance was strong in all Business Segments. Order intake remained healthy, and sales grew year-on-year. Thanks to sales growth and good strategy execution, profitability improved year-on-year, and we posted an all-time high quarterly comparable EBITA margin - 14.3%. This is an excellent achievement, and I would like to thank the whole Konecranes team for the strong performance. The demand environment remained healthy in Q2, although our order intake declined 11.6% year-on-year on a comparable currency basis. The orderbook was nearly €3.0 billion at the end of June, 12.8% lower than a year ago on a comparable currency basis. Delivery capability continued to be good. Group sales exceeded €1 billion and were 13.0% higher versus a year ago on a comparable currency basis. Sales grew in all three Business Segments. Our comparable EBITA margin improved year-on-year and was 14.3%, mainly driven by pricing and higher volumes, as well as good strategy execution. Profitability improved in all three Business Segments. Service had yet another strong quarter. Order intake increased 8.5% year-on-year in comparable currencies. Sales increased 8.8% year-on-year in comparable currencies. The comparable EBITA margin improved year-on-year to an all-time high of 22.1%, mainly driven by pricing and higher volumes. The agreement base value continued to grow and in comparable currencies was 5.9% higher at the end of Q2 versus a year ago. We have also continued to expand our field service network through bolt-on acquisitions and acquired Dungs Kran- und Anlagentechnik Gmbh in the Lower Rhine region in Germany in the beginning of July. Industrial Equipment’s external orders decreased 10.9% year-on-year in comparable currencies but remained close to the previous’ quarter’s level. External sales increased by 6.8% year-on-year in comparable currencies. Driven by volume growth and good strategy execution, the comparable EBITA margin increased year-on-year to an all-time high of 9.8%. The comparable EBITA margin was also positively impacted by approximately €4 million of favorable resolution of project related claims. In Port Solutions, order intake totaled €308 million, decreasing 26.9% year-on-year in comparable currencies against a strong comparison period. Port Solutions had a good delivery quarter, and sales grew 25.0% year-on-year in comparable currencies. The comparable EBITA margin was an all-time high, 10.5%, and the improvement was mainly driven by pricing, volume growth and mix. Port Solutions ended the quarter with an orderbook value of over EUR 1.6 billion. Regarding the market outlook, we expect the demand environment within our industrial customers to remain healthy. Although customer decision-making is taking somewhat longer for larger industrial projects, our sales funnels continue at a high level, and we keep receiving new sales cases. As for our port customers, container throughput continues to be on a high level, and long-term prospects related to container handling remain good. Our Port Solutions sales pipeline includes a good mix of projects of all sizes. Quarterly order intake fluctuation is normal for the business, as the booking of orders depends on the timing of customer decision-making. Our strategy execution has progressed better than initially expected. As a result, we updated our financial guidance in June, and upgraded our profitability guidance for this year. We now expect our net sales to remain on the same level or to increase in 2024 compared to 2023, and our comparable EBITA margin to improve from the previous year. That said, we are not expecting our profitability to improve sequentially in Q3 versus Q2. Overall, Q2 was one of Konecranes’ strongest quarters ever. Our performance improvement demonstrates that we are doing the right things as a company, and moving what really matters. On a rolling twelve-month basis, we are now within our profitability target range on the Group level and in Service. Next, our aim is to do that across all our three Business Segments on a continuous basis. ANALYST AND PRESS BRIEFING A live international webcast and telephone conference for analysts, investors and media will be arranged today at 11:30 a.m. EEST. The event will be held in English. The half-year financial report will be presented by President and CEO Anders Svensson and CFO Teo Ottola. Questions may be presented at the end of the conference. The conference will be recorded, and an on-demand version of the conference will be published on the company´s website later during the day. The webcast can be watched through the following link: https://konecranes.videosync.fi/q2-2024 To ask questions, the telephone conference can be joined by registering through the following link: https://palvelu.flik.fi/teleconference/?id=50049972 Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue. Questions can also be presented in writing through the question form, while watching the webcast. NEXT REPORT Konecranes Plc will publish its interim report, January-September 2024 on October 25, 2024. KONECRANES PLC Kiira Fröberg Vice President, Investor Relations FURTHER INFORMATION Kiira Fröberg, Vice President, Investor Relations, tel. +358 (0) 20 427 2050 IMPORTANT NOTICE The information in this release contains forward-looking statements, which are information on Konecranes’ current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Konecranes’ control that could cause Konecranes’ actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Konecranes’ present and future business strategies and the environment in which it will operate in the future. Konecranes is a global leader in material handling solutions, serving a broad range of customers across multiple industries. We consistently set the industry benchmark, from everyday improvements to the breakthroughs at moments that matter most, because we know we can always find a safer, more productive and sustainable way. That's why, with around 16,600 professionals in over 50 countries, Konecranes is trusted every day to lift, handle and move what the world needs. In 2023, Group sales totalled EUR 4.0 billion. Konecranes shares are listed on Nasdaq Helsinki (symbol: KCR). DISTRIBUTION Nasdaq Helsinki Major media www.konecranes.com

SAS files monthly operating reports with U.S. court and announces certain financial information for the Group

In connection with these Court filings, SAS announces certain consolidated financial information for the SAS Group as of June 30, 2024, see table below. The financial information has not been audited or reviewed by SAS’ auditor. []Financial Information, SAS Group million SEK (million USD)[1)] November 1, 2023 – June 30, 2024Revenue 27,927 (2,622)Net income for the period -3,366 (-316) As of June 30, 2024Total assets 58,785 (5,519)Total liabilities 69,337 (6,510)Cash and cash equivalents 8,908 (836) 1) Amounts in SEK have been recalculated to USD based on the Swedish Riksbank’s SEK/USD exchange rate of 10.6507 as of June 30, 2024. SAS publishes a press release in connection with each monthly operating report filing, other than for the months when the filings coincide with the publication of SAS’ interim reports. Additional information about the Chapter 11 process is available at the Company’s dedicated restructuring website, https://sasgroup.net/transformation. Court filings and other documents related to the chapter 11 process in the U.S. are available on a separate website administered by SAS’ claims agent, Kroll Restructuring Administration LLC, at https://cases.ra.kroll.com/SAS. Information is also available by calling (844) 242-7491 (U.S./Canada) or +1 (347) 338-6450 (International), as well as by email at SASInfo@ra.kroll.com. Advisors Weil, Gotshal & Manges LLP is serving as global legal counsel and Mannheimer Swartling Advokatbyrå AB is serving as Swedish legal counsel to SAS. Seabury Securities LLC and Skandinaviska Enskilda Banken AB are serving as investment bankers. Seabury is also serving as restructuring advisor. For further information, please contact:SAS Press office, +46 8 797 29 44Investor Relations, +46 70 997 7070 SAS, Scandinavia’s leading airline, with main hubs in Copenhagen, Oslo and Stockholm, flies to destinations in Europe, USA and Asia. Spurred by a Scandinavian heritage and sustainability values, SAS aims to be the driving force in sustainable aviation and in the transition toward net zero emissions. We are continuously reducing our carbon emissions through using more sustainable aviation fuel, investing in new fuel-efficient aircraft and technology innovation together with partners – thereby contributing towards the industry target of net zero CO2 emissions by 2050. In addition to flight operations, SAS offers ground handling services, technical maintenance and air cargo services. Learn more at https://www.sasgroup.net

Half-year report, Q2 2024

January–June 2024 compared with January–June 2023 · Net sales increased to SEK 9,849m (9,395). The sales increase was mainly as a result of higher delivery volumes due to a gradual ramp up of production at mills where strategic capital expenditures have recently been made. · EBITDA amounted to SEK 3,484m (3,755). Lower selling prices were offset by higher delivery volumes, positive exchange rate effects and effective cost control. · EBITDA margin was 35.4% (40.0). · Operating profit declined to SEK 2,438m (2,825). · Operating cash flow amounted to SEK 1,203m (1,851). · Earnings per share was SEK 2.49 (3.06). April–June 2024 compared with April–June 2023 · Net sales increased to SEK 5,291m (4,582), mainly attributable to higher selling prices and higher delivery volumes. · EBITDA amounted to SEK 1,888m (1,700) and EBITDA margin was 35.7% (37.1). Higher selling prices had a positive impact on earnings. April–June 2024 compared with January–March 2024 · Net sales increased to SEK 5,291m (4,558), mainly attributable to higher selling prices and higher delivery volumes. · EBITDA increased to SEK 1,888m (1,596) and EBITDA margin was 35.7% (35.0). The increase was primarily attributable to higher selling prices.  KEY FIGURES Quarter Jan-JunSEKm 2024:2 2023:2 % 2024:1 % 2024 2023 %Net sales 5,291 4,582 15 4,558 16 9,849 9,395 5EBITDA 1,888 1,700 11 1,596 18 3,484 3,755 -7EBITDA margin, % 35.7 37.1 35.0 35.4 40.0Operating profit 1,361 1,229 11 1,077 26 2,438 2,825 -14Net Profit 960 916 5 789 22 1,749 2,129 -18Earnings per share SEK 1.37 1.32 1.12 2.49 3.06 Operating cash flow 526 648 677 1,203 1,851Net Debt / EBITDA (LTM) 1.8x 1.3x 1.8x 1.8x 1.3x  SUMMARY OF THE SECOND QUARTER OF 2024 SCA’s earnings for the second quarter were stronger compared with the preceding quarter and the year-earlier quarter. Demand for fiber-based products gradually grew during the first half of the year, which led to progressively higher selling prices that positively impacted earnings. The high rate of self-sufficiency in wood raw material, energy and logistics continued to contribute to effective cost control and the strategic capital expenditures recently made in pulp and packaging paper resulted in higher delivery volumes. The supply of wood raw material to SCA’s industries was stable. The price of sawlogs and pulpwood continued to rise slightly compared with the preceding quarter. Seasonally stronger demand combined with higher sawlog costs led to increasing selling prices for solid-wood products compared with the preceding quarter. Demand in the Pulp segment remained at a good level with increased delivery volumes and progressively higher selling prices compared with the preceding quarter. Demand for packaging material continued to increase during the quarter, leading to stronger demand for kraftliner and progressively higher selling prices compared with the preceding quarter. Seasonally lower demand for electricity and solid biofuel combined with a weaker market for liquid biofuel led to lower selling prices and delivery volumes in the Renewable Energy segment.  INVITATION TO PRESS CONFERENCE ON HALF-YEAR REPORT 2024 Members of the media and analysts are hereby invited to attend a press conference where this interim report will be presented by the President and CEO, Ulf Larsson, and by the CFO, Andreas Ewertz. Time: Friday, July 26, 2024 at 10:00 a.m. The press conference will be webcast live at www.sca.com. It is also possible to participate by telephone by calling: Sweden:+46 (0)8 505 204 24 UK:+44 (0)33 0551 0200 US:+1 786 697 3501 Specify “SCA Q2”. For further information, please contact Andreas Ewertz, CFO, +46 (0)60 19 31 97 Josefine Bonnevier, Investor Relations Director, +46 (0)60 19 33 90 Anders Edholm, SVP Sustainability and Communications, +46 (0)60 19 32 12 Please note: This is information that SCA is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of the contact person set out below, on July 26, 2024 at 8:00 a.m. CEST. The report has been reviewed by the company’s auditors. Anders Edholm, SVP Sustainability and Communications, +46 (0)60 19 32 12 The core of SCA’s business is the growing forest, Europe’s largest private forest holding. Around this unique resource, we have built a well-developed value chain based on renewable raw material from our own and others’ forests. We offer packaging paper, pulp, wood products, renewable energy, services for forest owners and efficient transport solutions. 2022 the forest products company SCA had approximately 3,400 employees and sales amounted to approximately SEK 18 bn. SCA was founded in 1929 and has its headquarters in Sundsvall, Sweden. For more information, visit www.sca.com

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

The TRANSFORM trial is a double-blind, randomized, placebo-controlled Phase 2b study investigating the effect of setanaxib 800 mg AM + 400 mg PM, (“1200 mg arm”) and 800 mg BID (“1600 mg arm”) over 24 weeks of treatment. The basis for the analysis consisted of a dataset of 76 patients with primary biliary cholangitis (PBC) and elevated liver stiffness. The treatment groups were relatively well-balanced with no clinically relevant differences between the groups observed at baseline. The result is particularly encouraging as over 40% of the trial population was on dual therapy, ie was receiving UDCA (ursodeoxycholic acid) and either Ocaliva (obeticholic acid) or Bezafibrate (PPAR agonist) as base therapy and 13% were receiving all three therapies during the study, reflecting setanaxib having clinically relevant incremental benefit beyond existing standard of care. Patients treated with setanaxib showed statistically significant improvements in the primary endpoint of ALP of 19% in the 1600mg arm and 14% in the 1200mg arm and showed positive trends on liver stiffness assessed by FibroScan® at 24 weeks. Setanaxib treatment was generally well tolerated with overall number of TEAEs (treatment emergent adverse events), as well as serious TEAEs, being similar between active treatment and placebo. The frequency of TEAEs leading to study discontinuation was higher in patients receiving active treatment compared to placebo. “It is very encouraging to see a statistically significant treatment effect in this hard-to-treat population which is already on multiple medications in this relatively small study,” said Professor Dave Jones OBE; Director, NHIP Academy; Director, Newcastle Centre for Rare Disease; Professor of Liver Immunology, Newcastle University; and Honorary Consultant Hepatologist, Newcastle upon Tyne Hospitals. “These positive data provide further clinical evidence of the potential of setanaxib in multiple rare diseases, and we are very pleased that we now have additional positive clinical evidence in support of our unique, first in class NOX platform.  We also look forward to the read out of the investigator led study in IPF as well as the ongoing study in Alport syndrome in due course.” said CEO Renée Aguiar-Lucander. “I am delighted that we have seen statistically significant and clinically meaningful improvements in ALP with encouraging trends in other outcomes in this population of patients with PBC. I’d like to extend my thanks to investigators, clinical trial site staff, and most importantly patients, who have all contributed to this important study.” said CMO Richard Philipson. The company is conducting additional clinical trials with setanaxib and is expecting the investigator led Phase 2 trial in IPF (idiopathic pulmonary fibrosis) to provide top line data in Q4 2024 / Q1, 2025. There is also an ongoing Phase 2 proof of concept trial in Alport syndrome, which is expected to deliver top line data in 2025.

CS MEDICA Leverages Strategic Partnerships for CANNASEN® Brand Launch in APAC and MENA

CS MEDICA announces an advancement in its expansion strategy with the upcoming launch of CANNASEN® in the Asia-Pacific (APAC) and Middle East/North Africa (MENA) regions. This launch utilizes strong partnerships and a Minimum Viable Product (MVP) approach to establish the CANNASEN® brand. CS MEDICA will distribute 36,000 units of CANNASEN® to APAC and MENA at a value of €419,000 starting August 2024. This initiative aims to gather consumer insights to perfect product alignment and readiness for new production cycles. This approach is vital in regions characterized by rapid growth, strict regulations, and challenging market penetration.  Key Highlights: · Strategic Expansion: Introducing CANNASEN® to the rapidly growing APAC and MENA markets, targeting alternative OTC and CBD-infused products. · MVP Seeding Launch: Employing online platforms to evaluate market response and refine offerings. · Go-to-Market Synergies: Facilitating quicker market entry and readiness for new production with a defined pull effect. · Stock Challenges: Tackling stock issues related to local language, expiry, and regulatory compliance. · Local Partnerships and Regulatory Adaptation: Enhancing brand visibility and ensuring compliance in regions with stringent regulations and developing markets for products containing CBD, in contrast to the more mature US and EU markets.  New Dual Distribution Agreement to Address Market Entry Barriers in Asia In response to previous market challenges, especially in China, our flexible MVP approach allows for proactive adjustments based on real-time feedback, parallel with our long-term joint venture track. A new dual distribution deal with IBG Best Life AB enhances our entry strategy, covering essential markets such as Hong Kong, China, and Thailand, with initial orders due by August. This partnership builds on previous cooperations from their Swedish office to help navigate Asian market complexities effectively. CEO of CS MEDICA, Lone Henriksen emphasizes, "Recognizing we haven't fully decoded market dynamics in these regions, our targeted strategies, including our partnership with IBG Best Life AB, are essential for adapting our offerings and penetrating the Asian markets more effectively." 

CHMP has adopted a negative opinion on lecanemab for the EU

Lecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong, and Israel and is being marketed in the U.S., Japan and China. Eisai is responsible for the clinical development, applications for market approval and commercialization of lecanemab for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region. --- This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on July 26, 2024, at 12:40 p.m. CET. For further information, please contact: Oskar Bosson, VP Communications and IRE-mail:  oskar.bosson@bioarctic.sePhone: +46 70 410 71 80  About lecanemab (generic name, brand name: Leqembi[®])Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong and Israel as treatment for early Alzheimer’s disease (mild cognitive impairment and mild dementia due to Alzheimer’s disease). Lecanemab approvals were based on the large global Phase 3 Clarity AD study. In the Clarity AD study, lecanemab met its primary endpoint and all key secondary endpoints with statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference , and simultaneously published in the New England Journal of Medicine , a peer-reviewed medical journal. Eisai has also submitted applications for approval of lecanemab in 11 other countries and regions, including the European Union (EU). A supplemental Biologics License Application (sBLA) for intravenous maintenance dosing was submitted to the U.S. Food and Drug Administration (FDA) in March 2024. The rolling submission of a Biologics License Application (BLA) for maintenance dosing of a subcutaneous injection formulation, which is being developed to enhance convenience for patients, was initiated in the U.S. under Fast Track status in May 2024. Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the collaboration between BioArctic and EisaiSince 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales. About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

Eisai will seek re-examination of CHMP opinion för lecanemab

“We are surprised and very disappointed by the CHMP’s opinion posted today. Foremost  the negative opinion adopted by the CHMP is sad for all patients, caregivers and healthcare professionals in the EU who will now have to wait longer for a treatment which can effectively change the course of this devastating disease. We know that for these patients, time is what they value the most, and potentially denying them a treatment which has been shown to delay the onset of more severe stages of the diseases is of course not what they or we had hoped for,” said Gunilla Osswald, BioArctic’s CEO. “This is not the final verdict however, and our partner Eisai will seek re-examination of the CHMP opinion and continue work with authorities to ensure this treatment is available for eligible people living with early Alzheimer’s disease in the EU as soon as possible.” A formal request for re-examination allows the applicant a 60-day period to provide the CHMP with the grounds for the re-examination request. The CHMP, led by new rapporteurs, will have 60 days to respond. Lecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong and Israel, and is being marketed in the U.S., Japan and China. Alzheimer’s disease currently affects 6.9 million people in Europe,[1] and this figure is expected to nearly double by 2050 as aging populations increase.[2] Eisai is responsible for the clinical development, applications for market approval and commercialization of lecanemab for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region. --- This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on July 26, 2024, at 13:15 p.m. CET.  For further information, please contact: Oskar Bosson, VP Communications and IRE-mail:  oskar.bosson@bioarctic.sePhone: +46 70 410 71 80  About lecanemab (generic name, brand name: Leqembi[®])Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong, and Israel  as treatment for early Alzheimer’s disease (mild cognitive impairment and mild dementia due to Alzheimer’s disease). Lecanemab approvals were based on the large global Phase 3 Clarity AD study. In the Clarity AD study, lecanemab met its primary endpoint and all key secondary endpoints with statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference , and simultaneously published in the New England Journal of Medicine , a peer-reviewed medical journal. Eisai has also submitted applications for approval of lecanemab in 11 other countries and regions, including the European Union (EU). A supplemental Biologics License Application (sBLA) for intravenous maintenance dosing was submitted to the U.S. Food and Drug Administration (FDA) in March 2024. The rolling submission of a Biologics License Application (BLA) for maintenance dosing of a subcutaneous injection formulation, which is being developed to enhance convenience for patients, was initiated in the U.S. under Fast Track status in May 2024. Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the collaboration between BioArctic and EisaiSince 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales. About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com. [1] European Medicines Agency. Involvement of patients in Scientific Advisory Group and Ad Hoc Expert meetings at EMA. Available at: https://www.ema.europa.eu/system/files/documents/other/involvement_of_patients_in_scientific_advisory_group-en.pdf. Last accessed: June 2024. [2] European Medicines Agency. The Centralised Procedure at the EMA. Available at: https://www.ema.europa.eu/en/documents/presentation/presentation-centralised-procedure-european-medicines-agency_en.pdf. Last accessed: June 2024.

Borr Drilling Limited – Contracting Update

Borr Drilling Limited (NYSE and OSE: “BORR”) is pleased to announce new contract commitments for three of its premium jack-up rigs, the “Arabia I”, the “Gunnlod” and the “Norve”.  These commitments cover a total of 1,779 days and $332 million in contract revenue, including mobilization and demobilization compensation.  The “Arabia I” which had its work scope suspended earlier this year in Saudi Arabia has secured a new long-term contract in Brazil. The contract period is 4 years firm plus a 4 years unpriced option. This contract is expected to commence in Q1 2025 in cooperation with an experienced local partner for Petrobras.  In Southeast Asia, the “Gunnlod” has received a binding Letter of Award from an operator in Malaysia.  The award covers a firm scope of seven wells, with an anticipated duration of 210 days, and is expected to commence in November 2024. In Africa, the “Norve” has secured a 109 days extension with BW Energy in Gabon.  This extension will keep the “Norve” contracted until February 2025 when it will commence its subsequent contract with Marathon Oil in Equatorial Guinea. Additionally, the Company previously announced the award of 180 days firm plus 180 days option commitment in Congo for ENI. The “Gerd” will execute this program that is expected to commence in October 2024. The rig is currently operating in the UAE and will commence mobilization to West Africa in September immediately following the completion of its current contract. Chief Commercial Officer, Bruno Morand, commented: “These new awards reinforce Borr Drilling’s ability to secure strategic commitments by leveraging our premium fleet, strong operational performance, and global footprint. Year to date, the Company has secured 13 new contracts contributing $644m in contract value, implying an average equivalent day rate of approximately $185,000. The new long-term award in Brazil for the “Arabia I” will be a vast improvement over its previous contract with a day-rate increase of over 60%. Following these awards, all our delivered rigs are committed. Based on already secured commitments and ongoing negotiations, we are confident that the new build Vali will be contracted and operating shortly after its delivery later this year.” Hamilton, Bermuda 26 July 2024 Forward looking statements This press release includes forward looking statements, which do not reflect historical facts and may be identified by words such as "will", "expect", "estimate" and similar expressions and include statements relating to contract awards, letter of awards,  contract duration and value and expected start and end dates, and other non-historical statements. Such forward looking statements are subject to risks, uncertainties, contingencies and other factors could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements included herein, including risks related to contracting, including our ability to convert LOAs into contracts, the final terms and start dates of such contracts, actual performance under drilling contracts, the risk that backlog may not be realized, and other risks and uncertainties described in the section entitled "Risk Factors" in our most recent annual report on Form 20-F and other filings with the Securities and Exchange Commission. Such risks, uncertainties, contingencies and other factors could cause actual events to differ materially from the expectations expressed or implied by the forward -looking statements included herein. These forward-looking statements are made only as of the date of this release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

The European Commission has granted a full marketing authorization of Kinpeygo®. The granting of the full approval results in a significantly broader label for patients with primary IgAN, moving from a urine protein excretion (UPCR) limitation of > 1.5g/g to encompassing the entire study population, defined as UPCR of ≥ 0.8g/g, or proteinuria of ≥1.0 g/g over 24 hours. This expanded label is based on full two-year data set from the Phase 3 NefIgArd clinical trial, published in leading medical journal The Lancet [(1)][.] “This is an important event for patients suffering from IgAN in Europe as Kinpeygo represents the first ever fully approved medication for this rare kidney disease.  The long-term confirmatory trial met its eGFR endpoint with high statistical significance and we are delighted that the European Commission has granted a full approval for the broader population” said Renee Aguiar-Lucander, CEO. Kinpeygo is marketed in in the EU and UK exclusively by Calliditas’ commercial partner, STADA Arzneimittel AG. The full marketing authorization for Kinpeygo covers the European Union (EU) member states as well as Iceland, Norway and Liechtenstein. Also, Kinpeygo’s status as an orphan drug for a rare disease, subject to 10-year market exclusivity running until 2032, was confirmed by the Commission. This approval triggers a milestone payment of ten million EUR to Calliditas, which will be recognized as revenue in the third quarter. 1. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomized phase 3 trial - The Lancet